

PLOS Pathogens

siRNA Screen Identifies Trafficking Host Factors that Modulate Alphavirus Infection

--Manuscript Draft--

Manuscript Number:	PPATHOGENS-D-15-01498R2
Full Title:	siRNA Screen Identifies Trafficking Host Factors that Modulate Alphavirus Infection
Short Title:	Host modulators of pathogenic alphavirus infection
Article Type:	Research Article
Section/Category:	Virology
Keywords:	Alphavirus; Arp3; chikungunya; CHIKV; EEEV; eastern equine encephalitis; PIP5K1; Rac1; Sindbis; Togaviridae; togavirus; Venezuelan equine encephalitis; VEEV; WEEV; western equine encephalitis
Corresponding Author:	Sina Bavari USAMRIID Frederick, Maryland UNITED STATES
Corresponding Author Secondary Information:	
Corresponding Author's Institution:	USAMRIID
Corresponding Author's Secondary Institution:	
First Author:	Sheli R Radoshitzky
First Author Secondary Information:	
Order of Authors:	Sheli R Radoshitzky
	Gianluca Pegoraro
	Xiǎoli Chī
	Lián Dǒng
	Chih-Yuan Chiang
	Lucas Jozwick
	Jeremiah C. Clester
	Christopher L. Cooper
	Duane Courier
	David P. Langan
	Knashka Underwood
	Kathleen A Kuehl
	Mei G Sun
	Yíngyún Cǎi
	Shuǐqíng Yú
	Robin Burk
	Rouzbeh Zamani
	Krishna Kota
	Jens H. Kuhn
	Sina Bavari
Order of Authors Secondary Information:	

UNCLASSIFIED

DISTRIBUTION STATEMENT A: Approved for public release; distribution is unlimited.

Abstract:	Little is known about the repertoire of cellular factors involved in the replication of pathogenic alphaviruses. To uncover molecular regulators of alphavirus infection and to identify candidate drug targets, we performed a high-content imaging-based siRNA screen. We revealed an actin-remodeling pathway involving Rac1, PIP5K1- α , and Arp3, as essential for infection by pathogenic alphaviruses. Infection causes cellular actin rearrangements into large bundles of actin filaments termed actin foci. Actin foci are generated late in infection concomitantly with alphavirus envelope (E2) expression and are dependent on the activities of Rac1 and Arp3. E2 associates with actin in alphavirus-infected cells and co-localizes with Rac1-PIP5K1- α along actin filaments in the context of actin foci. Finally, Rac1, Arp3, and actin polymerization inhibitors interfere with E2 trafficking from the trans-Golgi network to the cell surface, suggesting a plausible model in which transport of E2 to the cell surface is mediated via Rac1- and Arp3-dependent actin remodeling.
Suggested Reviewers:	<p>Kartik Chandran, Ph.D. Associate Professor, Albert Einstein College of Medicine kartik.chandran@einstein.yu.edu Expert in virus-host interactions and screens for identification of host modulators of virus infection</p> <p>Scott C Weaver, M.S., Ph.D. Professor, Institute for Human Infections and Immunity, The University of Texas Medical Branch at Galveston (UTMB) sweaver@utmb.edu Expert in alphavirus research</p> <p>Michael Farzan, Ph.D. Professor, The Scripps Research Institute (TSRI), Florida campus mfarzan@scripps.edu Expert in virus-host interaction</p> <p>Robert Davey, Ph.D. Texas Biomedical Research Institute rdavey@txbiomed.org Expert in imaging-based screens and virus-host cell interactions (including pathogenic alphaviruses)</p>
Opposed Reviewers:	<p>Ilya Frolov The University of Texas Medical Branch at Galveston (UTMB)</p> <p>Non-financial competing interests</p> <p>Sara Cherry University of Pennsylvania</p> <p>Non-financial competing interests</p> <p>Margaret Kielian Department of Cell Biology, Albert Einstein College of Medicine</p> <p>Non-financial competing interests</p>
Additional Information:	
Question	Response
<p>Data Availability</p> <p>PLOS journals require authors to make all data underlying the findings described in their manuscript fully available, without restriction and from the time of publication, with only rare exceptions to address legal and ethical concerns (see the PLOS Data Policy and FAQ for further details). When submitting a manuscript, authors must provide a Data Availability Statement that describes where the data</p>	Yes - all data are fully available without restriction

UNCLASSIFIED

DISTRIBUTION STATEMENT A: Approved for public release; distribution is unlimited.

<p>underlying their manuscript can be found.</p> <p>Your answers to the following constitute your statement about data availability and will be included with the article in the event of publication. Please note that simply stating 'data available on request from the author' is not acceptable. If, however, your data are only available upon request from the author(s), you must answer "No" to the first question below, and explain your exceptional situation in the text box provided.</p> <p>Do the authors confirm that all data underlying the findings described in their manuscript are fully available without restriction?</p>	
<p>Please describe where your data may be found, writing in full sentences. Your answers should be entered into the box below and will be published in the form you provide them, if your manuscript is accepted. If you are copying our sample text below, please ensure you replace any instances of XXX with the appropriate details.</p> <p>If your data are all contained within the paper and/or Supporting Information files, please state this in your answer below. For example, "All relevant data are within the paper and its Supporting Information files."</p> <p>If your data are held or will be held in a public repository, include URLs, accession numbers or DOIs. For example, "All XXX files are available from the XXX database (accession number(s) XXX, XXX)." If this information will only be available after acceptance, please indicate this by ticking the box below.</p> <p>If neither of these applies but you are able to provide details of access elsewhere, with or without limitations, please do so in the box below. For example:</p> <p>"Data are available from the XXX Institutional Data Access / Ethics Committee for researchers who meet the criteria for access to confidential data."</p> <p>"Data are from the XXX study whose authors may be contacted at XXX."</p> <p>* typeset</p>	<p>All relevant data are within the paper and its Supporting Information files</p>
<p>Additional data availability information:</p>	

UNCLASSIFIED

DISTRIBUTION STATEMENT A: Approved for public release; distribution is unlimited.



DEPARTMENT OF THE ARMY
US ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES
1425 PORTER STREET
FORT DETRICK, MARYLAND 21702-5011

Richard J. Kuhn, Associate Editor
Michael Diamond, Section Editor
PLOS Pathogens

January 26, 2016

Dear Dr. Kuhn and Dr. Diamond:

Upon your encouragement, we would like to submit to you a newly revised and expanded version of our manuscript “**siRNA Screen Identifies Trafficking Host Factors that Modulate Alphavirus Infection**” by Radoshitzky *et al.* for publication in *PLOS Pathogens*.

We thank the old and new reviewers for their now very positive assessment of our work. We have addressed their constructive criticisms as follows:

- (i) we performed TUNEL staining to exclude apoptosis as a possible confounding factor in our assays, and provide the results in the form of a table and a figure in the response to reviewers file. As expected, apoptosis does not occur within the timeline of our readout;
- (ii) we have clarified that many of our assays were performed in the context of a single infection cycle;
- (iii) we have included densitometry in our western blot figures;
- (iv) we have increased the size of several figures to more clearly demonstrate the tubulin and actin perturbances induced by the inhibitors; and
- (v) we have made several text modifications to clarify the potential shortcomings of the presented IP assay.

We look to you for advice on whether to include the TUNEL staining results within the manuscript. We further ask for your guidance on whether to delete or maintain subfigure

UNCLASSIFIED

panels as some reviewers recognize the density of the manuscript and the wealth of presented data.

We are confident that these new supportive data and revisions make the manuscript even stronger and that the manuscript now fulfills the high scientific expectations of the *PLOS Pathogens* Editorial Board.

Best regards,

Sina Bavari, Ph.D.

Science Director

US Army Medical Research Institute of Infectious Diseases (USAMRIID)

Frederick, MD 21702-5011

301-619-0010 (office)

sina.bavari.civ@mail.mil

Part I - Summary

Reviewer #2: The authors have addressed most of my concerns and have provided additional information as figures.

Our response: we thank the reviewer for confirming that we have addressed most of the concerns associated with our initial submission.

Reviewer #4: The authors have identified membrane trafficking factors that are involved during VEEV infection. The factors Rac1, Arp and PIP5K1 were identified. This is novel information.

Response: We thank the reviewer for acknowledging the novelty of our findings.

However, the impact of this finding is obscured by the hypothesis that these factors are mediating direct binding of E2 with actin, which would not be possible at the budding stage of maturation.

Response: Our manuscript did not contain any hypothesis that Rac1, Arp3, and/or PIP5K1 are mediating direct binding of E2 with actin. We did not claim anywhere that the association of E2 and actin is direct. However, the reviewer made us aware that the reader might get a wrong impression, which is why we now use the word “associate” and not “bind” throughout. It is of course possible that other viral proteins (like alphaviral capsid, which is thought to bind E2) or other host proteins facilitate this association. We have now modified the manuscript to make this point even clearer.

We also did not suggest or claim that E2 associates with actin at the budding stage of the viral lifecycle. Our hypothesis, laid out in the discussion, is that E2 is associated with actin during trafficking from the TGN to the cell surface. As previous publications have shown, E2 and actin association at this stage is possible via the 33 amino acid residues of the E2 cytoplasmic domain that are located in the cytoplasm at that time [1]. In addition, previous studies have also shown that this cytoplasmic domain is available and can interact with other proteins such as the alphavirus capsid protein [2].

Reviewer #5: This manuscript is a revision of previously submitted and reviewed work. It examines the role of actin and mediators of actin function in alphavirus infection. The roles of these proteins have been previously discussed for another alphavirus, Semliki Forest virus, in entry steps of infection. The current work differs by examining the role of actin in egress of virus, something that has not been done in any detail, particularly for the New World alphaviruses. From the view of this reviewer, the most important aspect of the work is the role of PIP5K1 in egress. This effector of actin polymerization is not overly studied and is novel

in the way it interacts with virus proteins. In general, the work has a high level of detail and is analyzed carefully and rigorously. The criticisms below can be addressed without the need of additional experiments and mostly address issues of readability.

Our response: we thank the reviewer for confirming that our experiments have been performed carefully and rigorously and that our conclusions are important.

Part II – Major Issues: Key Experiments Required for Acceptance

Reviewer #2: One major issue still exists in the manuscript, that is E2 binding to actin by IP. If you take the E2 out of the ER and Golgi membrane after lysis it probably binds actin and that is not similar to glycoprotein transport during virus infection. CPV-II structures contain attached cores and those associating with filaments shown by EM is equivalent to actin binding to E2.

Our response: If we understand the reviewer correctly, no additional experiments are required as we have shown by EM that CPV-II structures with viral cores are associated with (or in the vicinity of) actin filaments in infected cells (Figure 6C). We have now further revised the manuscript to include the concern associated with the IP assay.

Reviewer #4: The major flaw I see in this study is that there is no single cycle growth curve of any of the viruses done.

Our response: the reviewer probably overlooked important information provided in the materials and method section. Our presented data include qRT-PCR and E2-expression image-based assays using an MOI of 10 for VEEV in a single infection cycle growth-curve analysis (Figures 3C and D, S3A). Furthermore, many experiments were performed to confirm our results in the context of a single VEEV infection cycle:

- Effect of the siRNAs, as well as Rac1, Arp3, and actin inhibitors on intracellular vRNA levels (Figures 3H-I, 4G)
- Effect of Rac1, Arp3, and actin inhibitors on VEEV infection rate in order-of-addition experiments (Figures S3B, 4B)
- Effect of nocodazole and actin inhibitors on VEEV titer in primary human astrocytes (Figures 4E, S4A)
- IP analysis of E2 and actin association in lysed cells (Figure 6D)
- Effect of Rac1, Arp3, and actin inhibitors on E2 cell-surface expression (Figures 7B and C).

Instead, unnecessary technology is used which further perturbs the system which is going into apoptosis.

We agree with the reviewer that apoptosis is a concern. For assays that involve

two infection cycles (20 h overall infection time), we not only measured virus infection rates, but also utilized image-based analysis to measure cell number (shown for most treatments within the manuscript) and nucleus size (using Hoechst 33342 dye) as nuclear condensation and fragmentation are two hallmarks of apoptosis. Because VEEV (as well as RVFV [3]) infection induces apoptosis of infected cells, we optimized our assays so that the readout time will be before cell death is prominent based on Hoechst staining (see Table 1 for reviewers below).

To further address the reviewer's concern, we now include results obtained with the TUNEL assay on VEEV-infected cells (MOI=0.5, infection time = 20 h), as well as positive-control cells (DNase I-treated as a positive control for TUNEL and staurosporine-treated as a positive control for apoptosis) (see Figure 1 for reviewers). These results demonstrate that even in our assays that involve two infection cycles, apoptosis is not prominent. Furthermore, as demonstrated in Figure 5A, VEEV and CHIKV infection induce actin foci formation whereas RVFV infection does not, and yet all these viruses induce apoptosis. Finally, in most experiments we also included representative images, which show actin rearrangements in cells with normal morphology (and normal nuclei morphology – i.e., no nuclei fragmentation). Thus, actin rearrangements are in all likelihood a result of virus infection and not a result of cell death or apoptosis.

Table 1 for reviewers: Examples of results obtained with an Opera confocal reader following VEEV infection (MOI=0.5, infection time = 20 h)

Parameter: % virus antigen positive cells		Parameter: Average Nucleus Size	
Mock-infected cells	VEEV-infected cells	Mock-infected cells	VEEV-infected cells
0.00	62.15	126.09	121.12
0.05	62.42	127.90	121.65
0.02	59.24	125.91	118.62
0.00	54.92	127.57	117.81
0.00	50.02	127.72	117.95
0.03	62.15	127.84	122.21




Figure 1 for reviewers: HeLa cells were infected with VEEV (MOI=0.5) for 1 h and fixed 20 h later. Non- infected (mock) cells were used as a control. Alternatively, cells were treated with increasing concentrations of staurosporine. Cells were stained using the Click-iT TUNEL Alexa Fluor Imaging assay (Thermo Fisher Scientific, shown in green). DNase I treatment was used as a positive control. Following TUNEL staining, virus-positive cells were detected using an anti-E2 antibody (shown in red) as described in the manuscript. Hoechst (shown in blue) and cell mask (not shown) were used for nucleus/cytoplasm staining. (A) Opera confocal imager was used to measure %TUNEL positive cells. (B) Representative images of (A).

The presentation of the data is, as the authors state "dense" but could be simplified by scaling down the amount of data presented.

We agree with the reviewer that the manuscript is dense and that a wealth of data is presented. This abundance of partially redundant data is due to the continuing requests for additional data by old and new reviewers. If we omit data as requested by this single reviewer, we might encounter requests upon resubmission to add these data by the other reviewers. We therefore look to the editor for advice on this matter.

Reviewer #5: Fig. S4B and Fig. 5A that are meant to show disruption or changes in actin polymerization are too small to tell. For S4B each cell seems to have the same actin staining level. For 5A a more detailed image would be more revealing of the changes that occur. Higher magnification showing lack of actin fibers is

needed to make the point. This is in stark contrast to the very good images in Fig 6, where the magnification shows the necessary detail needed to interpret the findings.

Our response: The reviewer seems to have confused the presented data as Figure S4B shows tubulin (not actin) staining. We agree, however, that the images are too small and have now provided better images and increased the image size so disruption of tubulin polymerization is obvious. For comparison see reference [4].

Figure 5A was taken with an Opera confocal reader. In order for us to quantitatively analyze the amount of actin foci per cell (Figures 5B and 5C), we use the Opera confocal reader to acquire and analyze images from more than 500 cells. Consequently, our resolution is limited in this type of assay and analysis. That is why in Figure 6 and S6 we repeated the infections to characterize in better resolution the nature of the observed actin changes (or remodeling) using a Leica SP5 TCS 2C STED confocal system.

Part III – Minor Issues: Editorial and Data Presentation Modifications

Reviewer #2: Authors still state that E2 binds actin and I do not believe IP is the best way to show this binding. In lines 437 and 457 authors say that E2 binds actin.

437 Fig 6. Alphavirus E2 co-localizes with actin filaments and binds to actin.
and 457 Alphavirus E2 Glycoprotein Interacts with Actin.

Our response: We apologize for this oversight and have now modified “binds” to “associates” and further revised the text to reflect the concerns associated with the IP assay as performed.

Reviewer #4: Too many panels and pictures. It is not necessary to show all the data. In fact, some of the pictures are so small that the content is lost.

Our response: We agree with the reviewer that we show an exorbitant amount of data for a single paper. This is due to the various requests of by now five reviewers, all of whom would like to see different points of the paper emphasized (see reviewer 5, who requests even more data to be presented in the figures). We have of course no problem with deleting figures or data panels but would prefer instructions from the editor on which panels to cut.

Reviewer #5: Figure 1B should include densitometry of blots and then correlation to expression levels to virus replication can be made.

Our response: We agree with the reviewer that densitometry is a useful addition. We have now included densitometry of the blots in Figure 1B. We observe a

general, but not absolute correlation between the densitometry data and virus infection rate as expected for a semiquantitative method.

For the section using Mo-MLV pseudotypes (which is to be commended): While siRNA was tested, were the chemical inhibitors, EHT1864 and CK548 evaluated in this system?

Our response: No, we have not evaluated the inhibitors with the pseudotype system. Other reviewers (see comments above) believe that the manuscript is too dense as it is and that the siRNA treatments are less disruptive in nature than the inhibitor treatments.

Fig. 3. Why not connect the time points and model the kinetic of infection?

Our response: Since our manuscript is not focused on modeling the kinetics of infection, we did not perform any such modeling. However, if the reviewer strongly believes and the editor agrees that this is essential information for confirming the message of the manuscript we will include such data analysis.

Fig. S4B and Fig. 5A that are meant to show disruption or changes in actin polymerization are too small to tell. For S4B each cell seems to have the same actin staining level. For 5A a more detailed image would be more revealing of the changes that occur. Higher magnification showing lack of actin fibers is needed to make the point. This is in stark contrast to the very good images in Fig 6, where the magnification shows the necessary detail needed to interpret the findings.

Our response: This is a repeat of a concern mentioned previously. Please see our response above.

Fig. 5D is very interesting but please give example of image showing actin foci. A better description of size of foci is important as foci size has mechanistic implications.

Our response: Actin foci (visually reminiscent of balls of yarn) in Figure 5D are indicated by asterisks. The sizes of the foci are variable. However, according to our high-resolution confocal images (Figure 5F and Figure 6A) the diameter of actin foci varies in size between 5-11 μm . This information is now included in the text.

The section on the role of Rac1 and Arp3 in actin foci formation needs a better explanation. Rac1 and Arp3 certainly mediate actin foci formation in other systems but what would be the alternatives as they play rather key roles. In contrast, Fig. 5F is interesting as it clearly shows colocalization of actin, virus and PIP5K1. The PIP5K1 experiment seems more focused on a specific effector than Rac1 and Arp3.

Our response: We agree with the reviewer that specific details in regard to the exact roles of Rac1 and Arp3 in actin foci formation still have to be determined. However, in our view, this will be the objective of interesting follow-up work as this manuscript is already too dense in information (as pointed out repeatedly by various reviewers). The main message of our manuscript is that Rac1 and Arp3 play a crucial role in actin foci formation during alphavirus infection, that Rac1 and PIP5K1-alpha co-localize with actin foci in infected cells, and that inhibitors of Rac1 and Arp3 interfere with transport of E2 from the TGN to the cell surface. The reviewer agrees that we demonstrated these three key points and that no further experiments are necessary, which is why we would prefer to leave the text as is rather than adding additional speculations.

Fig. 6D needs to be evaluated by densitometry. Results can be cited in text. On page 20 a better explanation of CPV1 and 2 structure composition and function are needed for the reader.

Our response: We have evaluated Figure 6D by densitometry and have included the results in the revised text. We have included further explanation on CPV1 and 2 structure and function in the introduction (page 4) as the Results section is intended for description of our results rather than summary of current knowledge.

1. Liu N, Brown DT (1993) Transient translocation of the cytoplasmic (endo) domain of a type I membrane glycoprotein into cellular membranes. *J Cell Biol* 120: 877-883.
2. Jose J, Snyder JE, Kuhn RJ (2009) A structural and functional perspective of alphavirus replication and assembly. *Future Microbiol* 4: 837-856.
3. Austin D, Baer A, Lundberg L, Shafagati N, Schoonmaker A, et al. (2012) p53 Activation following Rift Valley fever virus infection contributes to cell death and viral production. *PLoS One* 7: e36327.
4. Prudent R, Vassal-Stermann E, Nguyen CH, Pillet C, Martinez A, et al. (2012) Pharmacological inhibition of LIM kinase stabilizes microtubules and inhibits neoplastic growth. *Cancer Res* 72: 4429-4439.

siRNA Screen Identifies Trafficking Host Factors that Modulate Alphavirus Infection

Sheli R. Radoshitzky¹, Gianluca Pegoraro¹, Xiǎolì Chī¹, Lián Dǒng¹, Chih-Yuan Chiang¹,
Lucas Jozwick¹, Jeremiah C. Clester¹, Christopher L. Cooper¹, Duane Courier¹, David P.
Langan¹, Knashka Underwood¹, Kathleen A. Kuehl², Mei G. Sun², Yíngyún Cài³, Shuǐqìng
Yú³, Robin Burk³, Rouzbeh Zamani¹, Krishna Kota¹, Jens H. Kuhn³, Sina Bavari^{1,*}

¹Molecular and Translational Sciences Division, ²Pathology Division, United States Army
Medical Research Institute of Infectious Diseases (USAMRIID), Frederick, MD, USA,

³Integrated Research Facility at Fort Detrick (IRF-Frederick), Division of Clinical Research
(DCR), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of
Health (NIH), Fort Detrick, Frederick, MD, USA

*For correspondence: sina.bavari.civ@mail.mil

Short title: Host modulators of pathogenic alphavirus infection

Abbreviation list: Chikungunya virus, CHIKV; cytopathic vacuoles, CPV; eastern equine encephalitis
virus, EEEV; Ebola virus, EBOV; Moloney murine leukemia virus, MoMLV; Rift Valley fever virus,
RVFV; Sindbis virus, SINV; stimulated emission depletion, STED; Venezuelan equine encephalitis virus,
VEEV; western equine encephalitis virus, WEEV; *trans Golgi* network, TGN

Abstract

Little is known about the repertoire of cellular factors involved in the replication of pathogenic alphaviruses. To uncover molecular regulators of alphavirus infection and to identify candidate drug targets, we performed a high-content imaging-based siRNA screen. We revealed an actin-remodeling pathway involving Rac1, PIP5K1- α , and Arp3, as essential for infection by pathogenic alphaviruses. Infection causes cellular actin rearrangements into large bundles of actin filaments termed actin foci. Actin foci are generated late in infection concomitantly with alphavirus envelope (E2) expression and are dependent on the activities of Rac1 and Arp3. E2 associates with actin in alphavirus-infected cells and co-localizes with Rac1-PIP5K1- α along actin filaments in the context of actin foci. Finally, Rac1, Arp3, and actin polymerization inhibitors interfere with E2 trafficking from the trans-Golgi network to the cell surface, suggesting a plausible model in which transport of E2 to the cell surface is mediated via Rac1- and Arp3-dependent actin remodeling.

Author Summary

Alphaviruses, such as Chikungunya or Venezuelan equine encephalitis viruses, are significant human pathogens that cause arthritis or fatal encephalitis in humans. For productive infection of cells, alphaviruses rely on a repertoire of cellular host proteins, including trafficking factors that mediate transport of viral components across the cell. We have performed a functional screen to identify cellular factors that are crucial for this transport process. We show that Rac1, PIP5K1- α , and the Arp2/3 complex are cellular regulators of alphavirus infection. These factors are important for major cellular actin rearrangements that occur at a late stage of virus infection and are virus-induced. Concomitantly, these factors might be essential for trafficking of the viral E2

surface glycoprotein from the *trans*-Golgi network (TGN) to the cell surface. E2 was found to associate with actin, as well as to co-localize with Rac1, PIP5K1- α , and actin filaments. Late E2-containing vesicles, termed cytopathic vacuoles II (CPV-II), were also imaged along and at the end of actin filaments in alphavirus-infected cells.

Keywords: alphavirus; actin; Arp3; chikungunya; CHIKV; EEEV; eastern equine encephalitis; PIP5K1; Rac1; Venezuelan equine encephalitis; VEEV; WEEV; eastern equine encephalitis

Introduction

Viral infection requires extensive subcellular trafficking, including cell entry, delivery of the genome to replication sites, and transport of viral proteins to and assembly of viral particles at the plasma membrane for egress. To this end, viruses make use of different cellular cues and signals to hijack existing endocytic and secretory pathways, cellular motor proteins, and cytoskeletal filaments.

Here we examine cellular trafficking machineries utilized by alphaviruses. Alphaviruses (family *Togaviridae*) are single-stranded, positive-sense RNA viruses that produce enveloped virions. Chikungunya virus (CHIKV), eastern equine encephalitis virus (EEEV), Venezuelan equine encephalitis virus (VEEV), and western equine encephalitis virus (WEEV) are the most medically important human alphaviruses that cause debilitating arthritides (CHIKV) or encephalitides (EEEV, VEEV, and WEEV) [1-3]. For instance, since December 2013, spread of CHIKV in the Caribbean has caused tens of thousands of human infections [4].

The alphavirus genome consists of two open reading frames encoding nonstructural and structural polyproteins. Four nonstructural proteins (nsP1-4) are required for transcription and

67 replication of viral RNA, and three main structural proteins (i.e., capsid protein C, envelope
68 glycoproteins E2 and E1) are the main constituents of virions. Alphavirus replication occurs
69 initially at the plasma membrane [5,6]. Replication complexes are subsequently internalized via
70 an endocytic process that requires a functional actin-myosin network. Following endocytosis,
71 replication complex-containing vesicles migrate via a microtubule-dependent mechanism to the
72 perinuclear area where they form stable, large and acidic compartments termed cytopathic
73 vacuoles (CPV)-I. CPV-I structures are derived from modified endosomes and lysosomes and
74 are associated with the alphaviral nonstructural proteins as well as viral RNA [7-9]. In the late
75 stage of alphavirus infection, *trans Golgi* network (TGN)-derived vacuoles marked with the
76 E1/E2 glycoproteins become predominant [10,11]. In these membrane vacuoles (termed CPV-
77 II), the viral glycoproteins are arranged in a tubular structure. CPV-II vacuoles have been
78 implicated in intracellular transport of alphavirus glycoproteins from the TGN to the site of
79 budding on the plasma membrane prior to virus egress [8,12].

80 siRNA screens have identified a number of host factors that possibly promote or restrict
81 nonpathogenic alphavirus infection [13-15]. However, detailed mechanistic studies regarding the
82 role of host factors in alphavirus trafficking have not been performed. In this study, we used an
83 RNAi-based screen to identify and validate trafficking host factors that are required for infection
84 by the pathogenic VEEV and other pathogenic alphavirus relatives. Mutagenesis-, chemical
85 inhibitor- and imaging-based approaches were further used to validate and decipher the role of
86 these factors in alphavirus infection.

87 **Results**

88 **High-content RNAi Screen Identifies Host Trafficking Regulators of Alphavirus Infection**

89 Small interfering RNA (siRNA) pools targeting each of 140 human trafficking genes were

transfected into HeLa cells. A non-targeting siRNA was used as a control. Cells were subsequently infected with VEEV (chosen as a prototype alphavirus for the screen) for 20 h and then fixed and stained with a VEEV E2-specific antibody (Fig 1A). Staining was performed without permeabilization to detect only E2 present on the cell surface. Cell number and infection rate were determined using quantitative high-content image-based analysis (see Materials and Methods). The infection rate of control siRNA-transfected cells was optimized to yield, on average, 70-80%. Analysis of the results revealed that siRNAs against 51 host trafficking factors decreased VEEV infection rate by >30% (Z-score <-2) (S1 Table).

Fig 1. siRNA Screen Identifies Host regulators of alphavirus infection.

(A) Schematic representation of the siRNA screen and the high-content quantitative image-based analysis of relative VEEV infection rates. HeLa cells were transfected with siRNAs against 140 host trafficking factors and inoculated with VEEV (MOI=0.5) for 20 h. Cells were fixed and immunostained for cell surface VEEV envelope glycoprotein (E2) expression. Infection rates were determined using an Opera confocal imager and normalized to infection rates observed using non-targeting control siRNA. Representative images of cells treated with control (Cont) or Rac1 siRNA are shown. VEEV E2 staining is shown in green and nucleus staining is shown in blue. (B) High-content quantitative image-based analysis was used to measure relative infection rates (normalized to control siRNA-treated cells) of VEEV (top panel) in HeLa cells pretreated with the indicated siRNAs. Cells were infected for 20 h (VEEV, MOI=0.5), fixed and stained with antibodies against E2. Values represent the mean \pm SD, n = 3. Protein levels of Rac1, Arp3, and actin (loading control) following siRNA treatments were determined by immunoblotting (bottom panel). mRNA levels of PIP5K1- α (PIP5K1A) following siRNA treatments were

determined by qRT-PCR. (C) VEEV titer following treatment of HeLa cells with siRNAs against Rac1, Arp3, PIP5K1A (PIP5k1 α), or control siRNA. Cells were inoculated with VEEV as in (B) and virus-containing media was analyzed by plaque assay. **, $p < 0.01$, Student's t test (between the sample and control siRNA).

To confirm results of the primary screen and to rule out potential off-target effects of individual siRNAs, we performed a secondary screen of deconvoluted siRNA pools. A hit was considered validated if at least 2 siRNAs from the set of 4 individual siRNAs targeting the gene product reduced the VEEV infection rate by $\geq 30\%$ and had a p -value of < 0.05 versus control siRNA-transfected wells. Wells that had low cell numbers (final cell number $< 70\%$ of the control siRNA-transfected well) due to combined effects of siRNA toxicity and VEEV cytopathic effects were excluded from further analyses. Analysis of the results led to validation of 19 (61%) out of the 31 primary hits (S2 Table).

Importantly, the list of validated hits was enriched for crucial regulators of the actin cytoskeleton. In particular, knockdown of four subunits of the heptameric Arp2/3 complex, ARPC4, ARPC5, ARPC1B (S2 Table), and ACTR3 (Arp3) (Fig 1B), significantly inhibited VEEV infection. In addition, Rac1, and PIP5K1- α (PIP5K1A) were also identified as hits (Fig 1B). The Arp2/3 complex plays a central role in actin dynamics by controlling filament nucleation [16,17]. Rac1 is a member of the Rho GTPase family and among its many functions modulates actin cytoskeleton organization [18]. PIP5K1- α is a lipid kinase involved in the synthesis of the signaling molecule phosphatidylinositol-4,5-bisphosphate (PI4,5P₂), which is a central regulator of the actin cytoskeleton in response to multiple signals [19].

Our siRNA results were further confirmed using single siRNAs against Rac1, Arp3, and

PIP5K1- α from another source (Fig 1B, siRNAs 5–7). We also observed a ≈ 10 to >30 fold reduction in VEEV titer following knockdown of these host factors (Fig 1C). Finally, siRNA-mediated knockdown of Rac1, Arp3, or PIP5K1- α inhibited infection of CHIKV (S1A and B Fig). These results indicate that Rac1, Arp3, and PIP5K1- α play an important role in alphavirus infections.

Rac1 and Arp3 Inhibitors Reduce Alphavirus Infection Rates

To validate the role of Rac1 and Arp3 in VEEV infection, we tested whether the Rac1 inhibitors EHT1864 and NSC23766 [20,21] and the Arp3 inhibitors CK548 and CK869 [22] could block VEEV infection. Upon treatment of HeLa cells with either of these inhibitors, VEEV infection rates were reduced in a dose-dependent manner (Fig 2A and B). Similar results were observed when the Rac1 inhibitors EHT1864 or NSC23766 or the Arp3 inhibitor CK548, were tested in primary human astrocytes (Fig 2C and D). These inhibitors were also effective in reducing infection rates of other alphaviruses. EHT1864 inhibited infections by CHIKV and the closely related Sindbis virus (SINV), and CK548 decreased CHIKV, SINV, EEEV, and WEEV infection rates (S2A and B Fig). None of the treatment conditions in either assays resulted in cytotoxicity. Overall, our results further confirm the importance of host factors Rac1 and Arp3 in alphavirus infection.

Fig 2. Rac1, Arp3 and formation of a Rac1:PIP5K1- α complex are important for VEEV infection.

(A) High-content quantitative image-based analysis of relative VEEV infection rates in HeLa cells pretreated with increasing concentrations of two Rac1 inhibitors (EHT1864 or NSC23766), two Arp3 inhibitors (CK548 or CK869), or DMSO. Cells were inoculated with compounds 1 h

prior to VEEV addition. Cells were fixed and stained with virus-specific antibodies 20 h later. Results are normalized to DMSO-treated samples. (B) Representative confocal images of (A). VEEV E2 staining is shown in green and nucleus/cytoplasm staining is shown in red. (C) Primary human astrocytes were treated with increasing concentrations of EHT1864, NSC23766, or CK548, and subsequently inoculated with VEEV (MOI=0.005). Cells were fixed 19 h later and stained and analyzed as in (A). (D) Representative confocal images of (C). VEEV E2 staining is shown in green and nucleus staining is shown in blue. (E) Flp-In T-REx 293 cells with tetracycline-inducible expression of wild-type Rac1, constitutively active Rac1 (G12V) or dominant-negative Rac1 (T17N) were generated, and analyzed for protein expression by immunoblotting (actin was used as a loading control). (F) High-content quantitative image-based analysis of VEEV or RVFV infection rates in Flp-In T-REx 293 cells pre-induced to express chloramphenicol acetyltransferase (CAT), wild-type Rac1, or variants thereof. Cells were fixed 18 h (VEEV) or 24 h (RVFV) after virus inoculation and stained with virus-specific antibodies. (G) Immunoblot of tetracycline-induced expression of wild-type Rac1, or Rac1 K186E in Flp-In T Rex 293 cells as in (E). (H) High-content quantitative image-based analysis of VEEV or RVFV infection rates in Flp-In T-REx 293 cells pre-induced to express CAT, wild-type Rac1, or Rac1 K186E. Cells were infected and stained as in (F).

Rac1 GTPase Function and Rac1:PIP5K1- α Complex Formation are Important for Alphavirus Infection

To determine if the function of Rac1 in alphavirus infection required Rac1's GTPase activity, we established tetracycline-inducible 293 Flp-In T-REx cell lines that express chloramphenicol acetyltransferase (CAT, used as a control), wild-type Rac1, constitutively active Rac1 (G12V),

or dominant-negative Rac1 (T17N) (Fig 2E) [23,24]. Rac1 expression in these cells was induced with tetracycline for 24 h, followed by infection with VEEV, or a non-alphavirus control (Rift Valley fever virus; RVFV strain ZH501, hereafter, RVFV) . Expression of both Rac1 mutant variants (G12V, T17N) reduced VEEV but not RVFV infection rates, whereas expression of wild-type Rac1 had no effect (Fig 2F, S2C Fig). Both Rac1 mutants also reduced VEEV titer in the media (Fig S2D). We also confirmed the importance of Rac1 GTPase activity during VEEV and CHIKV infection (S2F-G Fig). The inhibitory effects of both Rac1 mutant variants on alphavirus infection likely indicate that the role of Rac1 during infection requires completion of the GTP-GDP-exchange/GTP-hydrolysis cycle. Cycling between GTP- and GDP-bound states may be required for productive infection, and shifting the level of activity predominantly to either side may block signaling pathways that emanate from the turnover.

Rac1 also forms a complex with PIP5K1 kinases that are necessary for stimulation of PI4,5P₂ synthesis and actin assembly [25]. PIP5K1- α directly binds Rac1 via the polybasic tail of Rac1. Specific mutations within this region, such as K186E, abrogate Rac1:PIP5K1- α binding *in vitro* [26]. To examine whether Rac1:PIP5K1- α complex formation is important for VEEV infection, we used the tetracycline-inducible 293 Flp-In T-REx cell line to express Rac1 variant K186E (Fig 2G). Once induced, these cells and control cells expressing CAT or wild-type Rac1 were infected with VEEV or RVFV. Expression of Rac1 K186E reduced VEEV but not RVFV infection rates (Fig 2H, S2E Fig). VEEV titer in the media was also reduced (Fig S2D). Finally, we confirmed the importance of Rac1:PIP5K1- α complex formation to infection with CHIKV (S2H-I Fig). These results suggest that binding of Rac1 to PIP5K1- α plays a role in alphavirus infections.

Rac1 and Arp3 Do Not Affect Alphavirus Cell Entry or Replication but Later Stages of

Infection prior to Virus Budding

We used a multi-cycle VEEV in our screen. Consequently, Rac 1 and Arp3 could have acted at a number of stages of the VEEV lifecycle. To determine when Rac1 and Arp3 act, we first determined the time necessary for a single lifecycle (round) of VEEV TC-83 (live-attenuated vaccine strain) infection. To this end we measured virus particle release from HeLa cells to the media at different time points post virus inoculation using qRT-PCR analysis. Expression kinetics of the late alphaviral gene product, E2, was also analyzed. Virus particle release into the media was observed at 9 h post inoculation of HeLa cells (Fig 3A), suggesting an approximately 9-h replication cycle for VEEV under these conditions. E2 expression was detected as early as 7 h post virus inoculation (Fig 3B). Experiments performed with virulent VEEV IC-SH3 yielded similar results on expression of E2 and C proteins at these time points (Fig 3C). We confirmed our results with a one step-like growth curve analysis using a high MOI (MOI=10) and also measured intracellular viral RNA (vRNA) levels as a function of time. Significant increase in intracellular vRNA levels was found at 5 h post virus inoculation, suggesting that virus replication/transcription is initiated prior to this time point (Fig 3D).

Fig 3. Rac1 and Arp3 act at a late stage of alphavirus infection.

(A and B) Time course of VEEV TC-83 (MOI=2) infection in HeLa cells. (A) Media containing extracellular virions were harvested at the indicated time points for qRT-PCR analysis of virus copy number, and (B) cells were fixed, stained with VEEV E2-specific antibody and analyzed with an Opera confocal reader by high-content quantitative image-based analysis. (C) Representative confocal images of E2 or C expression in VEEV-infected (MOI=0.5) HeLa cells 7 h or 9 h following virus inoculation. Cells were stained with E2- or C-specific antibodies

(green) and counterstained with dye to show the nuclei (blue). **(D)** Viral copy number (intracellular vRNA) in HeLa cells at the indicated time points following VEEV TC-83 (MOI=10) inoculation was determined by qRT-PCR. **(E)** High-content quantitative image-based analysis of relative VEEV infection rates in time-of-addition experiments. VEEV-infected HeLa cells (MOI=0.5) were treated with increasing concentrations of the inhibitors at the indicated time points prior to (-1 h) or after (+1–7 h) virus addition. Cells were fixed 20 h after addition of virus, stained and analyzed as in **(B)**. Results are normalized to DMSO-treated samples. Values represent the mean \pm SD, $n = 3$. *, $p < 0.05$; **, $p < 0.01$; ***, $p < 0.001$; n.s., not significant, Student's t test (between the sample and DMSO-treated cells). **(F)** HeLa cells were transfected with siRNAs targeting Rac1, Arp3, or control siRNA. Two days later, cells were transduced with eGFP-expressing MoMLV pseudotyped with the envelope proteins of VEEV (E1/E2) or EBOV (GP_{1,2}). eGFP-expressing cells were measured as in **(B)**. Transduction rates were normalized to control siRNA-treated cells. *, $p < 0.05$; **, $p < 0.01$, Student's t test (between the sample and control siRNA) **(G)** Aliquots of the cells treated in **(E)** were lysed and analyzed for E2 expression by immunoblotting (GAPDH was used as a loading control). Densitometric analysis of western blots was performed with ImageJ. **(H-I)** VEEV copy number (intracellular vRNA) in HeLa cells following treatment with inhibitors or siRNAs as determined by qRT-PCR. **(H)** HeLa cells were inoculated with VEEV TC83 (MOI=2) and 5 h later treated with the indicated inhibitors. Cells were lysed and analyzed for virus copy number 11 h after virus addition. **(I)** HeLa cells were treated with the indicated siRNAs and 48 h later inoculated with VEEV TC83 (MOI=2). Cells were lysed and analyzed as in **(H)**.

To narrow down the lifecycle stage targeted by Rac1 and Arp3, we performed time-of-

addition experiments using inhibitors of these host factors. This time-based approach determines how long the addition of a compound can be postponed before losing its antiviral activity in cell culture. For example, if an inhibitor that targets viral fusion is present at the time when virus entry and fusion occurs within the viral lifecycle, it will be able to inhibit productive infection. In contrast, if this inhibitor is added after the entry/fusion process is completed, the inhibitor will no longer be effective in blocking infection.

As a positive control for infection inhibition, HeLa cells were pretreated with increasing concentrations of Rac1 or Arp3 inhibitors 1 h before addition of virus. Alternatively, inhibitors were added to the cells at different time points after virus inoculation (1, 3, 5, or 7 h, Fig 3E) but prior to virus release (9 h post inoculation). When the Rac1 inhibitor EHT1864 or the Arp3 inhibitor CK548 were added 1, 3, or 5 h after VEEV exposure, VEEV infection rates were reduced to that detected with the positive control condition (pretreatment). However, addition of inhibitors 7 h after virus inoculation had significantly less effect on infection, suggesting that the inhibitors lose their antiviral activity at this time. Similar results were obtained with VEEV TC-83 in the context of a single replication cycle (S3A and S3B Fig); both EHT1864 and CK548 inhibitors reduced VEEV TC-83 infection when they were added up to 7 h post inoculation. Furthermore, when the inhibitors were added to HeLa cells 5 h following VEEV inoculation, VEEV titer in the media was significantly reduced (approximately 80 to >7,000 fold reduction, S3C Fig). Since the inhibitors exhibited antiviral activity when they were added 5 h post virus inoculation but significantly lost their antiviral affect when they were added 7 h post virus inoculation, these results indicate that Rac1 and Arp3 most likely play a role in the VEEV life cycle sometime between 5 h and 7 h post virus inoculation. Since one lifecycle of the virus takes at least 9 h to complete, and since transcription/replication is initiated prior to 5 h post virus

inoculation, these results indicate that these inhibitors act at a late stage of virus infection.

To further confirm that Rac1 and Arp3 do not act at earlier stages (entry and replication), we first utilized a VEEV cell entry surrogate system composed of retroviral pseudotypes (Moloney murine leukemia virus, MoMLV) encoding eGFP and carrying the viral envelope proteins [27,28]. HeLa cells pretreated with control siRNA or with siRNAs targeting Rac1 or Arp3 were transduced with MoMLV-VEEV or MoMLV-EBOV (non-alphavirus control). As previously reported, MoMLV-EBOV entry into HeLa cells was reduced following knockdown of Rac1 or Arp3 [29,30] (Fig 5F). However, Rac1 or Arp3 knockdown had no or minimal effect on MoMLV-VEEV transduction rates, indicating that envelope-mediated entry of VEEV is independent of these two proteins.

Next, we examined the effect of the various inhibitors on total E2 protein levels in the context of virus infection. None of the inhibitors had an effect on E2 protein levels as determined by western blot analysis (Fig 3H).

Finally, we tested the effect of Rac1 and Arp3 on alphavirus replication in infected cells by treating cells with siRNAs as described above or with inhibitors against Rac1 or Arp3. Intracellular vRNA levels were determined by qRT-PCR. The siRNAs as well as the inhibitors had no significant effect on intracellular vRNA levels (Fig 3H-I). Similar results were obtained when the inhibitors were tested for their effect on CHIKV replication using a previously published replicon system (Fig S3D [31]).

Overall, these results indicate that Rac1 and Arp3 function after virus entry and replication, but prior to budding and release.

Actin Plays a Dual Role in Alphavirus Infection

As mentioned above, Rac1, Arp3, and PIP5K1A all affect cellular actin dynamics [16-19].

Previous studies have demonstrated a role for actin in alphavirus infection [32,33]. For example, in the early stages of infection of another alphavirus, Semliki Forest virus, replication complexes are internalized via an endocytic process that requires a functional actin-myosin network [7]. However, our time-of-addition experiments suggest that Rac1 and Arp3 play a role later in infection. We therefore investigated whether actin dynamics might play an additional role at later stages of infection.

To this end, we performed time-of-addition experiments (similar to the ones described above) with actin polymerization inhibitors. Cells were either pretreated with increasing concentrations of inhibitors before addition of virus (positive control) or preincubated with virus and subsequently treated with inhibitors at different time points after infection (Fig 4A-B). Compared to the positive control condition (pretreatment), the actin polymerization inhibitors, latrunculin A and cytochalasin D, were less effective in inhibiting VEEV infection when they were added 1 h after virus inoculation (Fig 4A-B). This loss of antiviral activity is possibly due to the previously described role of actin in internalization of alphavirus replication complexes [7]. Inhibition of VEEV infection rates remained similar if actin polymerization inhibitors were added up to 5 h after virus inoculation. However, additional loss of antiviral activity was observed when the inhibitors were added at 7 h post virus inoculation. These results suggest that actin polymerization inhibitors target two separate steps in VEEV's life cycle, one early in infection and one late in infection.

Fig 4. Actin polymerization plays a role at a late stage of alphavirus infection.

(A and B) High-content quantitative image-based analysis of relative VEEV and VEEV TC-83 infection rates in time-of-addition experiments. (A) VEEV-infected HeLa cells (MOI=0.5) were

320 treated with increasing concentrations of latrunculin A at the indicated time points prior to (-1 h)
321 or after (+1–7 h) virus addition. Cells were fixed 20 h after addition of virus and stained for high-
322 content quantitative image-based analysis with virus-specific antibodies. **(B)** VEEV TC-83
323 (MOI=1)-infected HeLa cells were treated with cytochalasin D as in **(A)**. Cells were fixed 12 h
324 after addition of virus, stained, and analyzed as in **(A)**. **(C)** HeLa cells were infected with VEEV
325 (MOI=0.5) for 3 h and then treated with increasing concentrations of cytochalasin B,
326 cytochalasin D, latrunculin A, or nocodazole. Cells were fixed in formalin 17 h later, stained, and
327 analyzed as in **(A)**. **(A-C)** Results are normalized to DMSO-treated samples. **(D)** HeLa cells were
328 infected as in **(C)** for 3 h and then treated with increasing concentrations of cytochalasin D, or
329 latrunculin A. After 17 h, virus titer in the supernatants was determined by plaque assay. Values
330 represent the mean \pm SD, $n = 2$. **(E)** Primary human astrocytes were infected with VEEV TC-83
331 (MOI=0.005) for 5 h and then treated with increasing concentrations of inhibitors. After 6 h,
332 virus titer in the supernatants was determined by plaque assay. **(F)** Aliquots of the cells treated in
333 **(A)** were lysed and analyzed for E2 expression by immunoblotting (GAPDH was used as a
334 loading control). Densitometric analysis of western blots was performed with ImageJ. **(G)** VEEV
335 copy number (intracellular vRNA) in HeLa cells following treatment with inhibitors as
336 determined by qRT-PCR. HeLa cells were inoculated with VEEV TC-83 (MOI=2) and 5 h later
337 treated with the indicated inhibitors. Cells were lysed and analyzed for virus copy number 11 h
338 after virus addition. **(A-C, E, G)** Values represent the mean \pm SD, $n = 3$. *, $p < 0.05$; **, $p < 0.01$;
339 ***, $p < 0.001$; n.s., not significant, Student's t test (between the sample and DMSO-treated cells).

341 To further validate our results that actin might play a role in the later stages of the
342 alphavirus lifecycle, we tested the effect of various doses of actin polymerization inhibitors

(latrunculin A, cytochalasin B and D) or a microtubule-depolymerizing agent (nocodazole) on VEEV infection rate when added at various time points post virus inoculation. HeLa cells and primary human astrocytes were inoculated with VEEV first and inhibitors were added 3 (HeLa) or 5 (astrocytes) h later. Disruption of actin dynamics by the actin polymerization inhibitors reduced VEEV infection rates and VEEV titer in a dose-dependent manner without cytotoxicity (Fig 4C-E). Although some nocodazole-mediated inhibition of viral infection was observed, inhibition was not as significant as that observed with actin polymerization inhibitors and was accompanied by increased cytotoxicity (Fig 4C and S4A Fig). Phalloidin and tubulin staining demonstrated that the actin and microtubule cytoskeleton morphology was indeed disrupted upon treatment with these inhibitors (S4B-C Fig). These results further imply that actin polymerization might have an essential role in later stages of VEEV infection.

To determine if the actin polymerization inhibitors (latrunculin A and cytochalasin D) might block viral replication or E2 expression at later stages of infection, we inoculated cells with VEEV TC83 and 5 h later treated them with the inhibitors. Intracellular vRNA levels were determined by qRT-PCR 11 h after virus inoculation. Alternatively, cells were lysed and analyzed for E2 expression by immunoblotting. Figure 4F-G shows that both inhibitors had no significant effect on vRNA levels as well as E2 expression levels. Finally, no effect on virus replication was observed when the inhibitors were tested for their effect on a CHIKV replicon system (Fig S4D [31]). Together, the data suggests that the role of actin in the later stages of infection does not involve viral replication or late gene expression.

Alphavirus Infections Cause Major Intracellular Actin Rearrangements Late in Infection

To assess the possible role of actin in the later stages of alphavirus infection, we assessed temporal changes of actin rearrangements during the course of viral infection. HeLa cells were

infected with VEEV, CHIKV, or RVFV (used as a control) and co-stained at the indicated time points with antibodies against viral proteins and phalloidin. Confocal microscopy revealed major changes in the actin-staining pattern within alphavirus-infected cells (VEEV, CHIKV), as indicated by the accumulation of actin in large structures in the cytoplasm (i.e., actin foci, indicated by asterisks in Fig 5A). These foci co-localized with the alphavirus envelope protein E2 (Fig 5A). In contrast, such actin rearrangements were not observed in RVFV- or mock-infected cells (Fig 5A).

Fig 5. Alphavirus infection causes actin rearrangements into actin foci that are Rac1- and Arp3-dependent and that co-localize with Rac1, PIP5K1- α , and E2.

(A) Representative confocal images of mock-, VEEV-, CHIKV-, or RVFV-infected HeLa cells (MOIs = 0.5, 5, or 3, respectively). Cells were fixed and stained with virus-specific antibodies (VEEV and CHIKV E2, RVFV NP; shown in green) and phalloidin (red) 18 h (VEEV) or 24 h (CHIKV, RVFV) after infection. Nucleus staining is shown in blue. Representative actin foci are indicated by asterisks. (B) High-content quantitative image-based analysis was used to measure infection rates of VEEV, CHIKV, and RVFV (left panel), and the number of actin foci per cell (number of actin foci/total cell number, right panel). Analysis is based on single Z sections. ^{***}, $p < 0.0001$, Student's t test (between the sample and mock). (C) VEEV-infected HeLa cells (MOI=0.5) were fixed in formalin at the indicated time points, stained and analyzed as in (B). (B–C) Values represent the mean \pm SD, $n \geq 12$. (D) Representative confocal images of VEEV-infected HeLa cells (MOI=0.5) pretreated with the Rac1 inhibitor EHT1864 or Arp3 inhibitor CK548. Cells were fixed 18 h after virus addition and stained with VEEV E2-specific antibody (green), phalloidin (red), and a nuclear stain (blue). (E) High-content quantitative image-based

analysis was used to measure infection rates of VEEV and the number of actin foci per cell. (F) Confocal images of VEEV-infected HeLa cells (MOI=5). Co-localization of HA-tagged PIP5K1- α (top panel) or Rac1 (bottom panel) (blue), actin (red), and VEEV E2 (green), at a single z section is shown, as well as single channel intensities measured along lines crossing different actin clusters. Insets: zoom on actin filaments indicated by white arrows. VEEV was added to HeLa cells that were reverse-transfected with a plasmid encoding HA-tagged PIP5K1- α or tetracycline-induced T-Rex HeLa cells that expressed Rac1 fused to eGFP. Cells were fixed 20 h later, permeabilized, and stained with VEEV E2-specific antibody, phalloidin, and an antibody against HA.

Actin foci (measured as the number of foci per cell) were further quantified in mock-, VEEV-, CHIKV-, and RVFV-infected cells (Fig 5B). These foci were detected as early as 7 h after VEEV inoculation (Fig 5C) and could also be detected upon infection with other alphaviruses (EEEV, WEEV, and SINV, S5A Fig). We also tested whether alphavirus nsP1, which was previously shown to mediate disruption of actin stress fibers and induction of filopodia-like extensions [34], could induce generation of actin foci. Expression of VEEV TC83 nsP1 in HeLa cells did induce filopodia-like extensions. However, no actin foci were observed (S5B Fig). Overall, our results demonstrate that, as early as 7 h post inoculation with alphaviruses, infection causes major cellular actin rearrangements leading to the formation of actin foci that are not nsP1-dependent and that co-localize with the alphavirus envelope protein E2.

Rac1 and Arp3 Inhibitors Reduce Actin Focus Formation in Alphavirus-infected Cells

Because our data suggested that the function of Rac1 and Arp3, and the formation of actin foci,

take place late in infection (Figure 3 and 5), we speculated that Rac1 and Arp3 proteins might play a role in this alphavirus-induced actin remodeling. To test this hypothesis, HeLa cells were treated with increasing concentrations of Rac1 or Arp3 inhibitors, infected with VEEV, and subsequently stained with fluorescent phalloidin and antibodies against E2. Treatment with either the Rac1 (EHT1864) or Arp3 (CK548) inhibitor significantly reduced the number of actin foci and the percentage of infected cells in a dose-dependent manner (Fig 5D-E). In fact, under these conditions actin foci were rarely observed in confocal images even in E2-positive cells. These observations clarify that Rac1 and Arp3 function upstream of the major actin rearrangements detected in VEEV-infected cells.

Rac1 and PIP5K1- α Co-localize with E2 on Actin Foci and Actin Filaments

Since Rac1-PIP5K1- α complex formation plays a role in alphavirus infection (Fig 2) and because Rac1 inhibitor reduced actin foci formation in alphavirus-infected cells (Fig 5), we next examined whether both host factors could be observed on actin foci and/or filaments within alphavirus-infected cells. Basal-to-apical confocal section series of VEEV-infected HeLa cells are shown in Fig 5F. PIP5K1- α and Rac1 show increased co-localization with actin foci and E2 towards the apical area (S5C-D Fig). Both host factors are also detected along actin filaments, where they co-localize with E2 (Fig 5F, inserts).

Organization and Morphology of Actin Foci and their Co-Localization with the E2 Glycoprotein

To better characterize the nature of the observed actin foci within infected cells, we performed sequential scanning of cells stained for actin and alphavirus E2 in both stimulated emission depletion (STED) microscopy and confocal microscopy imaging modes (for comparison, see S6A Fig). With improved resolution of STED microscopy, actin foci within infected cells were

found to be clusters of filamentous actin with a diameter range of 5-11 μm (Fig 6A). Actin filaments within the clusters are seen with VEEV E2 puncta at their ends or along them (Fig 6A). On the cell periphery, E2 puncta are localized in proximity to actin filaments (Fig 6A). E2 puncta are also observed at the ends of actin filaments in primary human astrocytes, and in CHIKV-infected HeLa cells (Fig 6B).

Fig 6. Alphavirus E2 co-localizes with actin filaments and associates with actin.

(A-B) Representative STED images of HeLa cells or primary human astrocytes infected with VEEV or with CHIKV (MOI=5). Cells were fixed, permeabilized, and stained with E2-specific antibodies (green) and phalloidin (red). Scale bar: 10 μm . (C) Electron-microscopic images of VEEV-infected HeLa cells (MOI=5). CPV-II structures and thin filaments, which probably correspond to actin, are indicated by filled and open arrows, respectively. An asterisk indicates CPV-I structures. (D) Western blot analysis of input lysates and immunoprecipitates (IP) of mock-, VEEV-, or RVFV-infected HeLa cells under different lysis conditions. Cells were infected for 8 h (MOI=1), lysed, and VEEV E2-, RVFV Gn-, or actin-binding proteins were immunoprecipitated using specific antibodies and immunoblotted with antibodies against VEEV E2, RVFV Gn, or actin. (*) indicates a non-specific band.

In a series of basal- (Section 7) to-apical (Section 25) confocal sections, a single VEEV-infected cell can be seen with an actin cluster (S6B Fig). E2 co-localizes with the actin cluster, and cytoplasm/nucleus staining demonstrates that the generated actin cluster is localized within the cell (S6C Fig). In contrast, co-localization of E2 and microtubules was not significant (S6B Fig).

We also performed electron-microscopic studies to examine the localization of cytoskeletal elements relative to alphaviral CPV-II structures, which compartmentalize the viral glycoproteins E1 and E2 and serve as transport vehicles for the glycoproteins from the TGN to the viral budding sites on the plasma membrane. Electron-microscopic studies of VEEV-infected cells (Fig 6C) show CPV-II structures alongside or at the end of thin filaments, which, based on size and morphology, most likely correspond to actin filaments [12]. CPV-I replication compartments are also present within these cells (Fig 6C, bottom right panel) [9].

Alphavirus E2 Glycoprotein Associates with Actin

Because alphavirus E2 co-localized with actin filaments in infected cells, we next tested whether VEEV E2 associates with actin. HeLa cells were infected with VEEV or RVFV (control) or left uninfected (mock). Virus envelope protein-binding factors were subsequently immunoprecipitated from cell lysates with antibodies to surface glycoproteins E2 (VEEV), or Gn (RVFV). Western blot analysis of the immunoprecipitated fraction (IP) showed enrichment of actin in E2 immunoprecipitates from VEEV-infected cells relative to mock-infected control (more than 4-fold increase by densitometry analysis, Fig 6D, left panel). Such an increase in immunoprecipitated actin was not observed or was minimal in Gn immunoprecipitates from RVFV-infected cells (1.5-fold or less increase by densitometry analysis, Fig 6D, middle panel). To confirm the E2-actin association, we repeated these immunoprecipitation assays using more stringent lysis and washing conditions and performed the reverse experiment using an antibody against actin to examine its ability to immunoprecipitate E2 from VEEV-infected cells. Our results show that antibodies against E2 immunoprecipitated actin (more than 8-fold increase by densitometry analysis) and antibodies against actin immunoprecipitated E2 (more than 4-fold increase by densitometry analysis) from VEEV-infected, but not from mock-infected cells (Fig

6D right panel). These results indicate that VEEV E2 either directly or indirectly associates with actin in lysates from infected cells. However, since our lysis buffer included detergent (NP-40), the observed association between E2 and actin was most likely not in the context of CPV-II structures.

Actin, Rac1, and Arp3 Inhibitors Interfere with Alphavirus E2 Trafficking from TGN to the Cell Surface

E2 was mainly localized in perinuclear puncta in cells treated with the Rac1 and Arp3 inhibitors, whereas in DMSO-treated cells E2 was found throughout the cytoplasm and at the plasma membrane (Fig 5D). Previous studies have demonstrated that the alphavirus glycoproteins E1/E2 are transported from the TGN to the cell surface via TGN-derived vacuoles [12,35], suggesting that the observed puncta might represent TGN or TGN-derived vacuoles. We therefore hypothesized that Rac1- and Arp3-dependent actin remodeling in alphavirus-infected cells might be important for trafficking of E1/E2. To test this hypothesis, primary human astrocytes were treated with DMSO, EHT1864, or CK548 and then infected with VEEV. Cells were stained with antibodies against VEEV E2 glycoprotein and the TGN marker TGN46. VEEV E2 was primarily located at the cell surface in control DMSO-treated cells (Fig 7A, zoom 1). In some of the cells, E2 puncta co-localized with TGN46. However, upon treatment with the Rac1 or Arp3 inhibitors, E2 localization in TGN46-positive puncta was significantly enhanced (Fig 7A, zoom 2 and 3) and less E2 glycoprotein was observed at the cell surface. Quantification of TGN46-to-cell-surface ratio of E2 staining intensity in control- or compound-treated VEEV-infected astrocytes is shown in S7A Fig. Similar experiments performed in HeLa cells using the inhibitors and the TGN marker GGA3 yielded comparable results (S7B Fig).

Figure 7. Actin, Rac1, and Arp3 inhibitors block E2 transport to cell surface.

(A) Representative confocal images of primary human astrocytes treated with DMSO, EHT1864, or CK548 and subsequently infected with VEEV (MOI=0.005) for 18 h. Cells were stained with VEEV E2 (green)- and TGN46-specific antibodies (red), and a nuclear stain (blue).

Representative cells showing co-localization of E2 and TGN46 are indicated with white arrows.

(B and C) Upper panel: Geometrical mean fluorescent intensity of cell-surface E2 staining in

HeLa cells infected with VEEV TC-83 (MOI=10) and treated with EHT1864, CK548,

cytochalasin D, latrunculin A, or nocodazole as measured by flow cytometry. HeLa cells were

infected with VEEV TC-83 for 5 h and subsequently treated with increasing concentrations of

the inhibitors or DMSO (control). Five (B) or six (C) h later cells were dissociated and stained

against VEEV E2 and with a 7-amino-actinomycin D viability dye. Bottom panel: Immunoblot

of total E2 expression in whole cell lysates of HeLa cells described in (B) and (C). GAPDH was

used as a loading control. Densitometric analysis of western blots was performed with ImageJ.

(D) Model for trafficking of alphavirus E2 from the TGN to the cell surface. (1) Biogenesis of

E1/E2-containing vacuoles (CPV-II) at the TGN is dependent on Arf1 and Rac1. (2) E1/E2-

containing CPV-II traffic to the cell surface via actin by a Rac1- and Arp3-dependent

mechanism. Rac1 and PIP5K1- α are also localized to these actin filaments. (3) Actin tunneling

nanotubes mediate alphavirion spread to neighboring cells.

In addition, we developed a flow cytometry-based assay for detection of VEEV E2 on the plasma membrane. We examined cell-surface expression of E2 following treatment with actin polymerization, microtubules depolymerization, Rac1, or Arp3 inhibitors. HeLa cells were infected with VEEV and 5 h later treated with increasing concentrations of EHT1864, CK548,

latrunculin A, cytochalasin D, or nocodazole. Cells were subsequently stained for surface expression of E2 and with the 7-amino-actinomycin D viability dye. Concomitantly, an aliquot of the cells of each treatment group was lysed and analyzed for total E2 expression in whole-cell lysates. None of the inhibitors significantly affected total protein levels of E2. However, the actin, Rac1, and Arp3 inhibitors decreased geometric mean fluorescence intensity of E2 on the cell surface in a dose-dependent manner (Fig 7B and 7C). In contrast, the microtubule inhibitor, nocodazole, had no effect on cell surface E2 expression. The effect of the actin, Rac1, and Arp3 inhibitors on E2 surface expression was specific as no or minimal effect was observed on surface expression of cellular CD44 (S7C Fig).

Overall, our data suggest that actin, Rac1, and Arp3, but not microtubule, inhibitors might interfere with trafficking of E2 from the TGN or TGN-derived vacuoles to the cell surface.

Localization of VEEV-induced Actin Foci, Rac1, and PIP5K1- α in Relation to the TGN

To examine if the actin remodeling observed in alphavirus-infected cells is associated with any TGN membrane structures, we stained VEEV-infected cells with the TGN marker TGN46. Actin clusters were observed in the vicinity of TGN46 (Fig S8A) and VEEV E2 was detected on these actin clusters as well as co-localized with the TGN marker. Rac1 was also found to co-localize with the TGN marker and E2, whereas PIP5K1- α co-localized with E2 but not with TGN46 (Fig S8B and C).

Discussion

Reorganization of the host cytoskeleton varies among infections by different viruses and can play a role in every stage of the viral life cycle. Examples include virion movement (surfing)

towards entry sites and actin-enhanced endocytic entry pathways as well as actin-based, filopodial extensions (termed tunnelling nanotubes) that act as bridges to facilitate virus spread (reviewed in [36-39]).

Here, using an siRNA screen, we identified trafficking host factors that are important for alphavirus infection and are crucial regulators of the actin cytoskeleton. To date, Rac1- and Arp2/3-mediated actin rearrangements have mainly been associated with virus uptake and entry [30,40-44]. Rac1 is predominantly known as a key regulator of the actin cytoskeleton at the plasma membrane [45]. There, Abelson interactor 1 (Abi1) and Wiskott-Aldrich syndrome protein (WASP) family verprolin-homologous protein (WAVE), but not neural (N)-WASP, are essential for Rac1-dependent membrane protrusion and macropinocytosis [46].

Recently, however, Rac1, the Arp2/3 complex, and actin have emerged as major factors in the secretory pathway in processes such as biogenesis and motion of Golgi-derived transport carriers to the plasma membrane [47-50]. During formation of TGN carriers, Rac1 functions downstream of ADP-ribosylation factor 1 (Arf1). Arf1 recruits clathrin/adaptor protein 1 (AP-1)-coated carriers and a complex composed of cytoplasmic fragile X mental retardation 1 (FMR1)-interacting protein (CYFIP), nucleosome assembly protein 1 (NAP1), and Abi1 to the TGN. Rac1 and its exchange factor Rho guanine nucleotide exchange factor 7 (ARHGEF7) bind CYFIP and trigger N-WASP- and Arp2/3-mediated actin polymerization necessary to tubulate clathrin-AP-1-coated carriers [51]. Therefore, during alphavirus infection, Rac1 could potentially be recruited to the TGN to mediate biogenesis of E2-containing vesicles and/or their transport from the TGN to the cell surface via actin (see model, Fig 7D). In support of this hypothesis, some of the host factors mentioned above, such as clathrin heavy chain 1 (CLTC), AP-1 subunits (AP1M1), and Arf1 were identified as hits in our primary and validation siRNA knockdown

573 screens (S1 and S2 Tables). Furthermore, siRNAs targeting N-WASP reduced the infection rate
574 of both VEEV and CHIKV (S1B Fig). Finally, during VEEV infection Rac1 was found to co-
575 localize with E2 at the TGN (Fig S8). Hence, it is plausible that Arf1 functions upstream of Rac1
576 to facilitate biogenesis and/or motion of E2 transport carriers from the TGN to the plasma
577 membrane and that this transport is mediated by N-WASP.

578 Viruses have evolved specific egress pathways for transporting viral components to the
579 plasma membrane, often using the cell's secretory pathway via the endoplasmic reticulum, the
580 Golgi, and even transport vesicles. Most exocytic transport of cellular secretory cargo to the
581 plasma membrane relies on microtubules for long-range translocations [52,53]. The microtubule
582 network is also emerging as the preferred cytoskeletal element recruited for transportation of
583 viral components to the cell surface [54-57]. Examples are delivery of influenza A virus
584 hemagglutinin membrane glycoprotein to the apical surface of MDCK cells [58] and vesicular
585 stomatitis Indiana virus glycoprotein G trafficking from the TGN-to-plasma membrane [59].

586 In contrast, our results demonstrate that transport of the alphavirus membrane glycoprotein
587 E2 is at least in part dependent on actin and actin regulators (Rac1 and Arp3). We hypothesize
588 that the coordinated activities of PIP5K1- α , Rac1, and the Arp2/3 complex might mediate
589 alphavirus envelope E2 trafficking from the TGN to the cell surface via actin. Several results
590 support this actin-dependent transport model (Fig 7D). First, time-of-addition experiments with
591 Rac1 and Arp3 inhibitors demonstrated that both factors function at a late stage of virus infection
592 (Fig 3). Second, within a similar time frame (concomitantly with E2 expression in infected cells)
593 major actin rearrangements into clusters occur in alphavirus-infected cells (Fig 3 and 5). Super
594 high-resolution fluorescence microscopy and electron microscopy show that E2 or E1/E2-
595 containing CPV-II structures, respectively, are localized along or at the end of actin filaments.

Rac1 and PIP5K1- α also co-localize with E2 on actin foci (Fig 5), and in infected cell lysates E2 envelope protein was found to associate (either directly or indirectly) with actin (Fig 6). Third, Rac1 and Arp3 inhibitors blocked formation of virus-induced actin clusters (Fig 5). In cells treated with actin, Rac1, or Arp3 inhibitors, most of the E2 staining was found to localize with TGN markers, and E2 levels at the cell surface were reduced (Fig 7). We have not yet examined the role of actin, PIP5K1- α , Rac1, and the Arp2/3 complex in E1 trafficking. However, since E1 and E2 are oligomerized into trimeric complexes during transit to the plasma membrane in CPV-II structures [60] we speculate that these host factors will have a similar function in trafficking of both viral proteins.

Actin dynamics are involved in numerous aspects of intracellular transport. However, little is known regarding manipulation of these host machineries by pathogenic alphaviruses. Viruses can serve as unique tools to decipher how a particular cargo recruits actin filament tracks and the host factors and motors associated with these movements. Our results suggest a previously unidentified role of host factors Rac1, Arp3 and PIP5K1- α late in alphavirus infection via actin remodeling that possibly mediates transport of alphavirus envelope glycoproteins from the TGN to the cell surface. It is important to note that although our data indicate that actin plays a major role in alphavirus glycoprotein transport, our experiments do not exclude the existence of other, parallel, transport mechanisms mediated by intermediate filaments or microtubules. Recombinant alphaviruses expressing tagged E2 could be useful to further substantiate our findings. However, until now, we have not succeeded in rescuing such viruses. Finally, our high-content siRNA screen reveals novel host regulators of alphavirus infection and potential therapy targets.

Materials and Methods

siRNA Screens

An arrayed library targeting 140 trafficking genes (Dharmacon Human ON-TARGETplus siRNA Library - Membrane Trafficking - SMARTpool, G-105500-05, Thermo Scientific, Lafayette, CO) was used to transiently reverse-transfected HeLa cells (10,000 cells per well, 96-well format) in triplicate at a 30 nM final concentration, using HiPerfect (Qiagen). Cells were washed on the following day and 24 h later infected with VEEV ICS-SH3 at a multiplicity of infection (MOI) of 0.5 for 20 h. Cells were fixed with 10% formalin (Val Tech Diagnostics), and stained for high-content quantitative image-based analysis. The screen was repeated three times. In 6 wells on each plate, cells were transfected with a negative control siRNA (NT, siCONTROL Non-Targeting siRNA #2, Dharmacon D-001210-02). The infection rate of control siRNA-transfected cells was optimized to yield, on average, 70–80%, following multiple virus replication cycles.

For the primary screen, siRNA pools were classified as hits if the average of triplicate wells showed that the percentage of VEEV-positive cells was decreased by more than 30% as compared to that observed with the control siRNA wells on the plate (Z-score <-2 SD). In the validation screen, the individual oligomers comprising each pool were placed into separate wells, and the screen was repeated. siRNA targets were considered validated if two or more of the individual oligomers were classified as hits compared to the control wells on the plate (similar parameters as above), and if the cell number was not less than 30% of the average of the negative control wells on the plate. The percent of infected cells relative to controls, as well as the normalized cell numbers (normalized to control siRNA) is provided in Table S1.

Table 1. Sources of human-sequence reagents

cDNA/Gene	Primer Function	Catalog Number /	Vendor
-----------	-----------------	------------------	--------

		Sequence	
RAC1-1	siRNA	J-003560-14/ GUGAUUUCAUA GCGAGUUU	Dharmacon/Thermo Scientific
RAC1-2	siRNA	J-003560-15/ GUAGUUCUCAG AUGCGUAA	Dharmacon/Thermo Scientific
RAC1-3	siRNA	J-003560-16/ AUGAAAGUGUC ACGGGUAA	Dharmacon/Thermo Scientific
RAC1-4	siRNA	J-003560-17/ GAACUGCUAUU UCCUCUAA	Dharmacon/Thermo Scientific
RAC1-5	siRNA	s11711	Applied Biosystems/Life Technologies
RAC1-6	siRNA	s117112	Applied Biosystems/Life Technologies
RAC1-7	siRNA	s11713	Applied Biosystems/Life Technologies
ACTR3-1	siRNA	J-012077-06/ GCAGUAAAGGA GCGCUAUA	Dharmacon/Thermo Scientific
ACTR3-2	siRNA	J-012077-07/ GUGAUUGGCAG CUGUAUUA	Dharmacon/Thermo Scientific

ACTR3-3	siRNA	J-012077-08/ GGAAUUGAGUG GUGGUAGA	Dharmacon/Thermo Scientific
ACTR3-4	siRNA	J-012077-09/ GCCAAAACCUA UUGAUGUA	Dharmacon/Thermo Scientific
ACTR3-5	siRNA	s19640	Applied Biosystems/Life Technologies
ACTR3-6	siRNA	s19641	Applied Biosystems/Life Technologies
ACTR3-7	siRNA	s19642	Applied Biosystems/Life Technologies
PIP5K1A-1	siRNA	J-004780-09/ ACACAGUACUC AGUUGAUA	Dharmacon/Thermo Scientific
PIP5K1A-2	siRNA	J-004780-10/ GCACAACGAGA GCCCUUAA	Dharmacon/Thermo Scientific
PIP5K1A-3	siRNA	J-004780-11/ GUGGUUCCCUA UUCUAUGU	Dharmacon/Thermo Scientific
PIP5K1A-4	siRNA	J-004780-12/ GUAAGACCCUG CAGCGUGA	Dharmacon/Thermo Scientific
PIP5K1A-5	siRNA	s15932	Applied Biosystems/Life

			Technologies
WASL-1	siRNA	s17132	Applied Biosystems/Life
			Technologies
WASL-2	siRNA	s17133	Applied Biosystems/Life
			Technologies
WASL-3	siRNA	s17134	Applied Biosystems/Life
			Technologies
PPIB	qRT-PCR	Hs00168719_m1	Applied Biosystems/Life
			Technologies
PIP5K1A	qRT-PCR	Hs00801004_s1	Applied Biosystems/Life
			Technologies
TC83 forward primer	qRT-PCR	CTTGGCAAACC TCTGGCAGC	Life Technologies
TC83 Probe	qRT-PCR	6FAM- CTCTTCATGCAA TGCCCTTCTCCT GTCA	Life Technologies
TC83 reverse primer	qRT-PCR	ATACCCACTCG GTTCCAGCG	Life Technologies
Rac1 K186E forward primer	Site-directed mutagenesis	5'-CCC GCC TCC CGT GAA GAA GAA GGA GAG AAA ATG CC-3'	Integrated DNA Technologies
Rac1 K186E reverse primer	Site-directed mutagenesis	5'-GGC ATT TTC TCT CCT TCT	Integrated DNA Technologies

TCT TCA CGG

GAG GCG GG-3'

641

642 **Cell Lines and Plasmid Constructs**

643 HeLa (ATCC, #CCL-2), BHK-21 (ATCC, #CCL-10), and Vero cells (ATCC, #CCL-81) were
644 maintained in Eagle's minimum essential medium supplemented with 10% fetal calf serum. T-
645 REx-HeLa cells expressing human wild type Rac1 fused to eGFP, and Flp-In 293 T-REx cells
646 expressing human wild type Rac1, Rac1 G12V, Rac1 T17N, Rac1 K186E or CAT upon
647 tetracycline induction were generated by using the T-REx System or the Flp-In T-REx system,
648 respectively, according to the manufacturer's instructions (Life Technologies). Cells were
649 induced to express wild-type human Rac1, variants thereof, or CAT in 96-well plates by adding
650 tetracycline (1 µg/ml) to the growth medium. Normal human astrocytes were obtained from
651 Lonza and maintained according to the provider's instructions. Plasmids encoding Rac1 variants
652 (wild-type Rac1, Rac1 T17N or Rac1 G12V) fused to a myc tag were purchased from the
653 Missouri S&T cDNA Resource Center (www.cdna.org). A plasmid encoding Rac1 K186E was
654 generated by using the QuikChange Lightning Site-Directed Mutagenesis Kit (Agilent
655 Technologies). A plasmid encoding pcDNA3-EGFP-Rac1-wt was obtained from Addgene.

656 **Antibodies, Dyes, and Pharmacological Inhibitors**

657 Mouse monoclonal antibodies against CHIKV (2D21-1), EEEV (1C2), VEEV (1A4A-1), WEEV
658 (9F12), and RVFV envelope glycoprotein Gn (4D4) and NP (R3-ID8-1-1) were obtained from
659 USAMRIID archives [61]. Goat antibody against VEEV capsid (C) or envelope protein was
660 generously provided by AlphaVax (via Kurt Kamrud). Rabbit antibodies against Arp3, actin, N-
661 WASP, GAPDH, FLAG, and HA were obtained from Sigma-Aldrich. Mouse monoclonal
662 antibodies against actin, CD44, GGA3, and Rac1 were purchased from BD Transduction

Laboratories. Rabbit antibody against α/β -tubulin was obtained from Cell Signaling Technology. Sheep anti-human TGN46 antibody was from AbD Serotec. Alexa Fluor-conjugated antibodies and phalloidin, Hoechst 33342, and HCS CellMask Red were obtained from Life Technologies. All chemical inhibitors were purchased from Sigma-Aldrich, with the exception of EHT1864 (Tocris Bioscience). Cells were incubated with inhibitors for 1 h before addition of viruses unless otherwise indicated in the figure legend.

Virus Infections, Viral Transduction, and Replicon Assays

Infections with VEEV IC-SH3, EEEV FL91-4679, WEEV CBA87, RVFV ZH501, and CHIKV AF15561 were conducted under Biosafety Laboratory 3 conditions. All alphaviruses were propagated in BHK-21 cells and purified via sucrose gradients. RVFV was propagated in Vero cells. Viral infectivity was titrated by plaque assays as previously described [62].

MoMLV-eGFP pseudotypes carrying the VEEV envelope proteins E1/E2 or Ebola virus envelope GP_{1,2} (control) were produced as previously described [27,28,63]. MoMLV-eGFP pseudotypes were added to siRNA-treated HeLa cells for 6 h. Cells were then washed and supplemented with growth medium. Cell transduction efficiency was determined 2 days later by measuring eGFP expression using an Opera confocal reader (PerkinElmer).

For CHIKV replicon assays, we used the previously described BHK-CHIKV-NCT cells, which contain the CHIKV replicon with two reporter genes, *Rluc* and *EGFP* [31]. BHK-CHIKV-NCT cells were seeded onto 96-well plates at densities of 2×10^4 cells/well, incubated overnight, and treated with the indicated compounds at various concentrations. After exposure for 48 h, the *Renilla* luciferase (*Rluc*) activity resulting from the translation of CHIKV-*Rluc* genomic RNA was determined from the lysates using a *Renilla* luciferase assay kit (Promega) with a Tecan microplate reader.

Immunoprecipitation and Western Blot Analyses

HeLa cells in 6-well plates were infected with VEEV TC-83 or RVFV MP12 (MOI=1) for 8 h. Cells were lysed in a mild lysis buffer (50 mM Tris pH 7.4, 50 mM NaCl, 0.2 mM EDTA, and 1% Triton X-100) or a lysis buffer (25 mM Tris pH 7.4, 150 mM NaCl, 1 mM EDTA, 5% glycerol, and 1% NP-40) from Pierce Crosslink Immunoprecipitation Kit supplemented with Complete protease inhibitor cocktail (Thermo Scientific Pierce). Cleared lysates were incubated overnight at 4°C with protein A/G beads (Thermo Scientific Pierce) and VEEV E2- or RVFV Gn-specific antibodies or with beads cross-linked to antibodies against VEEV E2 or actin. Cell lysate immunoprecipitates were analyzed by SDS-PAGE and immunoblotting using the indicated antibodies.

For western blot analyses, cells were lysed with RIPA lysis and extraction buffer supplemented with complete protease inhibitor cocktail (Thermo Scientific Pierce). Cleared lysates were analyzed by SDS-PAGE and immunoblotting using WesternBreeze chromogenic or chemiluminescent kits (Life Technologies) and the indicated antibodies. Densitometric analysis of western blots was performed with ImageJ [64].

Stimulated Emission Depletion Microscopy (STED)

Cells were grown on glass cover slips and inoculated with VEEV or CHIKV for 1 h. Cells were fixed 20 h (VEEV) or 48 h (CHIKV) later, permeabilized with 0.5% Triton X-100 (Sigma-Aldrich) in PBS, blocked with 3% BSA in PBS for 1 h, and stained using mouse anti-E2 antibodies (1:1,000 dilution), followed by ATTO 647N Goat Anti-Mouse IgG (Active Motif) (1:2,000 dilution). Actin was stained with Phalloidin ATTO 565 (Sigma-Aldrich) (1:80 dilution). Slides were mounted in ProLong Gold Antifade Reagent (Life Technologies) and dried overnight at room temperature before imaging. All confocal images were acquired on the Leica SP5 TCS

2C STED confocal system (Leica Microsystems) equipped with Leica's inverted DMI 6000 microscope and STED 100x oil objective. Images were acquired at an imaging speed of 400 Hz, pin hole set to Airy1, line average of 6, and 1024 X 1024 formats. For STED of ATTO dyes, the pulsed Ti:SA infra red laser (Mai Tai, model # MAI TAI BB990, Spectra-Physics) was tuned to 740 nm.

Electron Microscopy

HeLa cells grown on a MatTek dish (MatTek corporation, MA) were infected with VEEV TC83 (MOI=5) for 20 h. Cells were fixed for 1 h in primary fixative (2.5% formaldehyde, 2.5% glutaraldehyde, 0.1 M sodium cacodylate, pH 7.4), washed three times in ice-cold 0.1 M sodium cacodylate buffer, incubated with 1% osmium tetroxide in 0.1 M sodium cacodylate for 1 h, washed three times with distilled water, stained and stabilized on ice in ice-cold 2% uranyl acetate for 1 h and successively dehydrated on ice in ethanol series of 22%, 50%, 75%, and 95%. The cells were then dehydrated three times at room temperature in 100% ethanol and infiltrated in well-mixed 50% ethanol, 50% Durcupan ACM resin (Fluka, Sigma-Aldrich) for 1 h with agitation. Cells were infiltrated twice by 100% Durcupan ACM for 3 h with agitation, after which the samples were placed in an oven and allowed to polymerized at 60 °C for at least 48 h. The glass coverslip was peeled away from the bottom using a razor blade and the selected area was cut out and glued to a block for sectioning. Thin sections (approximately 80 nm) were collected and pre-stained with 1% uranyl acetate and Sato lead before examination on a JEOL 1011 transmission electron microscope at 80 kV. Digital images were acquired using an AMT camera system.

Immunofluorescence and High-content Quantitative Image-based Analysis

Plasmid encoding HA-tagged PIP5K1 α was generously provided by Dr. Richard Anderson (University of Wisconsin). Plasmid encoding FLAG-tagged nsP1 was generated in-house by PCR. Plasmids were transiently reverse-transfected into HeLa cells on glass coverslips (Fisher Scientific) using Lipofectamine LTX Reagent (Life Technologies). T-REx HeLa cells on glass coverslips were induced with tetracycline for 24 h to express Rac1-eGFP. VEEV-infected cells were fixed, permeabilized, and blocked as described for STED. After incubation with primary antibodies and fluorescent secondary antibodies, slides were mounted as described for STED and air-dried before imaging with a Leica TCS-SP5 confocal/multiphoton microscope (Leica Microsystems). All confocal images represent a single plane acquired with a 100 \times oil objective. Similar experimental conditions were used for imaging studies of actin, tubulin, TGN46, and VEEV E2 in HeLa cells. Co-localization analysis of tubulin or actin with VEEV E2 was performed with the ImageJ program using the Interactive 3D Surface Plot plugin [64].

For analysis of the siRNA screen, cells were stained without prior permeabilization. Cells inoculated with CHIKV, EEEV, RVFV, WEEV or SINV or cells processed for phalloidin or TGN staining were permeabilized prior to blocking as described above. Cells were then stained with murine monoclonal antibodies against the indicated viral proteins (1:1,000 dilution) and, where indicated, against TGN46 or GGA3 (1:250 dilution). Subsequently, cells were stained with appropriate Alexa Fluor-conjugated antibodies (1:1,000 dilution), and Alexa Fluor 568 Phalloidin (1:100 dilution) where indicated. All infected cells were also stained with Hoechst 33342 and HCS CellMask DeepRed for nuclei and cytoplasm detection, respectively.

High-content quantitative imaging data were acquired and analyzed on an Opera QEHS (quadruple excitation high sensitivity) confocal reader (model 3842 and 5025; Perkin-Elmer), at two exposures using a $\times 10$ air, $\times 20$ water, or $\times 40$ water objective lenses as described in [65].

Analysis of the images was accomplished using Acapella 2.0, 2.6, 2.7 (Perkin-Elmer) scripts in Evoshell or the building-blocks interface in the Columbus image analysis server. Nuclei and cytoplasm staining were used to determine total cell number and cell borders, respectively. Mock-infected cells were used to establish a fluorescence intensity threshold for virus-specific staining. Quantification of virus positive cells was subsequently performed based on mean fluorescent intensities in the virus-specific staining channel. Infection rates were then determined by dividing the number of virus positive cells by the total number of cells measured. Detailed pipelines for image-based quantification of alphavirus-induced actin foci and TGN46-to-plasma membrane E2 staining intensity ratio are available upon request. At least 5000 cells and up to 15,000 cells were analyzed per replicate in drug- or siRNA-treated cells. For actin foci analysis, 1000–1500 cells were used per replicate. For analysis of TGN46-to-plasma membrane E2 staining intensity ratio, 700 cells were used per replicate.

Flow Cytometry

HeLa cells in 12-well plates were inoculated with VEEV TC-83 (MOI=10) for 5 h. DMSO, EHT1864, CK548, nocodazole, latrunculin A, or cytochalasin D were subsequently added at the indicated concentrations. Five or 6 h later, cells were detached with Cell Dissociation Buffer (Life Technologies) and washed with flow buffer (PBS/0.5% BSA/2mM EDTA). Cells were incubated with mouse anti-VEEV E2, or CD44 primary antibody (1:1,000 dilution in flow buffer) for 30 min on ice and then washed twice with ice-cold flow buffer. Cells were incubated for 20 min in the dark with Alexa Fluor 488 Goat Anti-Mouse IgG secondary antibody (Life Technologies) (1:5,000 dilution in ice-cold flow buffer) and with 7-amino-actinomycin D to exclude dead cells from analysis (1:500 dilution). Following two more washes with ice-cold flow

buffer, cells were fixed in 1% paraformaldehyde. Cytometric collection was performed using a FACS Canto II (BD Biosciences), and data were analyzed using Flowjo v7.6.5 (TreeStar).

qRT-PCR

VEEV TC-83 RNA yields in the media and in the cells as well as relative expression levels of PIP5K1 α in siRNA-treated HeLa cells were determined by qRT-PCR as previously described [65]. Serial 10-fold dilutions of the assayed (10^2 to 10^7 copies) virus were used as standards. Relative expression levels were determined by using the comparative C_T method.

Statistical Analysis

Data are representative of at least three independent experiments, and values are given as mean of triplicates \pm standard deviation (SD) unless otherwise indicated. Statistical significance was determined by the paired Student's t test.

Acknowledgments

We thank Laura Bollinger (IRF-Frederick), Thomas Postler (Columbia University), Philip Kranzusch (University of California, Berkeley), and David Cureton (Centers for Disease Control and Prevention) for critically editing the manuscript. We thank Candace Blancett (USAMRIID) for preparing EM samples. The content of this publication does not necessarily reflect the views or policies of the US Department of the Army, the US Department of Defense or the US Department of Health and Human Services or of the institutions and companies affiliated with the authors.

References

1. Weaver SC, Ferro C, Barrera R, Boshell J, Navarro JC (2004) Venezuelan equine encephalitis. *Annu Rev Entomol* 49: 141-174.

- 799 2. Zacks MA, Paessler S (2010) Encephalitic alphaviruses. *Vet Microbiol* 140: 281-286.
- 800 3. Weaver SC, Osorio JE, Livengood JA, Chen R, Stinchcomb DT (2012) Chikungunya virus
801 and prospects for a vaccine. *Expert Rev Vaccines* 11: 1087-1101.
- 802 4. Van Bortel W, Dorleans F, Rosine J, Blateau A, Rousset D, et al. (2014) Chikungunya
803 outbreak in the Caribbean region, December 2013 to March 2014, and the significance
804 for Europe. *Euro Surveill* 19.
- 805 5. Froshauer S, Kartenbeck J, Helenius A (1988) Alphavirus RNA replicase is located on the
806 cytoplasmic surface of endosomes and lysosomes. *J Cell Biol* 107: 2075-2086.
- 807 6. Frolova EI, Gorchakov R, Pereboeva L, Atasheva S, Frolov I (2010) Functional Sindbis virus
808 replicative complexes are formed at the plasma membrane. *J Virol* 84: 11679-11695.
- 809 7. Spuul P, Balistreri G, Kaariainen L, Ahola T (2010) Phosphatidylinositol 3-kinase-, actin-, and
810 microtubule-dependent transport of Semliki Forest Virus replication complexes from the
811 plasma membrane to modified lysosomes. *J Virol* 84: 7543-7557.
- 812 8. Grimley PM, Berezesky IK, Friedman RM (1968) Cytoplasmic structures associated with an
813 arbovirus infection: loci of viral ribonucleic acid synthesis. *J Virol* 2: 1326-1338.
- 814 9. Kujala P, Ikaheimonen A, Ehsani N, Vihinen H, Auvinen P, et al. (2001) Biogenesis of the
815 Semliki Forest virus RNA replication complex. *J Virol* 75: 3873-3884.
- 816 10. Garoff H, Wilschut J, Liljestrom P, Wahlberg JM, Bron R, et al. (1994) Assembly and entry
817 mechanisms of Semliki Forest virus. *Arch Virol Suppl* 9: 329-338.
- 818 11. Griffiths G, Quinn P, Warren G (1983) Dissection of the Golgi complex. I. Monensin inhibits
819 the transport of viral membrane proteins from medial to trans Golgi cisternae in baby
820 hamster kidney cells infected with Semliki Forest virus. *J Cell Biol* 96: 835-850.

- 821 12. Soonsawad P, Xing L, Milla E, Espinoza JM, Kawano M, et al. (2010) Structural evidence of
822 glycoprotein assembly in cellular membrane compartments prior to alphavirus budding. J
823 Virol 84: 11145-11151.
- 824 13. Orvedahl A, Sumpter R, Jr., Xiao G, Ng A, Zou Z, et al. (2011) Image-based genome-wide
825 siRNA screen identifies selective autophagy factors. Nature 480: 113-117.
- 826 14. Rose PP, Hanna SL, Spiridigliozzi A, Wannissorn N, Beiting DP, et al. (2011) Natural
827 resistance-associated macrophage protein is a cellular receptor for Sindbis virus in both
828 insect and mammalian hosts. Cell Host Microbe 10: 97-104.
- 829 15. Panda D, Rose PP, Hanna SL, Gold B, Hopkins KC, et al. (2013) Genome-wide RNAi screen
830 identifies SEC61A and VCP as conserved regulators of Sindbis virus entry. Cell Rep 5:
831 1737-1748.
- 832 16. Pollard TD (2007) Regulation of actin filament assembly by Arp2/3 complex and formins.
833 Annu Rev Biophys Biomol Struct 36: 451-477.
- 834 17. Goley ED, Welch MD (2006) The ARP2/3 complex: an actin nucleator comes of age. Nat
835 Rev Mol Cell Biol 7: 713-726.
- 836 18. Hall A (1998) Rho GTPases and the actin cytoskeleton. Science 279: 509-514.
- 837 19. Martin TFJ (1998) Phosphoinositide lipids as signaling molecules: common themes for
838 signal transduction, cytoskeletal regulation, and membrane trafficking. Annual Review of
839 Cell and Developmental Biology 14: 231-264.
- 840 20. Gao Y, Dickerson JB, Guo F, Zheng J, Zheng Y (2004) Rational design and characterization
841 of a Rac GTPase-specific small molecule inhibitor. Proc Natl Acad Sci U S A 101: 7618-
842 7623.

- 843 21. Shutes A, Onesto C, Picard V, Leblond B, Schweighoffer F, et al. (2007) Specificity and
844 mechanism of action of EHT 1864, a novel small molecule inhibitor of Rac family small
845 GTPases. *J Biol Chem* 282: 35666-35678.
- 846 22. Nolen BJ, Tomasevic N, Russell A, Pierce DW, Jia Z, et al. (2009) Characterization of two
847 classes of small molecule inhibitors of Arp2/3 complex. *Nature* 460: 1031-1034.
- 848 23. Feig LA, Cooper GM (1988) Inhibition of NIH 3T3 cell proliferation by a mutant ras protein
849 with preferential affinity for GDP. *Mol Cell Biol* 8: 3235-3243.
- 850 24. Bourne HR, Sanders DA, McCormick F (1991) The GTPase superfamily: conserved
851 structure and molecular mechanism. *Nature* 349: 117-127.
- 852 25. Tolia KF, Hartwig JH, Ishihara H, Shibasaki Y, Cantley LC, et al. (2000) Type I alpha
853 phosphatidylinositol-4-phosphate 5-kinase mediates Rac-dependent actin assembly. *Curr*
854 *Biol* 10: 153-156.
- 855 26. Chao WT, Daquinag AC, Ashcroft F, Kunz J (2010) Type I PIPK-alpha regulates directed
856 cell migration by modulating Rac1 plasma membrane targeting and activation. *J Cell Biol*
857 190: 247-262.
- 858 27. Kolokoltsov AA, Fleming EH, Davey RA (2006) Venezuelan equine encephalitis virus entry
859 mechanism requires late endosome formation and resists cell membrane cholesterol
860 depletion. *Virology* 347: 333-342.
- 861 28. Radoshitzky SR, Warfield KL, Chi X, Dong L, Kota K, et al. (2011) Ebolavirus delta-peptide
862 immunoadhesins inhibit marburgvirus and ebolavirus cell entry. *J Virol* 85: 8502-8513.
- 863 29. Saeed MF, Kolokoltsov AA, Freiberg AN, Holbrook MR, Davey RA (2008)
864 Phosphoinositide-3 kinase-Akt pathway controls cellular entry of Ebola virus. *PLoS*
865 *Pathog* 4: e1000141.

- 866 30. Nanbo A, Imai M, Watanabe S, Noda T, Takahashi K, et al. (2010) Ebolavirus is internalized
867 into host cells via macropinocytosis in a viral glycoprotein-dependent manner. *PLoS*
868 *Pathog* 6: e1001121.
- 869 31. Pohjala L, Utt A, Varjak M, Lulla A, Merits A, et al. (2011) Inhibitors of alphavirus entry
870 and replication identified with a stable Chikungunya replicon cell line and virus-based
871 assays. *PLoS One* 6: e28923.
- 872 32. Karmysheva B, Mironova LL, Ovsianikova NV, Popova VD (1988) [Changes in cellular
873 microfilaments in viral infection]. *Vopr Virusol* 33: 711-717.
- 874 33. Paingankar MS, Arankalle VA (2014) Identification of chikungunya virus interacting
875 proteins in mammalian cells. *J Biosci* 39: 389-399.
- 876 34. Laakkonen P, Auvinen P, Kujala P, Kaariainen L (1998) Alphavirus replicase protein NSP1
877 induces filopodia and rearrangement of actin filaments. *J Virol* 72: 10265-10269.
- 878 35. Griffiths G, Fuller SD, Back R, Hollinshead M, Pfeiffer S, et al. (1989) The dynamic nature
879 of the Golgi complex. *J Cell Biol* 108: 277-297.
- 880 36. Radtke K, Dohner K, Sodeik B (2006) Viral interactions with the cytoskeleton: a hitchhiker's
881 guide to the cell. *Cell Microbiol* 8: 387-400.
- 882 37. Yamauchi Y, Helenius A (2013) Virus entry at a glance. *J Cell Sci* 126: 1289-1295.
- 883 38. Brandenburg B, Zhuang X (2007) Virus trafficking - learning from single-virus tracking. *Nat*
884 *Rev Microbiol* 5: 197-208.
- 885 39. Taylor MP, Koyuncu OO, Enquist LW (2011) Subversion of the actin cytoskeleton during
886 viral infection. *Nat Rev Microbiol* 9: 427-439.
- 887 40. Sanchez EG, Quintas A, Perez-Nunez D, Nogal M, Barroso S, et al. (2012) African swine
888 fever virus uses macropinocytosis to enter host cells. *PLoS Pathog* 8: e1002754.

- 889 41. Mercer J, Helenius A (2008) Vaccinia virus uses macropinocytosis and apoptotic mimicry to
890 enter host cells. *Science* 320: 531-535.
- 891 42. Amstutz B, Gastaldelli M, Kalin S, Imelli N, Boucke K, et al. (2008) Subversion of CtBP1-
892 controlled macropinocytosis by human adenovirus serotype 3. *EMBO J* 27: 956-969.
- 893 43. Wang JL, Zhang JL, Chen W, Xu XF, Gao N, et al. (2010) Roles of small GTPase Rac1 in
894 the regulation of actin cytoskeleton during dengue virus infection. *PLoS Negl Trop Dis* 4.
- 895 44. Schelhaas M, Shah B, Holzer M, Blattmann P, Kuhling L, et al. (2012) Entry of human
896 papillomavirus type 16 by actin-dependent, clathrin- and lipid raft-independent
897 endocytosis. *PLoS Pathog* 8: e1002657.
- 898 45. Bustelo XR, Ojeda V, Barreira M, Sauzeau V, Castro-Castro A (2012) Rac-ing to the plasma
899 membrane: the long and complex work commute of Rac1 during cell signaling. *Small*
900 *GTPases* 3: 60-66.
- 901 46. Innocenti M, Gerboth S, Rottner K, Lai FP, Hertzog M, et al. (2005) Abi1 regulates the
902 activity of N-WASP and WAVE in distinct actin-based processes. *Nat Cell Biol* 7: 969-
903 976.
- 904 47. Anitei M, Hoflack B (2012) Bridging membrane and cytoskeleton dynamics in the secretory
905 and endocytic pathways. *Nat Cell Biol* 14: 11-19.
- 906 48. Wang B, Wylie FG, Teasdale RD, Stow JL (2005) Polarized trafficking of E-cadherin is
907 regulated by Rac1 and Cdc42 in Madin-Darby canine kidney cells. *Am J Physiol Cell*
908 *Physiol* 288: C1411-1419.
- 909 49. Kraynov VS, Chamberlain C, Bokoch GM, Schwartz MA, Slabaugh S, et al. (2000)
910 Localized Rac activation dynamics visualized in living cells. *Science* 290: 333-337.

- 911 50. Fucini RV, Chen JL, Sharma C, Kessels MM, Stamnes M (2002) Golgi vesicle proteins are
912 linked to the assembly of an actin complex defined by mAbp1. *Mol Biol Cell* 13: 621-
913 631.
- 914 51. Anitei M, Stange C, Parshina I, Baust T, Schenck A, et al. (2010) Protein complexes
915 containing CYFIP/Sra/PIR121 coordinate Arf1 and Rac1 signalling during clathrin-AP-1-
916 coated carrier biogenesis at the TGN. *Nat Cell Biol* 12: 330-340.
- 917 52. Puertollano R, van der Wel NN, Greene LE, Eisenberg E, Peters PJ, et al. (2003)
918 Morphology and dynamics of clathrin/GGA1-coated carriers budding from the trans-
919 Golgi network. *Mol Biol Cell* 14: 1545-1557.
- 920 53. Wacker I, Kaether C, Kromer A, Migala A, Almers W, et al. (1997) Microtubule-dependent
921 transport of secretory vesicles visualized in real time with a GFP-tagged secretory
922 protein. *J Cell Sci* 110 (Pt 13): 1453-1463.
- 923 54. Diefenbach RJ, Miranda-Saksena M, Douglas MW, Cunningham AL (2008) Transport and
924 egress of herpes simplex virus in neurons. *Rev Med Virol* 18: 35-51.
- 925 55. Chambers R, Takimoto T (2010) Trafficking of Sendai virus nucleocapsids is mediated by
926 intracellular vesicles. *PLoS One* 5: e10994.
- 927 56. Collier KE, Heaton NS, Berger KL, Cooper JD, Saunders JL, et al. (2012) Molecular
928 determinants and dynamics of hepatitis C virus secretion. *PLoS Pathog* 8: e1002466.
- 929 57. Gaudin R, de Alencar BC, Jouve M, Berre S, Le Boudier E, et al. (2012) Critical role for the
930 kinesin KIF3A in the HIV life cycle in primary human macrophages. *J Cell Biol* 199:
931 467-479.

- 932 58. van Zeijl MJ, Matlin KS (1990) Microtubule perturbation inhibits intracellular transport of an
 933 apical membrane glycoprotein in a substrate-dependent manner in polarized Madin-
 934 Darby canine kidney epithelial cells. *Cell Regul* 1: 921-936.
- 935 59. Toomre D, Keller P, White J, Olivo JC, Simons K (1999) Dual-color visualization of trans-
 936 Golgi network to plasma membrane traffic along microtubules in living cells. *J Cell Sci*
 937 112 (Pt 1): 21-33.
- 938 60. Jose J, Snyder JE, Kuhn RJ (2009) A structural and functional perspective of alphavirus
 939 replication and assembly. *Future Microbiol* 4: 837-856.
- 940 61. Battles JK, Dalrymple JM (1988) Genetic variation among geographic isolates of Rift Valley
 941 fever virus. *Am J Trop Med Hyg* 39: 617-631.
- 942 62. Mudhasani R, Tran JP, Retterer C, Radoshitzky SR, Kota KP, et al. (2013) IFITM-2 and
 943 IFITM-3 but not IFITM-1 restrict Rift Valley fever virus. *J Virol* 87: 8451-8464.
- 944 63. Radoshitzky SR, Abraham J, Spiropoulou CF, Kuhn JH, Nguyen D, et al. (2007) Transferrin
 945 receptor 1 is a cellular receptor for New World haemorrhagic fever arenaviruses. *Nature*
 946 446: 92-96.
- 947 64. Schneider CA, Rasband WS, Eliceiri KW (2012) NIH Image to ImageJ: 25 years of image
 948 analysis. *Nat Methods* 9: 671-675.
- 949 65. Radoshitzky SR, Dong L, Chi X, Clester JC, Retterer C, et al. (2010) Infectious Lassa virus,
 950 but not filoviruses, is restricted by BST-2/tetherin. *J Virol* 84: 10569-10580.

951

952 **Supporting Information**

953 **S1 Table. Summary of the primary siRNA screen.**

The primary screen was performed using a pool of four siRNA duplexes per gene from a Dharmacon Membrane Trafficking library. The measured effects of each annotated siRNA pool on VEEV infection rate and cell number is normalized to that observed with control siRNA.

S2 Table. Summary of the follow-up siRNA screen.

For the deconvolution screen, the four individual duplexes siRNAs from each siRNA pool were used. The measured effects of each annotated siRNA duplex on VEEV infection rate and cell number is normalized to that observed with control siRNA.

S1 Fig. siRNA screen identifies host regulators of alphavirus infection.

(A) High-content quantitative image-based analysis was used to measure relative infection rates (normalized to control siRNA-treated cells) of CHIKV in HeLa cells pretreated with the indicated siRNAs. Cells were infected for 24 h (CHIKV, MOI=5), fixed and stained with antibodies against E2. (B) HeLa cells were pretreated with the indicated siRNAs and infected for 20 h with VEEV (MOI=0.5) or for 24 h with CHIKV (MOI=5). Cells were fixed, stained, and analyzed as in (A). Protein levels of N-WASP and actin (loading control) following siRNA treatment were determined by immunoblotting. Values represent the mean \pm SD, n = 3.

S2 Fig. Rac1, Arp3, and formation of a Rac1:PIP5K1- α complex are important for alphavirus infection.

(A) Primary human astrocytes were treated with increasing concentrations of CK548 and subsequently infected with EEEV or WEEV (MOI=0.005). Cells were fixed in formalin 19 h after infection, stained with virus-specific antibodies and analyzed using an Opera confocal

imager. Results are normalized to DMSO-treated samples. **(B)** HeLa cells were treated with CK548 or EHT1864 and subsequently infected with CHIKV or SINV (MOI=5). Cells were fixed 20 h (SINV) or 48 h (CHIKV) later and analyzed as in **(A)**. **(C)** Representative confocal images of **(Fig 2F)**. VEEV E2 glycoprotein staining is shown in green and nucleus/cytoplasm staining is shown in red. **(D)** Flp-In T-REx 293 cells pre-induced to express chloramphenicol acetyltransferase (CAT), wild-type Rac1, or variants thereof were infected with VEEV (MOI=0.1). After 18 h, virus titer in the supernatants was determined by plaque assay. **, $p < 0.01$, Student's t test (between samples and CAT). **(E)** Representative confocal images of **(Fig 2H)**. Coloring as in **(C)**. **(F)** Confocal images of Flp-In T-REx 293 cells that were induced as in **(D)**, inoculated with WEEV (MOI=0.005), fixed 18 h later, and stained with virus-specific antibodies (green) and nuclear stain (blue). **(G, H)** High-content quantitative image-based analysis of CHIKV infection rates in Flp-In T-REx 293 cells pre-induced as in **(D)**. Cells were fixed 24 h after virus inoculation and stained with virus-specific antibodies. **(I)** Representative confocal images of **(G, H)**. CHIKV E2 glycoprotein staining is shown in green and nucleus/cytoplasm staining is shown in red. All values represent the mean \pm SD, $n = 3$.

Fig S3. Rac1 and Arp3 act at a late stage of alphavirus infection.

(A) Time course of VEEV TC-83 (MOI=10) infection in HeLa cells. Media containing extracellular virus were harvested at the indicated time points for qRT-PCR analysis of virion copy number (left panel), and cells were fixed, stained with VEEV E2-specific antibody and analyzed with an Opera confocal reader by high-content quantitative image-based analysis (right panel). **(B)** High-content quantitative image-based analysis of relative VEEV TC-83 infection rates (normalized to DMSO-treated samples) in time-of-addition experiments. VEEV-infected

1000 HeLa cells (MOI=1) were treated with increasing concentrations of the Rac1 inhibitor EHT1864,
1001 or the Arp3 inhibitor CK548 at the indicated time points prior to (-1 h) or after (+1–7 h) virus
1002 addition. Cells were fixed 12 h after addition of virus and stained with virus-specific antibodies.
1003 Values represent the mean \pm SD, n = 3. (C) Plaque assays were used to measure VEEV titer in
1004 supernatants of HeLa cells pretreated with the indicated concentrations of the inhibitors. Cells
1005 were treated with inhibitors 5 h after inoculation with VEEV (MOI=0.5), and virus-containing
1006 media was harvested for analysis 17 h later. Values represent the mean \pm SD, n = 3. **, $p < 0.01$,
1007 Student's *t* test (between samples and DMSO). (D) BHK-CHIKV-NCT cells expressing a
1008 CHIKV replicon with a *Renilla* luciferase reporter were treated with increasing concentrations of
1009 EHT1864, CK548, or T705 (a nucleotide prodrug, positive control). After 48 h, *Renilla*
1010 luciferase (Rluc) activity was determined from the lysates.

1011

1012 **S4 Fig. Actin polymerization plays a role at a late stage of alphavirus infection.**

1013 (A) HeLa cells or primary human astrocytes were infected with VEEV (MOI=0.5) or VEEV TC-
1014 83 (MOI=0.005) for 3 h (HeLa) or 5 h (astrocytes) and then treated with increasing
1015 concentrations of nocodazole. After 6 h (astrocytes) or 17 h (HeLa), virus titer in the
1016 supernatants was determined by plaque assay. Values represent the mean \pm SD, n = 3. (B)
1017 Representative confocal images of (Fig 4C). VEEV E2 staining is shown in green, nucleus
1018 staining is shown in blue, and tubulin staining is shown in red (top panel: magnification: 10x;
1019 bottom panel: magnification: 40x). (C). Representative confocal images of (Fig 4C). VEEV E2
1020 staining is shown in green, nucleus staining is shown in blue, and actin staining is shown in red
1021 (top panel: magnification: 10x; bottom panel: magnification: 40x). (D) BHK-CHIKV-NCT cells
1022 expressing a CHIKV replicon with a *Renilla* luciferase reporter were treated with increasing

concentrations of the indicated inhibitors. After 48 h, *Renilla* luciferase (Rluc) activity was determined from the lysates.

S5 Fig. Alphavirus infection causes actin rearrangements into actin foci that co-localize with Rac1, PIP5K1- α , and E2.

(A) HeLa cells were inoculated with WEEV (MOI=2), EEEV (MOI=1), or SINV (MOI=5), fixed 24 h later, and stained with virus-specific antibodies and fluorescent phalloidin. High-content quantitative image-based analysis was used to measure virus infection rates (left panel) as well as number of actin foci per cell (right panel). ***, $p < 0.0001$, Student's t test (between samples and mock). (B) HeLa cells were transfected with an expression plasmids encoding VEEV nsP1-FLAG. Cells were fixed 24 h later and stained with antibodies against FLAG (green), and fluorescent phalloidin (red). Confocal images of single Z sections are shown as well as a Z stack image (merged Z sections) of actin staining. Representative actin filopodia are indicated by asterisks. (C-D) Basal-to-apical confocal section series of VEEV-infected HeLa cells (MOI=5). Co-localization of HA-tagged PIP5K1- α (C) or Rac1 (D) (blue), actin (red), and VEEV E2 (green), at different z sections is shown, as well as single channel intensities measured along lines crossing different actin clusters. Insets: zoom on actin filaments indicated by white arrows. Nuclei are indicated by asterisks. VEEV was added to (C) HeLa cells that were reverse-transfected with a plasmid encoding HA-tagged PIP5K1- α or (D) tetracycline-induced T-Rex HeLa cells that expressed Rac1 fused to eGFP. Cells were fixed 20 h later, permeabilized, and stained with VEEV E2-specific antibody, phalloidin, and an antibody against HA (C).

S6 Fig. Alphavirus E2 co-localizes with actin but not with tubulin.

(A) Representative images of VEEV-infected HeLa cells from Fig. 6A in confocal and STED microscopy modes. E2 glycoprotein is shown in green and actin in red. (B) Co-localization of tubulin (blue), actin (red), and E2 (green) in a VEEV-infected cell at different z sections from base (Section 7) to apex (section 25). HeLa cells were infected with VEEV (MOI=5) for 20 h and stained with antibodies against E2, tubulin, and fluorescent phalloidin. Pixel intensities of tubulin (red) and E2 (green) staining are shown (bottom graphs). (C) Representative images of VEEV-infected HeLa cells (as in B) stained with E2-specific antibodies (green), phalloidin (red) and CellMask (grey in merge). Analysis of cell borders based on CellMask staining was performed within the Columbus programming environment.

S7 Fig. Rac1 and Arp3 inhibitors block E2 transport to cell surface.



(A) High-content quantitative image-based analysis was used to measure the TGN46-to-plasma membrane E2 staining intensity ratio in VEEV-infected astrocytes. *, $p < 0.05$, **, $p < 0.001$, Student's *t* test (between samples and DMSO). (B) Representative confocal images of HeLa cells treated with DMSO, EHT1864 or CK548 at the indicated concentrations and subsequently infected with VEEV (MOI=0.5). Cells were fixed and stained with VEEV E2 (green) and GGA3 (red)-specific antibodies and counterstained with Hoechst 3342 (blue) 20 h after infection (magnification: 40x). Representative cells showing co-localization of E2 and GGA3 are indicated with white arrows. (C) Geometrical mean fluorescent intensity of cell-surface CD44 staining in HeLa cells treated with EHT1864, CK548, cytochalasin D, latrunculin A, or nocodazole as measured by flow cytometry. HeLa cells were treated with increasing concentrations of the inhibitors or DMSO (control). Six h later cells were dissociated and stained against CD44 and with a 7-AAD viability dye.

1069

1070 **S8 Fig. Localization of actin foci, Rac1, and PIP5K1- α relative to TGN46.**


1071 VEEV (MOI=5) was added to (A) HeLa cells, or (B) HeLa cells that were reverse-transfected
1072 with a plasmid encoding HA-tagged PIP5K1- α or (C) tetracycline-induced T-Rex HeLa cells that
1073 express Rac1 fused to eGFP. Cells were fixed 20 h later, permeabilized, and stained with VEEV
1074 E2- and TGN46-specific antibodies, as well as with phalloidin (A), and an antibody against HA
1075 (B). Co-localization of actin (A), PIP5K1- α (B) or Rac1 (C), with TGN46 (white), and VEEV E2
1076 (green), at a single z section.

DISTRIBUTION STATEMENT A: Approved for public release; distribution is unlimited.

Fig. 1


UNCLASSIFIED

DISTRIBUTION STATEMENT A: Approved for public release; distribution is unlimited.

Fig. 2


UNCLASSIFIED

DISTRIBUTION STATEMENT A: Approved for public release; distribution is unlimited.

Fig. 3


UNCLASSIFIED

DISTRIBUTION STATEMENT A: Approved for public release; distribution is unlimited.

Fig. 4


UNCLASSIFIED

DISTRIBUTION STATEMENT A: Approved for public release; distribution is unlimited.




UNCLASSIFIED


DISTRIBUTION STATEMENT A: Approved for public release; distribution is unlimited.

Fig. 6

DISTRIBUTION STATEMENT A: Approved for public release; distribution is unlimited.




UNCLASSIFIED

Fig. S1

UNCLASSIFIED


DISTRIBUTION STATEMENT A: Approved for public release; distribution is unlimited.

Fig. S2




UNCLASSIFIED





DISTRIBUTION STATEMENT A: Approved for public release; distribution is unlimited.

Fig. S3

UNCLASSIFIED


Fig. S4

DISTRIBUTION STATEMENT A: Approved for public release; distribution is unlimited.

Fig. S5**A****B****C****D**


UNCLASSIFIED

DISTRIBUTION STATEMENT A: Approved for public release; distribution is unlimited.




UNCLASSIFIED

Fig. S7



UNCLASSIFIED

DISTRIBUTION STATEMENT A: Approved for public release; distribution is unlimited.



UNCLASSIFIED



[Click here to access/download](#)
Supporting Information
S1_Table.xlsx





[Click here to access/download](#)
Supporting Information
S2_Table.xlsx



siRNA Screen Identifies Trafficking Host Factors that Modulate Alphavirus Infection

Sheli R. Radoshitzky¹, Gianluca Pegoraro¹, Xiǎolì Chī¹, Lián Dǒng¹, Chih-Yuan Chiang¹,
Lucas Jozwick¹, Jeremiah C. Clester¹, Christopher L. Cooper¹, Duane Courier¹, David P.
Langan¹, Knashka Underwood¹, Kathleen A. Kuehl², Mei G. Sun², Yíngyún Cài³, Shuǐqìng
Yú³, Robin Burk³, Rouzbeh Zamani¹, Krishna Kota¹, Jens H. Kuhn³, Sina Bavari^{1,*}

¹Molecular and Translational Sciences Division, ²Pathology Division, United States Army
Medical Research Institute of Infectious Diseases (USAMRIID), Frederick, MD, USA,

³Integrated Research Facility at Fort Detrick (IRF-Frederick), Division of Clinical Research
(DCR), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of
Health (NIH), Fort Detrick, Frederick, MD, USA

*For correspondence: sina.bavari.civ@mail.mil

Short title: Host modulators of pathogenic alphavirus infection

Abbreviation list: Chikungunya virus, CHIKV; cytopathic vacuoles, CPV; eastern equine encephalitis
virus, EEEV; Ebola virus, EBOV; Moloney murine leukemia virus, MoMLV; Rift Valley fever virus,
RVFV; Sindbis virus, SINV; stimulated emission depletion, STED; Venezuelan equine encephalitis virus,
VEEV; western equine encephalitis virus, WEEV; *trans Golgi* network, TGN

Abstract

Little is known about the repertoire of cellular factors involved in the replication of pathogenic alphaviruses. To uncover molecular regulators of alphavirus infection and to identify candidate drug targets, we performed a high-content imaging-based siRNA screen. We revealed an actin-remodeling pathway involving Rac1, PIP5K1- α , and Arp3, as essential for infection by pathogenic alphaviruses. Infection causes cellular actin rearrangements into large bundles of actin filaments termed actin foci. Actin foci are generated late in infection concomitantly with alphavirus envelope (E2) expression and are dependent on the activities of Rac1 and Arp3. E2 associates with actin in alphavirus-infected cells and co-localizes with Rac1-PIP5K1- α along actin filaments in the context of actin foci. Finally, Rac1, Arp3, and actin polymerization inhibitors interfere with E2 trafficking from the trans-Golgi network to the cell surface, suggesting a plausible model in which transport of E2 to the cell surface is mediated via Rac1- and Arp3-dependent actin remodeling.

Author Summary

Alphaviruses, such as Chikungunya or Venezuelan equine encephalitis viruses, are significant human pathogens that cause arthritis or fatal encephalitis in humans. For productive infection of cells, alphaviruses rely on a repertoire of cellular host proteins, including trafficking factors that mediate transport of viral components across the cell. We have performed a functional screen to identify cellular factors that are crucial for this transport process. We show that Rac1, PIP5K1- α , and the Arp2/3 complex are cellular regulators of alphavirus infection. These factors are important for major cellular actin rearrangements that occur at a late stage of virus infection and are virus-induced. Concomitantly, these factors might be essential for trafficking of the viral E2

surface glycoprotein from the *trans*-Golgi network (TGN) to the cell surface. E2 was found to associate with actin, as well as to co-localize with Rac1, PIP5K1- α , and actin filaments. Late E2-containing vesicles, termed cytopathic vacuoles II (CPV-II), were also imaged along and at the end of actin filaments in alphavirus-infected cells.

Keywords: alphavirus; actin; Arp3; chikungunya; CHIKV; EEEV; eastern equine encephalitis; PIP5K1; Rac1; Venezuelan equine encephalitis; VEEV; WEEV; eastern equine encephalitis

Introduction

Viral infection requires extensive subcellular trafficking, including cell entry, delivery of the genome to replication sites, and transport of viral proteins to and assembly of viral particles at the plasma membrane for egress. To this end, viruses make use of different cellular cues and signals to hijack existing endocytic and secretory pathways, cellular motor proteins, and cytoskeletal filaments.

Here we examine cellular trafficking machineries utilized by alphaviruses. Alphaviruses (family *Togaviridae*) are single-stranded, positive-sense RNA viruses that produce enveloped virions. Chikungunya virus (CHIKV), eastern equine encephalitis virus (EEEV), Venezuelan equine encephalitis virus (VEEV), and western equine encephalitis virus (WEEV) are the most medically important human alphaviruses that cause debilitating arthritides (CHIKV) or encephalitides (EEEV, VEEV, and WEEV) [1-3]. For instance, since December 2013, spread of CHIKV in the Caribbean has caused tens of thousands of human infections [4].

The alphavirus genome consists of two open reading frames encoding nonstructural and structural polyproteins. Four nonstructural proteins (nsP1-4) are required for transcription and

67 replication of viral RNA, and three main structural proteins (i.e., capsid protein C, envelope
68 glycoproteins E2 and E1) are the main constituents of virions. Alphavirus replication occurs
69 initially at the plasma membrane [5,6]. Replication complexes are subsequently internalized via
70 an endocytic process that requires a functional actin-myosin network. Following endocytosis,
71 replication complex-containing vesicles migrate via a microtubule-dependent mechanism to the
72 perinuclear area where they form stable, large and acidic compartments termed cytopathic
73 vacuoles (CPV)-I. CPV-I structures are derived from modified endosomes and lysosomes and
74 are associated with the alphaviral nonstructural proteins as well as viral RNA [7-9]. In the late
75 stage of alphavirus infection, *trans Golgi* network (TGN)-derived vacuoles marked with the
76 E1/E2 glycoproteins become predominant [10,11]. In these membrane vacuoles (termed CPV-
77 II), the viral glycoproteins are arranged in a tubular structure. CPV-II vacuoles have been
78 implicated in intracellular transport of alphavirus glycoproteins from the TGN to the site of
79 budding on the plasma membrane prior to virus egress [8,12].

80 siRNA screens have identified a number of host factors that possibly promote or restrict
81 nonpathogenic alphavirus infection [13-15]. However, detailed mechanistic studies regarding the
82 role of host factors in alphavirus trafficking have not been performed. In this study, we used an
83 RNAi-based screen to identify and validate trafficking host factors that are required for infection
84 by the pathogenic VEEV and other pathogenic alphavirus relatives. Mutagenesis-, chemical
85 inhibitor- and imaging-based approaches were further used to validate and decipher the role of
86 these factors in alphavirus infection.

87 **Results**

88 **High-content RNAi Screen Identifies Host Trafficking Regulators of Alphavirus Infection**

89 Small interfering RNA (siRNA) pools targeting each of 140 human trafficking genes were

transfected into HeLa cells. A non-targeting siRNA was used as a control. Cells were subsequently infected with VEEV (chosen as a prototype alphavirus for the screen) for 20 h and then fixed and stained with a VEEV E2-specific antibody (Fig 1A). Staining was performed without permeabilization to detect only E2 present on the cell surface. Cell number and infection rate were determined using quantitative high-content image-based analysis (see Materials and Methods). The infection rate of control siRNA-transfected cells was optimized to yield, on average, 70-80%. Analysis of the results revealed that siRNAs against 51 host trafficking factors decreased VEEV infection rate by >30% (Z-score <-2) (S1 Table).

Fig 1. siRNA Screen Identifies Host regulators of alphavirus infection.

(A) Schematic representation of the siRNA screen and the high-content quantitative image-based analysis of relative VEEV infection rates. HeLa cells were transfected with siRNAs against 140 host trafficking factors and inoculated with VEEV (MOI=0.5) for 20 h. Cells were fixed and immunostained for cell surface VEEV envelope glycoprotein (E2) expression. Infection rates were determined using an Opera confocal imager and normalized to infection rates observed using non-targeting control siRNA. Representative images of cells treated with control (Cont) or Rac1 siRNA are shown. VEEV E2 staining is shown in green and nucleus staining is shown in blue. (B) High-content quantitative image-based analysis was used to measure relative infection rates (normalized to control siRNA-treated cells) of VEEV (top panel) in HeLa cells pretreated with the indicated siRNAs. Cells were infected for 20 h (VEEV, MOI=0.5), fixed and stained with antibodies against E2. Values represent the mean \pm SD, n = 3. Protein levels of Rac1, Arp3, and actin (loading control) following siRNA treatments were determined by immunoblotting (bottom panel). mRNA levels of PIP5K1- α (PIP5K1A) following siRNA treatments were

determined by qRT-PCR. (C) VEEV titer following treatment of HeLa cells with siRNAs against Rac1, Arp3, PIP5K1A (PIP5k1 α), or control siRNA. Cells were inoculated with VEEV as in (B) and virus-containing media was analyzed by plaque assay. **, $p < 0.01$, Student's t test (between the sample and control siRNA).

To confirm results of the primary screen and to rule out potential off-target effects of individual siRNAs, we performed a secondary screen of deconvoluted siRNA pools. A hit was considered validated if at least 2 siRNAs from the set of 4 individual siRNAs targeting the gene product reduced the VEEV infection rate by $\geq 30\%$ and had a p -value of < 0.05 versus control siRNA-transfected wells. Wells that had low cell numbers (final cell number $< 70\%$ of the control siRNA-transfected well) due to combined effects of siRNA toxicity and VEEV cytopathic effects were excluded from further analyses. Analysis of the results led to validation of 19 (61%) out of the 31 primary hits (S2 Table).

Importantly, the list of validated hits was enriched for crucial regulators of the actin cytoskeleton. In particular, knockdown of four subunits of the heptameric Arp2/3 complex, ARPC4, ARPC5, ARPC1B (S2 Table), and ACTR3 (Arp3) (Fig 1B), significantly inhibited VEEV infection. In addition, Rac1, and PIP5K1- α (PIP5K1A) were also identified as hits (Fig 1B). The Arp2/3 complex plays a central role in actin dynamics by controlling filament nucleation [16,17]. Rac1 is a member of the Rho GTPase family and among its many functions modulates actin cytoskeleton organization [18]. PIP5K1- α is a lipid kinase involved in the synthesis of the signaling molecule phosphatidylinositol-4,5-bisphosphate (PI4,5P₂), which is a central regulator of the actin cytoskeleton in response to multiple signals [19].

Our siRNA results were further confirmed using single siRNAs against Rac1, Arp3, and

PIP5K1- α from another source (Fig 1B, siRNAs 5–7). We also observed a ≈ 10 to >30 fold reduction in VEEV titer following knockdown of these host factors (Fig 1C). Finally, siRNA-mediated knockdown of Rac1, Arp3, or PIP5K1- α inhibited infection of CHIKV (S1A and B Fig). These results indicate that Rac1, Arp3, and PIP5K1- α play an important role in alphavirus infections.

Rac1 and Arp3 Inhibitors Reduce Alphavirus Infection Rates

To validate the role of Rac1 and Arp3 in VEEV infection, we tested whether the Rac1 inhibitors EHT1864 and NSC23766 [20,21] and the Arp3 inhibitors CK548 and CK869 [22] could block VEEV infection. Upon treatment of HeLa cells with either of these inhibitors, VEEV infection rates were reduced in a dose-dependent manner (Fig 2A and B). Similar results were observed when the Rac1 inhibitors EHT1864 or NSC23766 or the Arp3 inhibitor CK548, were tested in primary human astrocytes (Fig 2C and D). These inhibitors were also effective in reducing infection rates of other alphaviruses. EHT1864 inhibited infections by CHIKV and the closely related Sindbis virus (SINV), and CK548 decreased CHIKV, SINV, EEEV, and WEEV infection rates (S2A and B Fig). None of the treatment conditions in either assays resulted in cytotoxicity. Overall, our results further confirm the importance of host factors Rac1 and Arp3 in alphavirus infection.

Fig 2. Rac1, Arp3 and formation of a Rac1:PIP5K1- α complex are important for VEEV infection.

(A) High-content quantitative image-based analysis of relative VEEV infection rates in HeLa cells pretreated with increasing concentrations of two Rac1 inhibitors (EHT1864 or NSC23766), two Arp3 inhibitors (CK548 or CK869), or DMSO. Cells were inoculated with compounds 1 h

prior to VEEV addition. Cells were fixed and stained with virus-specific antibodies 20 h later. Results are normalized to DMSO-treated samples. (B) Representative confocal images of (A). VEEV E2 staining is shown in green and nucleus/cytoplasm staining is shown in red. (C) Primary human astrocytes were treated with increasing concentrations of EHT1864, NSC23766, or CK548, and subsequently inoculated with VEEV (MOI=0.005). Cells were fixed 19 h later and stained and analyzed as in (A). (D) Representative confocal images of (C). VEEV E2 staining is shown in green and nucleus staining is shown in blue. (E) Flp-In T-REx 293 cells with tetracycline-inducible expression of wild-type Rac1, constitutively active Rac1 (G12V) or dominant-negative Rac1 (T17N) were generated, and analyzed for protein expression by immunoblotting (actin was used as a loading control). (F) High-content quantitative image-based analysis of VEEV or RVFV infection rates in Flp-In T-REx 293 cells pre-induced to express chloramphenicol acetyltransferase (CAT), wild-type Rac1, or variants thereof. Cells were fixed 18 h (VEEV) or 24 h (RVFV) after virus inoculation and stained with virus-specific antibodies. (G) Immunoblot of tetracycline-induced expression of wild-type Rac1, or Rac1 K186E in Flp-In T Rex 293 cells as in (E). (H) High-content quantitative image-based analysis of VEEV or RVFV infection rates in Flp-In T-REx 293 cells pre-induced to express CAT, wild-type Rac1, or Rac1 K186E. Cells were infected and stained as in (F).

Rac1 GTPase Function and Rac1:PIP5K1- α Complex Formation are Important for Alphavirus Infection

To determine if the function of Rac1 in alphavirus infection required Rac1's GTPase activity, we established tetracycline-inducible 293 Flp-In T-REx cell lines that express chloramphenicol acetyltransferase (CAT, used as a control), wild-type Rac1, constitutively active Rac1 (G12V),

or dominant-negative Rac1 (T17N) (Fig 2E) [23,24]. Rac1 expression in these cells was induced with tetracycline for 24 h, followed by infection with VEEV, or a non-alphavirus control (Rift Valley fever virus; RVFV strain ZH501, hereafter, RVFV) . Expression of both Rac1 mutant variants (G12V, T17N) reduced VEEV but not RVFV infection rates, whereas expression of wild-type Rac1 had no effect (Fig 2F, S2C Fig). Both Rac1 mutants also reduced VEEV titer in the media (Fig S2D). We also confirmed the importance of Rac1 GTPase activity during VEEV and CHIKV infection (S2F-G Fig). The inhibitory effects of both Rac1 mutant variants on alphavirus infection likely indicate that the role of Rac1 during infection requires completion of the GTP-GDP-exchange/GTP-hydrolysis cycle. Cycling between GTP- and GDP-bound states may be required for productive infection, and shifting the level of activity predominantly to either side may block signaling pathways that emanate from the turnover.

Rac1 also forms a complex with PIP5K1 kinases that are necessary for stimulation of PI4,5P₂ synthesis and actin assembly [25]. PIP5K1- α directly binds Rac1 via the polybasic tail of Rac1. Specific mutations within this region, such as K186E, abrogate Rac1:PIP5K1- α binding *in vitro* [26]. To examine whether Rac1:PIP5K1- α complex formation is important for VEEV infection, we used the tetracycline-inducible 293 Flp-In T-REx cell line to express Rac1 variant K186E (Fig 2G). Once induced, these cells and control cells expressing CAT or wild-type Rac1 were infected with VEEV or RVFV. Expression of Rac1 K186E reduced VEEV but not RVFV infection rates (Fig 2H, S2E Fig). VEEV titer in the media was also reduced (Fig S2D). Finally, we confirmed the importance of Rac1:PIP5K1- α complex formation to infection with CHIKV (S2H-I Fig). These results suggest that binding of Rac1 to PIP5K1- α plays a role in alphavirus infections.

Rac1 and Arp3 Do Not Affect Alphavirus Cell Entry or Replication but Later Stages of

Infection prior to Virus Budding

We used a multi-cycle VEEV in our screen. Consequently, Rac 1 and Arp3 could have acted at a number of stages of the VEEV lifecycle. To determine when Rac1 and Arp3 act, we first determined the time necessary for a single lifecycle (round) of VEEV TC-83 (live-attenuated vaccine strain) infection. To this end we measured virus particle release from HeLa cells to the media at different time points post virus inoculation using qRT-PCR analysis. Expression kinetics of the late alphaviral gene product, E2, was also analyzed. Virus particle release into the media was observed at 9 h post inoculation of HeLa cells (Fig 3A), suggesting an approximately 9-h replication cycle for VEEV under these conditions. E2 expression was detected as early as 7 h post virus inoculation (Fig 3B). Experiments performed with virulent VEEV IC-SH3 yielded similar results on expression of E2 and C proteins at these time points (Fig 3C). We confirmed our results with a one step-like growth curve analysis using a high MOI (MOI=10) and also measured intracellular viral RNA (vRNA) levels as a function of time. Significant increase in intracellular vRNA levels was found at 5 h post virus inoculation, suggesting that virus replication/transcription is initiated prior to this time point (Fig 3D).

Fig 3. Rac1 and Arp3 act at a late stage of alphavirus infection.

(A and B) Time course of VEEV TC-83 (MOI=2) infection in HeLa cells. (A) Media containing extracellular virions were harvested at the indicated time points for qRT-PCR analysis of virus copy number, and (B) cells were fixed, stained with VEEV E2-specific antibody and analyzed with an Opera confocal reader by high-content quantitative image-based analysis. (C) Representative confocal images of E2 or C expression in VEEV-infected (MOI=0.5) HeLa cells 7 h or 9 h following virus inoculation. Cells were stained with E2- or C-specific antibodies

(green) and counterstained with dye to show the nuclei (blue). **(D)** Viral copy number (intracellular vRNA) in HeLa cells at the indicated time points following VEEV TC-83 (MOI=10) inoculation was determined by qRT-PCR. **(E)** High-content quantitative image-based analysis of relative VEEV infection rates in time-of-addition experiments. VEEV-infected HeLa cells (MOI=0.5) were treated with increasing concentrations of the inhibitors at the indicated time points prior to (-1 h) or after (+1–7 h) virus addition. Cells were fixed 20 h after addition of virus, stained and analyzed as in **(B)**. Results are normalized to DMSO-treated samples. Values represent the mean \pm SD, $n = 3$. *, $p < 0.05$; **, $p < 0.01$; ***, $p < 0.001$; n.s., not significant, Student's t test (between the sample and DMSO-treated cells). **(F)** HeLa cells were transfected with siRNAs targeting Rac1, Arp3, or control siRNA. Two days later, cells were transduced with eGFP-expressing MoMLV pseudotyped with the envelope proteins of VEEV (E1/E2) or EBOV (GP_{1,2}). eGFP-expressing cells were measured as in **(B)**. Transduction rates were normalized to control siRNA-treated cells. *, $p < 0.05$; **, $p < 0.01$, Student's t test (between the sample and control siRNA) **(G)** Aliquots of the cells treated in **(E)** were lysed and analyzed for E2 expression by immunoblotting (GAPDH was used as a loading control). Densitometric analysis of western blots was performed with ImageJ. **(H-I)** VEEV copy number (intracellular vRNA) in HeLa cells following treatment with inhibitors or siRNAs as determined by qRT-PCR. **(H)** HeLa cells were inoculated with VEEV TC83 (MOI=2) and 5 h later treated with the indicated inhibitors. Cells were lysed and analyzed for virus copy number 11 h after virus addition. **(I)** HeLa cells were treated with the indicated siRNAs and 48 h later inoculated with VEEV TC83 (MOI=2). Cells were lysed and analyzed as in **(H)**.

To narrow down the lifecycle stage targeted by Rac1 and Arp3, we performed time-of-

addition experiments using inhibitors of these host factors. This time-based approach determines how long the addition of a compound can be postponed before losing its antiviral activity in cell culture. For example, if an inhibitor that targets viral fusion is present at the time when virus entry and fusion occurs within the viral lifecycle, it will be able to inhibit productive infection. In contrast, if this inhibitor is added after the entry/fusion process is completed, the inhibitor will no longer be effective in blocking infection.

As a positive control for infection inhibition, HeLa cells were pretreated with increasing concentrations of Rac1 or Arp3 inhibitors 1 h before addition of virus. Alternatively, inhibitors were added to the cells at different time points after virus inoculation (1, 3, 5, or 7 h, Fig 3E) but prior to virus release (9 h post inoculation). When the Rac1 inhibitor EHT1864 or the Arp3 inhibitor CK548 were added 1, 3, or 5 h after VEEV exposure, VEEV infection rates were reduced to that detected with the positive control condition (pretreatment). However, addition of inhibitors 7 h after virus inoculation had significantly less effect on infection, suggesting that the inhibitors lose their antiviral activity at this time. Similar results were obtained with VEEV TC-83 in the context of a single replication cycle (S3A and S3B Fig); both EHT1864 and CK548 inhibitors reduced VEEV TC-83 infection when they were added up to 7 h post inoculation. Furthermore, when the inhibitors were added to HeLa cells 5 h following VEEV inoculation, VEEV titer in the media was significantly reduced (approximately 80 to >7,000 fold reduction, S3C Fig). Since the inhibitors exhibited antiviral activity when they were added 5 h post virus inoculation but significantly lost their antiviral affect when they were added 7 h post virus inoculation, these results indicate that Rac1 and Arp3 most likely play a role in the VEEV life cycle sometime between 5 h and 7 h post virus inoculation. Since one lifecycle of the virus takes at least 9 h to complete, and since transcription/replication is initiated prior to 5 h post virus

inoculation, these results indicate that these inhibitors act at a late stage of virus infection.

To further confirm that Rac1 and Arp3 do not act at earlier stages (entry and replication), we first utilized a VEEV cell entry surrogate system composed of retroviral pseudotypes (Moloney murine leukemia virus, MoMLV) encoding eGFP and carrying the viral envelope proteins [27,28]. HeLa cells pretreated with control siRNA or with siRNAs targeting Rac1 or Arp3 were transduced with MoMLV-VEEV or MoMLV-EBOV (non-alphavirus control). As previously reported, MoMLV-EBOV entry into HeLa cells was reduced following knockdown of Rac1 or Arp3 [29,30] (Fig 5F). However, Rac1 or Arp3 knockdown had no or minimal effect on MoMLV-VEEV transduction rates, indicating that envelope-mediated entry of VEEV is independent of these two proteins.

Next, we examined the effect of the various inhibitors on total E2 protein levels in the context of virus infection. None of the inhibitors had an effect on E2 protein levels as determined by western blot analysis (Fig 3H).

Finally, we tested the effect of Rac1 and Arp3 on alphavirus replication in infected cells by treating cells with siRNAs as described above or with inhibitors against Rac1 or Arp3. Intracellular vRNA levels were determined by qRT-PCR. The siRNAs as well as the inhibitors had no significant effect on intracellular vRNA levels (Fig 3H-I). Similar results were obtained when the inhibitors were tested for their effect on CHIKV replication using a previously published replicon system (Fig S3D [31]).

Overall, these results indicate that Rac1 and Arp3 function after virus entry and replication, but prior to budding and release.

Actin Plays a Dual Role in Alphavirus Infection

As mentioned above, Rac1, Arp3, and PIP5K1A all affect cellular actin dynamics [16-19].

Previous studies have demonstrated a role for actin in alphavirus infection [32,33]. For example, in the early stages of infection of another alphavirus, Semliki Forest virus, replication complexes are internalized via an endocytic process that requires a functional actin-myosin network [7]. However, our time-of-addition experiments suggest that Rac1 and Arp3 play a role later in infection. We therefore investigated whether actin dynamics might play an additional role at later stages of infection.

To this end, we performed time-of-addition experiments (similar to the ones described above) with actin polymerization inhibitors. Cells were either pretreated with increasing concentrations of inhibitors before addition of virus (positive control) or preincubated with virus and subsequently treated with inhibitors at different time points after infection (Fig 4A-B). Compared to the positive control condition (pretreatment), the actin polymerization inhibitors, latrunculin A and cytochalasin D, were less effective in inhibiting VEEV infection when they were added 1 h after virus inoculation (Fig 4A-B). This loss of antiviral activity is possibly due to the previously described role of actin in internalization of alphavirus replication complexes [7]. Inhibition of VEEV infection rates remained similar if actin polymerization inhibitors were added up to 5 h after virus inoculation. However, additional loss of antiviral activity was observed when the inhibitors were added at 7 h post virus inoculation. These results suggest that actin polymerization inhibitors target two separate steps in VEEV's life cycle, one early in infection and one late in infection.

Fig 4. Actin polymerization plays a role at a late stage of alphavirus infection.

(A and B) High-content quantitative image-based analysis of relative VEEV and VEEV TC-83 infection rates in time-of-addition experiments. (A) VEEV-infected HeLa cells (MOI=0.5) were

320 treated with increasing concentrations of latrunculin A at the indicated time points prior to (-1 h)
321 or after (+1–7 h) virus addition. Cells were fixed 20 h after addition of virus and stained for high-
322 content quantitative image-based analysis with virus-specific antibodies. **(B)** VEEV TC-83
323 (MOI=1)-infected HeLa cells were treated with cytochalasin D as in **(A)**. Cells were fixed 12 h
324 after addition of virus, stained₂ and analyzed as in **(A)**. **(C)** HeLa cells were infected with VEEV
325 (MOI=0.5) for 3 h and then treated with increasing concentrations of cytochalasin B,
326 cytochalasin D, latrunculin A, or nocodazole. Cells were fixed in formalin 17 h later, stained₂ and
327 analyzed as in **(A)**. **(A-C)** Results are normalized to DMSO-treated samples. **(D)** HeLa cells were
328 infected as in **(C)** for 3 h and then treated with increasing concentrations of cytochalasin D, or
329 latrunculin A. After 17 h, virus titer in the supernatants was determined by plaque assay. Values
330 represent the mean \pm SD, $n = 2$. **(E)** Primary human astrocytes were infected with VEEV TC-83
331 (MOI=0.005) for 5 h and then treated with increasing concentrations of inhibitors. After 6 h,
332 virus titer in the supernatants was determined by plaque assay. **(F)** Aliquots of the cells treated in
333 **(A)** were lysed and analyzed for E2 expression by immunoblotting (GAPDH was used as a
334 loading control). Densitometric analysis of western blots was performed with ImageJ. **(G)** VEEV
335 copy number (intracellular vRNA) in HeLa cells following treatment with inhibitors as
336 determined by qRT-PCR. HeLa cells were inoculated with VEEV TC-83 (MOI=2) and 5 h later
337 treated with the indicated inhibitors. Cells were lysed and analyzed for virus copy number 11 h
338 after virus addition. **(A-C, E, G)** Values represent the mean \pm SD, $n = 3$. *, $p < 0.05$; **, $p < 0.01$;
339 ***, $p < 0.001$; n.s., not significant, Student's t test (between the sample and DMSO-treated cells).

341 To further validate our results that actin might play a role in the later stages of the
342 alphavirus lifecycle, we tested the effect of various doses of actin polymerization inhibitors

(latrunculin A, cytochalasin B and D) or a microtubule-depolymerizing agent (nocodazole) on VEEV infection rate when added at various time points post virus inoculation. HeLa cells and primary human astrocytes were inoculated with VEEV first and inhibitors were added 3 (HeLa) or 5 (astrocytes) h later. Disruption of actin dynamics by the actin polymerization inhibitors reduced VEEV infection rates and VEEV titer in a dose-dependent manner without cytotoxicity (Fig 4C-E). Although some nocodazole-mediated inhibition of viral infection was observed, inhibition was not as significant as that observed with actin polymerization inhibitors and was accompanied by increased cytotoxicity (Fig 4C and S4A Fig). Phalloidin and tubulin staining demonstrated that the actin and microtubule cytoskeleton morphology was indeed disrupted upon treatment with these inhibitors (S4B-C Fig). These results further imply that actin polymerization might have an essential role in later stages of VEEV infection.

To determine if the actin polymerization inhibitors (latrunculin A and cytochalasin D) might block viral replication or E2 expression at later stages of infection, we inoculated cells with VEEV TC83 and 5 h later treated them with the inhibitors. Intracellular vRNA levels were determined by qRT-PCR 11 h after virus inoculation. Alternatively, cells were lysed and analyzed for E2 expression by immunoblotting. Figure 4F-G shows that both inhibitors had no significant effect on vRNA levels as well as E2 expression levels. Finally, no effect on virus replication was observed when the inhibitors were tested for their effect on a CHIKV replicon system (Fig S4D [31]). Together, the data suggests that the role of actin in the later stages of infection does not involve viral replication or late gene expression.

Alphavirus Infections Cause Major Intracellular Actin Rearrangements Late in Infection

To assess the possible role of actin in the later stages of alphavirus infection, we assessed temporal changes of actin rearrangements during the course of viral infection. HeLa cells were

infected with VEEV, CHIKV, or RVFV (used as a control) and co-stained at the indicated time points with antibodies against viral proteins and phalloidin. Confocal microscopy revealed major changes in the actin-staining pattern within alphavirus-infected cells (VEEV, CHIKV), as indicated by the accumulation of actin in large structures in the cytoplasm (i.e., actin foci, indicated by asterisks in Fig 5A). These foci co-localized with the alphavirus envelope protein E2 (Fig 5A). In contrast, such actin rearrangements were not observed in RVFV- or mock-infected cells (Fig 5A).

Fig 5. Alphavirus infection causes actin rearrangements into actin foci that are Rac1- and Arp3-dependent and that co-localize with Rac1, PIP5K1- α , and E2.

(A) Representative confocal images of mock-, VEEV-, CHIKV-, or RVFV-infected HeLa cells (MOIs = 0.5, 5, or 3, respectively). Cells were fixed and stained with virus-specific antibodies (VEEV and CHIKV E2, RVFV NP; shown in green) and phalloidin (red) 18 h (VEEV) or 24 h (CHIKV, RVFV) after infection. Nucleus staining is shown in blue. Representative actin foci are indicated by asterisks. (B) High-content quantitative image-based analysis was used to measure infection rates of VEEV, CHIKV, and RVFV (left panel), and the number of actin foci per cell (number of actin foci/total cell number, right panel). Analysis is based on single Z sections. ^{***}, $p < 0.0001$, Student's t test (between the sample and mock). (C) VEEV-infected HeLa cells (MOI=0.5) were fixed in formalin at the indicated time points, stained and analyzed as in (B). (B–C) Values represent the mean \pm SD, $n \geq 12$. (D) Representative confocal images of VEEV-infected HeLa cells (MOI=0.5) pretreated with the Rac1 inhibitor EHT1864 or Arp3 inhibitor CK548. Cells were fixed 18 h after virus addition and stained with VEEV E2-specific antibody (green), phalloidin (red), and a nuclear stain (blue). (E) High-content quantitative image-based

analysis was used to measure infection rates of VEEV and the number of actin foci per cell. (F) Confocal images of VEEV-infected HeLa cells (MOI=5). Co-localization of HA-tagged PIP5K1- α (top panel) or Rac1 (bottom panel) (blue), actin (red), and VEEV E2 (green), at a single z section is shown, as well as single channel intensities measured along lines crossing different actin clusters. Insets: zoom on actin filaments indicated by white arrows. VEEV was added to HeLa cells that were reverse-transfected with a plasmid encoding HA-tagged PIP5K1- α or tetracycline-induced T-Rex HeLa cells that expressed Rac1 fused to eGFP. Cells were fixed 20 h later, permeabilized, and stained with VEEV E2-specific antibody, phalloidin, and an antibody against HA.

Actin foci (measured as the number of foci per cell) were further quantified in mock-, VEEV-, CHIKV-, and RVFV-infected cells (Fig 5B). These foci were detected as early as 7 h after VEEV inoculation (Fig 5C) and could also be detected upon infection with other alphaviruses (EEEV, WEEV, and SINV, S5A Fig). We also tested whether alphavirus nsP1, which was previously shown to mediate disruption of actin stress fibers and induction of filopodia-like extensions [34], could induce generation of actin foci. Expression of VEEV TC83 nsP1 in HeLa cells did induce filopodia-like extensions. However, no actin foci were observed (S5B Fig). Overall, our results demonstrate that, as early as 7 h post inoculation with alphaviruses, infection causes major cellular actin rearrangements leading to the formation of actin foci that are not nsP1-dependent and that co-localize with the alphavirus envelope protein E2.

Rac1 and Arp3 Inhibitors Reduce Actin Focus Formation in Alphavirus-infected Cells

Because our data suggested that the function of Rac1 and Arp3, and the formation of actin foci,

take place late in infection (Figure 3 and 5), we speculated that Rac1 and Arp3 proteins might play a role in this alphavirus-induced actin remodeling. To test this hypothesis, HeLa cells were treated with increasing concentrations of Rac1 or Arp3 inhibitors, infected with VEEV, and subsequently stained with fluorescent phalloidin and antibodies against E2. Treatment with either the Rac1 (EHT1864) or Arp3 (CK548) inhibitor significantly reduced the number of actin foci and the percentage of infected cells in a dose-dependent manner (Fig 5D-E). In fact, under these conditions actin foci were rarely observed in confocal images even in E2-positive cells. These observations clarify that Rac1 and Arp3 function upstream of the major actin rearrangements detected in VEEV-infected cells.

Rac1 and PIP5K1- α Co-localize with E2 on Actin Foci and Actin Filaments

Since Rac1-PIP5K1- α complex formation plays a role in alphavirus infection (Fig 2) and because Rac1 inhibitor reduced actin foci formation in alphavirus-infected cells (Fig 5), we next examined whether both host factors could be observed on actin foci and/or filaments within alphavirus-infected cells. Basal-to-apical confocal section series of VEEV-infected HeLa cells are shown in Fig 5F. PIP5K1- α and Rac1 show increased co-localization with actin foci and E2 towards the apical area (S5C-D Fig). Both host factors are also detected along actin filaments, where they co-localize with E2 (Fig 5F, inserts).

Organization and Morphology of Actin Foci and their Co-Localization with the E2 Glycoprotein

To better characterize the nature of the observed actin foci within infected cells, we performed sequential scanning of cells stained for actin and alphavirus E2 in both stimulated emission depletion (STED) microscopy and confocal microscopy imaging modes (for comparison, see S6A Fig). With improved resolution of STED microscopy, actin foci within infected cells were

found to be clusters of filamentous actin [with a diameter range of 5-11 \$\mu\$ m](#) (Fig 6A). Actin filaments within the clusters are seen with VEEV E2 puncta at their ends or along them (Fig 6A). On the cell periphery, E2 puncta are localized in proximity to actin filaments (Fig 6A). E2 puncta are also observed at the ends of actin filaments in primary human astrocytes, and in CHIKV-infected HeLa cells (Fig 6B).

Fig 6. Alphavirus E2 co-localizes with actin filaments and [associates with](#) actin.

(A-B) Representative STED images of HeLa cells or primary human astrocytes infected with VEEV or with CHIKV (MOI=5). Cells were fixed, permeabilized, and stained with E2-specific antibodies (green) and phalloidin (red). Scale bar: 10 μ m. (C) Electron-microscopic images of VEEV-infected HeLa cells (MOI=5). CPV-II structures and thin filaments, which probably correspond to actin, are indicated by filled and open arrows, respectively. An asterisk indicates CPV-I structures. (D) Western blot analysis of input lysates and immunoprecipitates (IP) of mock-, VEEV-, or RVFV-infected HeLa cells under different lysis conditions. Cells were infected for 8 h (MOI=1), lysed, and VEEV E2-, RVFV Gn-, or actin-binding proteins were immunoprecipitated using specific antibodies and immunoblotted with antibodies against VEEV E2, RVFV Gn, or actin. (*) indicates a non-specific band.

In a series of basal- (Section 7) to-apical (Section 25) confocal sections, a single VEEV-infected cell can be seen with an actin cluster (S6B Fig). E2 co-localizes with the actin cluster, and cytoplasm/nucleus staining demonstrates that the generated actin cluster is localized within the cell (S6C Fig). In contrast, co-localization of E2 and microtubules was not significant (S6B Fig).

We also performed electron-microscopic studies to examine the localization of cytoskeletal elements relative to alphaviral CPV-II structures, which compartmentalize the viral glycoproteins E1 and E2 and serve as transport vehicles for the glycoproteins from the TGN to the viral budding sites on the plasma membrane. Electron-microscopic studies of VEEV-infected cells (Fig 6C) show CPV-II structures alongside or at the end of thin filaments, which, based on size and morphology, most likely correspond to actin filaments [12]. CPV-I replication compartments are also present within these cells (Fig 6C, bottom right panel) [9].

Alphavirus E2 Glycoprotein Associates with Actin

Because alphavirus E2 co-localized with actin filaments in infected cells, we next tested whether VEEV E2 associates with actin. HeLa cells were infected with VEEV or RVFV (control) or left uninfected (mock). Virus envelope protein-binding factors were subsequently immunoprecipitated from cell lysates with antibodies to surface glycoproteins E2 (VEEV), or Gn (RVFV). Western blot analysis of the immunoprecipitated fraction (IP) showed enrichment of actin in E2 immunoprecipitates from VEEV-infected cells relative to mock-infected control (more than 4-fold increase by densitometry analysis, Fig 6D, left panel). Such an increase in immunoprecipitated actin was not observed or was minimal in Gn immunoprecipitates from RVFV-infected cells (1.5-fold or less increase by densitometry analysis, Fig 6D, middle panel). To confirm the E2-actin association, we repeated these immunoprecipitation assays using more stringent lysis and washing conditions and performed the reverse experiment using an antibody against actin to examine its ability to immunoprecipitate E2 from VEEV-infected cells. Our results show that antibodies against E2 immunoprecipitated actin (more than 8-fold increase by densitometry analysis) and antibodies against actin immunoprecipitated E2 (more than 4-fold increase by densitometry analysis) from VEEV-infected, but not from mock-infected cells (Fig

6D right panel). These results indicate that VEEV E2 either directly or indirectly associates with actin in lysates from infected cells. However, since our lysis buffer included detergent (NP-40), the observed association between E2 and actin was most likely not in the context of CPV-II structures.

Actin, Rac1, and Arp3 Inhibitors Interfere with Alphavirus E2 Trafficking from TGN to the Cell Surface

E2 was mainly localized in perinuclear puncta in cells treated with the Rac1 and Arp3 inhibitors, whereas in DMSO-treated cells E2 was found throughout the cytoplasm and at the plasma membrane (Fig 5D). Previous studies have demonstrated that the alphavirus glycoproteins E1/E2 are transported from the TGN to the cell surface via TGN-derived vacuoles [12,35], suggesting that the observed puncta might represent TGN or TGN-derived vacuoles. We therefore hypothesized that Rac1- and Arp3-dependent actin remodeling in alphavirus-infected cells might be important for trafficking of E1/E2. To test this hypothesis, primary human astrocytes were treated with DMSO, EHT1864, or CK548 and then infected with VEEV. Cells were stained with antibodies against VEEV E2 glycoprotein and the TGN marker TGN46. VEEV E2 was primarily located at the cell surface in control DMSO-treated cells (Fig 7A, zoom 1). In some of the cells, E2 puncta co-localized with TGN46. However, upon treatment with the Rac1 or Arp3 inhibitors, E2 localization in TGN46-positive puncta was significantly enhanced (Fig 7A, zoom 2 and 3) and less E2 glycoprotein was observed at the cell surface. Quantification of TGN46-to-cell-surface ratio of E2 staining intensity in control- or compound-treated VEEV-infected astrocytes is shown in S7A Fig. Similar experiments performed in HeLa cells using the inhibitors and the TGN marker GGA3 yielded comparable results (S7B Fig).

Figure 7. Actin, Rac1, and Arp3 inhibitors block E2 transport to cell surface.

(A) Representative confocal images of primary human astrocytes treated with DMSO, EHT1864, or CK548 and subsequently infected with VEEV (MOI=0.005) for 18 h. Cells were stained with VEEV E2 (green)- and TGN46-specific antibodies (red), and a nuclear stain (blue).

Representative cells showing co-localization of E2 and TGN46 are indicated with white arrows.

(B and C) Upper panel: Geometrical mean fluorescent intensity of cell-surface E2 staining in

HeLa cells infected with VEEV TC-83 (MOI=10) and treated with EHT1864, CK548,

cytochalasin D, latrunculin A, or nocodazole as measured by flow cytometry. HeLa cells were

infected with VEEV TC-83 for 5 h and subsequently treated with increasing concentrations of

the inhibitors or DMSO (control). Five (B) or six (C) h later cells were dissociated and stained

against VEEV E2 and with a 7-amino-actinomycin D viability dye. Bottom panel: Immunoblot

of total E2 expression in whole cell lysates of HeLa cells described in (B) and (C). GAPDH was

used as a loading control. Densitometric analysis of western blots was performed with ImageJ.

(D) Model for trafficking of alphavirus E2 from the TGN to the cell surface. (1) Biogenesis of

E1/E2-containing vacuoles (CPV-II) at the TGN is dependent on Arf1 and Rac1. (2) E1/E2-

containing CPV-II traffic to the cell surface via actin by a Rac1- and Arp3-dependent

mechanism. Rac1 and PIP5K1- α are also localized to these actin filaments. (3) Actin tunneling

nanotubes mediate alphavirion spread to neighboring cells.

In addition, we developed a flow cytometry-based assay for detection of VEEV E2 on the plasma membrane. We examined cell-surface expression of E2 following treatment with actin polymerization, microtubules depolymerization, Rac1, or Arp3 inhibitors. HeLa cells were infected with VEEV and 5 h later treated with increasing concentrations of EHT1864, CK548,

latrunculin A, cytochalasin D, or nocodazole. Cells were subsequently stained for surface expression of E2 and with the 7-amino-actinomycin D viability dye. Concomitantly, an aliquot of the cells of each treatment group was lysed and analyzed for total E2 expression in whole-cell lysates. None of the inhibitors significantly affected total protein levels of E2. However, the actin, Rac1, and Arp3 inhibitors decreased geometric mean fluorescence intensity of E2 on the cell surface in a dose-dependent manner (Fig 7B and 7C). In contrast, the microtubule inhibitor, nocodazole, had no effect on cell surface E2 expression. The effect of the actin, Rac1, and Arp3 inhibitors on E2 surface expression was specific as no or minimal effect was observed on surface expression of cellular CD44 (S7C Fig).

Overall, our data suggest that actin, Rac1, and Arp3, but not microtubule, inhibitors might interfere with trafficking of E2 from the TGN or TGN-derived vacuoles to the cell surface.

Localization of VEEV-induced Actin Foci, Rac1, and PIP5K1- α in Relation to the TGN

To examine if the actin remodeling observed in alphavirus-infected cells is associated with any TGN membrane structures, we stained VEEV-infected cells with the TGN marker TGN46. Actin clusters were observed in the vicinity of TGN46 (Fig S8A) and VEEV E2 was detected on these actin clusters as well as co-localized with the TGN marker. Rac1 was also found to co-localize with the TGN marker and E2, whereas PIP5K1- α co-localized with E2 but not with TGN46 (Fig S8B and C).

Discussion

Reorganization of the host cytoskeleton varies among infections by different viruses and can play a role in every stage of the viral life cycle. Examples include virion movement (surfing)

towards entry sites and actin-enhanced endocytic entry pathways as well as actin-based, filopodial extensions (termed tunnelling nanotubes) that act as bridges to facilitate virus spread (reviewed in [36-39]).

Here, using an siRNA screen, we identified trafficking host factors that are important for alphavirus infection and are crucial regulators of the actin cytoskeleton. To date, Rac1- and Arp2/3-mediated actin rearrangements have mainly been associated with virus uptake and entry [30,40-44]. Rac1 is predominantly known as a key regulator of the actin cytoskeleton at the plasma membrane [45]. There, Abelson interactor 1 (Abi1) and Wiskott-Aldrich syndrome protein (WASP) family verprolin-homologous protein (WAVE), but not neural (N)-WASP, are essential for Rac1-dependent membrane protrusion and macropinocytosis [46].

Recently, however, Rac1, the Arp2/3 complex, and actin have emerged as major factors in the secretory pathway in processes such as biogenesis and motion of Golgi-derived transport carriers to the plasma membrane [47-50]. During formation of TGN carriers, Rac1 functions downstream of ADP-ribosylation factor 1 (Arf1). Arf1 recruits clathrin/adaptor protein 1 (AP-1)-coated carriers and a complex composed of cytoplasmic fragile X mental retardation 1 (FMR1)-interacting protein (CYFIP), nucleosome assembly protein 1 (NAP1), and Abi1 to the TGN. Rac1 and its exchange factor Rho guanine nucleotide exchange factor 7 (ARHGEF7) bind CYFIP and trigger N-WASP- and Arp2/3-mediated actin polymerization necessary to tubulate clathrin-AP-1-coated carriers [51]. Therefore, during alphavirus infection, Rac1 could potentially be recruited to the TGN to mediate biogenesis of E2-containing vesicles and/or their transport from the TGN to the cell surface via actin (see model, Fig 7D). In support of this hypothesis, some of the host factors mentioned above, such as clathrin heavy chain 1 (CLTC), AP-1 subunits (AP1M1), and Arf1 were identified as hits in our primary and validation siRNA knockdown

573 screens (S1 and S2 Tables). Furthermore, siRNAs targeting N-WASP reduced the infection rate
574 of both VEEV and CHIKV (S1B Fig). Finally, during VEEV infection Rac1 was found to co-
575 localize with E2 at the TGN (Fig S8). Hence, it is plausible that Arf1 functions upstream of Rac1
576 to facilitate biogenesis and/or motion of E2 transport carriers from the TGN to the plasma
577 membrane and that this transport is mediated by N-WASP.

578 Viruses have evolved specific egress pathways for transporting viral components to the
579 plasma membrane, often using the cell's secretory pathway via the endoplasmic reticulum, the
580 Golgi, and even transport vesicles. Most exocytic transport of cellular secretory cargo to the
581 plasma membrane relies on microtubules for long-range translocations [52,53]. The microtubule
582 network is also emerging as the preferred cytoskeletal element recruited for transportation of
583 viral components to the cell surface [54-57]. Examples are delivery of influenza A virus
584 hemagglutinin membrane glycoprotein to the apical surface of MDCK cells [58] and vesicular
585 stomatitis Indiana virus glycoprotein G trafficking from the TGN-to-plasma membrane [59].

586 In contrast, our results demonstrate that transport of the alphavirus membrane glycoprotein
587 E2 is at least in part dependent on actin and actin regulators (Rac1 and Arp3). We hypothesize
588 that the coordinated activities of PIP5K1- α , Rac1, and the Arp2/3 complex might mediate
589 alphavirus envelope E2 trafficking from the TGN to the cell surface via actin. Several results
590 support this actin-dependent transport model (Fig 7D). First, time-of-addition experiments with
591 Rac1 and Arp3 inhibitors demonstrated that both factors function at a late stage of virus infection
592 (Fig 3). Second, within a similar time frame (concomitantly with E2 expression in infected cells)
593 major actin rearrangements into clusters occur in alphavirus-infected cells (Fig 3 and 5). Super
594 high-resolution fluorescence microscopy and electron microscopy show that E2 or E1/E2-
595 containing CPV-II structures, respectively, are localized along or at the end of actin filaments.

Rac1 and PIP5K1- α also co-localize with E2 on actin foci (Fig 5), [and in infected cell lysates](#) E2 envelope protein was found to associate (either directly or indirectly) with actin (Fig 6). [Third](#), Rac1 and Arp3 inhibitors blocked formation of virus-induced actin clusters (Fig 5). In cells treated with actin, Rac1, or Arp3 inhibitors, most of the E2 staining was found to localize with TGN markers, and E2 levels at the cell surface were reduced (Fig 7). We have not yet examined the role of actin, PIP5K1- α , Rac1, and the Arp2/3 complex in E1 trafficking. However, since E1 and E2 are oligomerized into trimeric complexes during transit to the plasma membrane in CPV-II structures [60] we speculate that these host factors will have a similar function in trafficking of both viral proteins.

Actin dynamics are involved in numerous aspects of intracellular transport. However, little is known regarding manipulation of these host machineries by pathogenic alphaviruses. Viruses can serve as unique tools to decipher how a particular cargo recruits actin filament tracks and the host factors and motors associated with these movements. Our results suggest a previously unidentified role of host factors Rac1, Arp3 and PIP5K1- α late in alphavirus infection via actin remodeling that possibly mediates transport of alphavirus envelope glycoproteins from the TGN to the cell surface. It is important to note that although our data indicate that actin plays a major role in alphavirus glycoprotein transport, our experiments do not exclude the existence of other, parallel, transport mechanisms mediated by intermediate filaments or microtubules. Recombinant alphaviruses expressing tagged E2 could be useful to further substantiate our findings. However, until now, we have not succeeded in rescuing such viruses. Finally, our high-content siRNA screen reveals novel host regulators of alphavirus infection and potential therapy targets.

Materials and Methods

siRNA Screens

An arrayed library targeting 140 trafficking genes (Dharmacon Human ON-TARGETplus siRNA Library - Membrane Trafficking - SMARTpool, G-105500-05, Thermo Scientific, Lafayette, CO) was used to transiently reverse-transfected HeLa cells (10,000 cells per well, 96-well format) in triplicate at a 30 nM final concentration, using HiPerfect (Qiagen). Cells were washed on the following day and 24 h later infected with VEEV ICS-SH3 at a multiplicity of infection (MOI) of 0.5 for 20 h. Cells were fixed with 10% formalin (Val Tech Diagnostics), and stained for high-content quantitative image-based analysis. The screen was repeated three times. In 6 wells on each plate, cells were transfected with a negative control siRNA (NT, siCONTROL Non-Targeting siRNA #2, Dharmacon D-001210-02). The infection rate of control siRNA-transfected cells was optimized to yield, on average, 70–80%, following multiple virus replication cycles.

For the primary screen, siRNA pools were classified as hits if the average of triplicate wells showed that the percentage of VEEV-positive cells was decreased by more than 30% as compared to that observed with the control siRNA wells on the plate (Z-score <-2 SD). In the validation screen, the individual oligomers comprising each pool were placed into separate wells, and the screen was repeated. siRNA targets were considered validated if two or more of the individual oligomers were classified as hits compared to the control wells on the plate (similar parameters as above), and if the cell number was not less than 30% of the average of the negative control wells on the plate. The percent of infected cells relative to controls, as well as the normalized cell numbers (normalized to control siRNA) is provided in Table S1.

Table 1. Sources of human-sequence reagents

cDNA/Gene	Primer Function	Catalog Number /	Vendor
-----------	-----------------	------------------	--------

		Sequence	
RAC1-1	siRNA	J-003560-14/ GUGAUUUCAUA GCGAGUUU	Dharmacon/Thermo Scientific
RAC1-2	siRNA	J-003560-15/ GUAGUUCUCAG AUGCGUAA	Dharmacon/Thermo Scientific
RAC1-3	siRNA	J-003560-16/ AUGAAAGUGUC ACGGGUAA	Dharmacon/Thermo Scientific
RAC1-4	siRNA	J-003560-17/ GAACUGCUAUU UCCUCUAA	Dharmacon/Thermo Scientific
RAC1-5	siRNA	s11711	Applied Biosystems/Life Technologies
RAC1-6	siRNA	s117112	Applied Biosystems/Life Technologies
RAC1-7	siRNA	s11713	Applied Biosystems/Life Technologies
ACTR3-1	siRNA	J-012077-06/ GCAGUAAAGGA GCGCUAUA	Dharmacon/Thermo Scientific
ACTR3-2	siRNA	J-012077-07/ GUGAUUGGCAG CUGUAUUA	Dharmacon/Thermo Scientific

ACTR3-3	siRNA	J-012077-08/ GGAAUUGAGUG GUGGUAGA	Dharmacon/Thermo Scientific
ACTR3-4	siRNA	J-012077-09/ GCCAAAACCUA UUGAUGUA	Dharmacon/Thermo Scientific
ACTR3-5	siRNA	s19640	Applied Biosystems/Life Technologies
ACTR3-6	siRNA	s19641	Applied Biosystems/Life Technologies
ACTR3-7	siRNA	s19642	Applied Biosystems/Life Technologies
PIP5K1A-1	siRNA	J-004780-09/ ACACAGUACUC AGUUGAUA	Dharmacon/Thermo Scientific
PIP5K1A-2	siRNA	J-004780-10/ GCACAACGAGA GCCCUUAA	Dharmacon/Thermo Scientific
PIP5K1A-3	siRNA	J-004780-11/ GUGGUUCCCUA UUCUAUGU	Dharmacon/Thermo Scientific
PIP5K1A-4	siRNA	J-004780-12/ GUAAGACCCUG CAGCGUGA	Dharmacon/Thermo Scientific
PIP5K1A-5	siRNA	s15932	Applied Biosystems/Life

			Technologies
WASL-1	siRNA	s17132	Applied Biosystems/Life
			Technologies
WASL-2	siRNA	s17133	Applied Biosystems/Life
			Technologies
WASL-3	siRNA	s17134	Applied Biosystems/Life
			Technologies
PPIB	qRT-PCR	Hs00168719_m1	Applied Biosystems/Life
			Technologies
PIP5K1A	qRT-PCR	Hs00801004_s1	Applied Biosystems/Life
			Technologies
TC83 forward primer	qRT-PCR	CTTGGCAAACC TCTGGCAGC	Life Technologies
TC83 Probe	qRT-PCR	6FAM- CTCTTCATGCAA TGCCCTTCTCCT GTCA	Life Technologies
TC83 reverse primer	qRT-PCR	ATACCCACTCG GTTCCAGCG	Life Technologies
Rac1 K186E forward primer	Site-directed mutagenesis	5'-CCC GCC TCC CGT GAA GAA GAA GGA GAG AAA ATG CC-3'	Integrated DNA Technologies
Rac1 K186E reverse primer	Site-directed mutagenesis	5'-GGC ATT TTC TCT CCT TCT	Integrated DNA Technologies

TCT TCA CGG

GAG GCG GG-3'

641

642 **Cell Lines and Plasmid Constructs**

643 HeLa (ATCC, #CCL-2), BHK-21 (ATCC, #CCL-10), and Vero cells (ATCC, #CCL-81) were
644 maintained in Eagle's minimum essential medium supplemented with 10% fetal calf serum. T-
645 REx-HeLa cells expressing human wild type Rac1 fused to eGFP, and Flp-In 293 T-REx cells
646 expressing human wild type Rac1, Rac1 G12V, Rac1 T17N, Rac1 K186E or CAT upon
647 tetracycline induction were generated by using the T-REx System or the Flp-In T-REx system,
648 respectively, according to the manufacturer's instructions (Life Technologies). Cells were
649 induced to express wild-type human Rac1, variants thereof, or CAT in 96-well plates by adding
650 tetracycline (1 µg/ml) to the growth medium. Normal human astrocytes were obtained from
651 Lonza and maintained according to the provider's instructions. Plasmids encoding Rac1 variants
652 (wild-type Rac1, Rac1 T17N or Rac1 G12V) fused to a myc tag were purchased from the
653 Missouri S&T cDNA Resource Center (www.cdna.org). A plasmid encoding Rac1 K186E was
654 generated by using the QuikChange Lightning Site-Directed Mutagenesis Kit (Agilent
655 Technologies). A plasmid encoding pcDNA3-EGFP-Rac1-wt was obtained from Addgene.

656 **Antibodies, Dyes, and Pharmacological Inhibitors**

657 Mouse monoclonal antibodies against CHIKV (2D21-1), EEEV (1C2), VEEV (1A4A-1), WEEV
658 (9F12), and RVFV envelope glycoprotein Gn (4D4) and NP (R3-ID8-1-1) were obtained from
659 USAMRIID archives [61]. Goat antibody against VEEV capsid (C) or envelope protein was
660 generously provided by AlphaVax (via Kurt Kamrud). Rabbit antibodies against Arp3, actin, N-
661 WASP, GAPDH, FLAG, and HA were obtained from Sigma-Aldrich. Mouse monoclonal
662 antibodies against actin, CD44, GGA3, and Rac1 were purchased from BD Transduction

Laboratories. Rabbit antibody against α/β -tubulin was obtained from Cell Signaling Technology. Sheep anti-human TGN46 antibody was from AbD Serotec. Alexa Fluor-conjugated antibodies and phalloidin, Hoechst 33342, and HCS CellMask Red were obtained from Life Technologies. All chemical inhibitors were purchased from Sigma-Aldrich, with the exception of EHT1864 (Tocris Bioscience). Cells were incubated with inhibitors for 1 h before addition of viruses unless otherwise indicated in the figure legend.

Virus Infections, Viral Transduction, and Replicon Assays

Infections with VEEV IC-SH3, EEEV FL91-4679, WEEV CBA87, RVFV ZH501, and CHIKV AF15561 were conducted under Biosafety Laboratory 3 conditions. All alphaviruses were propagated in BHK-21 cells and purified via sucrose gradients. RVFV was propagated in Vero cells. Viral infectivity was titrated by plaque assays as previously described [62].

MoMLV-eGFP pseudotypes carrying the VEEV envelope proteins E1/E2 or Ebola virus envelope GP_{1,2} (control) were produced as previously described [27,28,63]. MoMLV-eGFP pseudotypes were added to siRNA-treated HeLa cells for 6 h. Cells were then washed and supplemented with growth medium. Cell transduction efficiency was determined 2 days later by measuring eGFP expression using an Opera confocal reader (PerkinElmer).

For CHIKV replicon assays, we used the previously described BHK-CHIKV-NCT cells, which contain the CHIKV replicon with two reporter genes, *Rluc* and *EGFP* [31]. BHK-CHIKV-NCT cells were seeded onto 96-well plates at densities of 2×10^4 cells/well, incubated overnight, and treated with the indicated compounds at various concentrations. After exposure for 48 h, the *Renilla* luciferase (*Rluc*) activity resulting from the translation of CHIKV-*Rluc* genomic RNA was determined from the lysates using a *Renilla* luciferase assay kit (Promega) with a Tecan microplate reader.

Immunoprecipitation and Western Blot Analyses

HeLa cells in 6-well plates were infected with VEEV TC-83 or RVFV MP12 (MOI=1) for 8 h. Cells were lysed in a mild lysis buffer (50 mM Tris pH 7.4, 50 mM NaCl, 0.2 mM EDTA, and 1% Triton X-100) or a lysis buffer (25 mM Tris pH 7.4, 150 mM NaCl, 1 mM EDTA, 5% glycerol, and 1% NP-40) from Pierce Crosslink Immunoprecipitation Kit supplemented with Complete protease inhibitor cocktail (Thermo Scientific Pierce). Cleared lysates were incubated overnight at 4°C with protein A/G beads (Thermo Scientific Pierce) and VEEV E2- or RVFV Gn-specific antibodies or with beads cross-linked to antibodies against VEEV E2 or actin. Cell lysate immunoprecipitates were analyzed by SDS-PAGE and immunoblotting using the indicated antibodies.

For western blot analyses, cells were lysed with RIPA lysis and extraction buffer supplemented with complete protease inhibitor cocktail (Thermo Scientific Pierce). Cleared lysates were analyzed by SDS-PAGE and immunoblotting using WesternBreeze chromogenic or chemiluminescent kits (Life Technologies) and the indicated antibodies. Densitometric analysis of western blots was performed with ImageJ [64].

Stimulated Emission Depletion Microscopy (STED)

Cells were grown on glass cover slips and inoculated with VEEV or CHIKV for 1 h. Cells were fixed 20 h (VEEV) or 48 h (CHIKV) later, permeabilized with 0.5% Triton X-100 (Sigma-Aldrich) in PBS, blocked with 3% BSA in PBS for 1 h, and stained using mouse anti-E2 antibodies (1:1,000 dilution), followed by ATTO 647N Goat Anti-Mouse IgG (Active Motif) (1:2,000 dilution). Actin was stained with Phalloidin ATTO 565 (Sigma-Aldrich) (1:80 dilution). Slides were mounted in ProLong Gold Antifade Reagent (Life Technologies) and dried overnight at room temperature before imaging. All confocal images were acquired on the Leica SP5 TCS

2C STED confocal system (Leica Microsystems) equipped with Leica's inverted DMI 6000 microscope and STED 100x oil objective. Images were acquired at an imaging speed of 400 Hz, pin hole set to Airy1, line average of 6, and 1024 X 1024 formats. For STED of ATTO dyes, the pulsed Ti:SA infra red laser (Mai Tai, model # MAI TAI BB990, Spectra-Physics) was tuned to 740 nm.

Electron Microscopy

HeLa cells grown on a MatTek dish (MatTek corporation, MA) were infected with VEEV TC83 (MOI=5) for 20 h. Cells were fixed for 1 h in primary fixative (2.5% formaldehyde, 2.5% glutaraldehyde, 0.1 M sodium cacodylate, pH 7.4), washed three times in ice-cold 0.1 M sodium cacodylate buffer, incubated with 1% osmium tetroxide in 0.1 M sodium cacodylate for 1 h, washed three times with distilled water, stained and stabilized on ice in ice-cold 2% uranyl acetate for 1 h and successively dehydrated on ice in ethanol series of 22%, 50%, 75%, and 95%. The cells were then dehydrated three times at room temperature in 100% ethanol and infiltrated in well-mixed 50% ethanol, 50% Durcupan ACM resin (Fluka, Sigma-Aldrich) for 1 h with agitation. Cells were infiltrated twice by 100% Durcupan ACM for 3 h with agitation, after which the samples were placed in an oven and allowed to polymerized at 60 °C for at least 48 h. The glass coverslip was peeled away from the bottom using a razor blade and the selected area was cut out and glued to a block for sectioning. Thin sections (approximately 80 nm) were collected and pre-stained with 1% uranyl acetate and Sato lead before examination on a JEOL 1011 transmission electron microscope at 80 kV. Digital images were acquired using an AMT camera system.

Immunofluorescence and High-content Quantitative Image-based Analysis

Plasmid encoding HA-tagged PIP5K1 α was generously provided by Dr. Richard Anderson (University of Wisconsin). Plasmid encoding FLAG-tagged nsP1 was generated in-house by PCR. Plasmids were transiently reverse-transfected into HeLa cells on glass coverslips (Fisher Scientific) using Lipofectamine LTX Reagent (Life Technologies). T-REx HeLa cells on glass coverslips were induced with tetracycline for 24 h to express Rac1-eGFP. VEEV-infected cells were fixed, permeabilized, and blocked as described for STED. After incubation with primary antibodies and fluorescent secondary antibodies, slides were mounted as described for STED and air-dried before imaging with a Leica TCS-SP5 confocal/multiphoton microscope (Leica Microsystems). All confocal images represent a single plane acquired with a 100 \times oil objective. Similar experimental conditions were used for imaging studies of actin, tubulin, TGN46, and VEEV E2 in HeLa cells. Co-localization analysis of tubulin or actin with VEEV E2 was performed with the ImageJ program using the Interactive 3D Surface Plot plugin [64].

For analysis of the siRNA screen, cells were stained without prior permeabilization. Cells inoculated with CHIKV, EEEV, RVFV, WEEV or SINV or cells processed for phalloidin or TGN staining were permeabilized prior to blocking as described above. Cells were then stained with murine monoclonal antibodies against the indicated viral proteins (1:1,000 dilution) and, where indicated, against TGN46 or GGA3 (1:250 dilution). Subsequently, cells were stained with appropriate Alexa Fluor-conjugated antibodies (1:1,000 dilution), and Alexa Fluor 568 Phalloidin (1:100 dilution) where indicated. All infected cells were also stained with Hoechst 33342 and HCS CellMask DeepRed for nuclei and cytoplasm detection, respectively.

High-content quantitative imaging data were acquired and analyzed on an Opera QEHS (quadruple excitation high sensitivity) confocal reader (model 3842 and 5025; Perkin-Elmer), at two exposures using a $\times 10$ air, $\times 20$ water, or $\times 40$ water objective lenses as described in [65].

Analysis of the images was accomplished using Acapella 2.0, 2.6, 2.7 (Perkin-Elmer) scripts in Evoshell or the building-blocks interface in the Columbus image analysis server. Nuclei and cytoplasm staining were used to determine total cell number and cell borders, respectively. Mock-infected cells were used to establish a fluorescence intensity threshold for virus-specific staining. Quantification of virus positive cells was subsequently performed based on mean fluorescent intensities in the virus-specific staining channel. Infection rates were then determined by dividing the number of virus positive cells by the total number of cells measured. Detailed pipelines for image-based quantification of alphavirus-induced actin foci and TGN46-to-plasma membrane E2 staining intensity ratio are available upon request. At least 5000 cells and up to 15,000 cells were analyzed per replicate in drug- or siRNA-treated cells. For actin foci analysis, 1000–1500 cells were used per replicate. For analysis of TGN46-to-plasma membrane E2 staining intensity ratio, 700 cells were used per replicate.

Flow Cytometry

HeLa cells in 12-well plates were inoculated with VEEV TC-83 (MOI=10) for 5 h. DMSO, EHT1864, CK548, nocodazole, latrunculin A, or cytochalasin D were subsequently added at the indicated concentrations. Five or 6 h later, cells were detached with Cell Dissociation Buffer (Life Technologies) and washed with flow buffer (PBS/0.5% BSA/2mM EDTA). Cells were incubated with mouse anti-VEEV E2, or CD44 primary antibody (1:1,000 dilution in flow buffer) for 30 min on ice and then washed twice with ice-cold flow buffer. Cells were incubated for 20 min in the dark with Alexa Fluor 488 Goat Anti-Mouse IgG secondary antibody (Life Technologies) (1:5,000 dilution in ice-cold flow buffer) and with 7-amino-actinomycin D to exclude dead cells from analysis (1:500 dilution). Following two more washes with ice-cold flow

buffer, cells were fixed in 1% paraformaldehyde. Cytometric collection was performed using a FACS Canto II (BD Biosciences), and data were analyzed using Flowjo v7.6.5 (TreeStar).

qRT-PCR

VEEV TC-83 RNA yields in the media and in the cells as well as relative expression levels of PIP5K1 α in siRNA-treated HeLa cells were determined by qRT-PCR as previously described [65]. Serial 10-fold dilutions of the assayed (10^2 to 10^7 copies) virus were used as standards. Relative expression levels were determined by using the comparative C_T method.

Statistical Analysis

Data are representative of at least three independent experiments, and values are given as mean of triplicates \pm standard deviation (SD) unless otherwise indicated. Statistical significance was determined by the paired Student's t test.

Acknowledgments

We thank Laura Bollinger (IRF-Frederick), Thomas Postler (Columbia University), Philip Kranzusch (University of California, Berkeley), and David Cureton (Centers for Disease Control and Prevention) for critically editing the manuscript. We thank Candace Blancett (USAMRIID) for preparing EM samples. The content of this publication does not necessarily reflect the views or policies of the US Department of the Army, the US Department of Defense or the US Department of Health and Human Services or of the institutions and companies affiliated with the authors.

References

1. Weaver SC, Ferro C, Barrera R, Boshell J, Navarro JC (2004) Venezuelan equine encephalitis. *Annu Rev Entomol* 49: 141-174.

- 799 2. Zacks MA, Paessler S (2010) Encephalitic alphaviruses. *Vet Microbiol* 140: 281-286.
- 800 3. Weaver SC, Osorio JE, Livengood JA, Chen R, Stinchcomb DT (2012) Chikungunya virus
801 and prospects for a vaccine. *Expert Rev Vaccines* 11: 1087-1101.
- 802 4. Van Bortel W, Dorleans F, Rosine J, Blateau A, Rousset D, et al. (2014) Chikungunya
803 outbreak in the Caribbean region, December 2013 to March 2014, and the significance
804 for Europe. *Euro Surveill* 19.
- 805 5. Froshauer S, Kartenbeck J, Helenius A (1988) Alphavirus RNA replicase is located on the
806 cytoplasmic surface of endosomes and lysosomes. *J Cell Biol* 107: 2075-2086.
- 807 6. Frolova EI, Gorchakov R, Pereboeva L, Atasheva S, Frolov I (2010) Functional Sindbis virus
808 replicative complexes are formed at the plasma membrane. *J Virol* 84: 11679-11695.
- 809 7. Spuul P, Balistreri G, Kaariainen L, Ahola T (2010) Phosphatidylinositol 3-kinase-, actin-, and
810 microtubule-dependent transport of Semliki Forest Virus replication complexes from the
811 plasma membrane to modified lysosomes. *J Virol* 84: 7543-7557.
- 812 8. Grimley PM, Berezesky IK, Friedman RM (1968) Cytoplasmic structures associated with an
813 arbovirus infection: loci of viral ribonucleic acid synthesis. *J Virol* 2: 1326-1338.
- 814 9. Kujala P, Ikaheimonen A, Ehsani N, Vihinen H, Auvinen P, et al. (2001) Biogenesis of the
815 Semliki Forest virus RNA replication complex. *J Virol* 75: 3873-3884.
- 816 10. Garoff H, Wilschut J, Liljestrom P, Wahlberg JM, Bron R, et al. (1994) Assembly and entry
817 mechanisms of Semliki Forest virus. *Arch Virol Suppl* 9: 329-338.
- 818 11. Griffiths G, Quinn P, Warren G (1983) Dissection of the Golgi complex. I. Monensin inhibits
819 the transport of viral membrane proteins from medial to trans Golgi cisternae in baby
820 hamster kidney cells infected with Semliki Forest virus. *J Cell Biol* 96: 835-850.

- 821 12. Soonsawad P, Xing L, Milla E, Espinoza JM, Kawano M, et al. (2010) Structural evidence of
822 glycoprotein assembly in cellular membrane compartments prior to alphavirus budding. J
823 Virol 84: 11145-11151.
- 824 13. Orvedahl A, Sumpter R, Jr., Xiao G, Ng A, Zou Z, et al. (2011) Image-based genome-wide
825 siRNA screen identifies selective autophagy factors. Nature 480: 113-117.
- 826 14. Rose PP, Hanna SL, Spiridigliozzi A, Wannissorn N, Beiting DP, et al. (2011) Natural
827 resistance-associated macrophage protein is a cellular receptor for Sindbis virus in both
828 insect and mammalian hosts. Cell Host Microbe 10: 97-104.
- 829 15. Panda D, Rose PP, Hanna SL, Gold B, Hopkins KC, et al. (2013) Genome-wide RNAi screen
830 identifies SEC61A and VCP as conserved regulators of Sindbis virus entry. Cell Rep 5:
831 1737-1748.
- 832 16. Pollard TD (2007) Regulation of actin filament assembly by Arp2/3 complex and formins.
833 Annu Rev Biophys Biomol Struct 36: 451-477.
- 834 17. Goley ED, Welch MD (2006) The ARP2/3 complex: an actin nucleator comes of age. Nat
835 Rev Mol Cell Biol 7: 713-726.
- 836 18. Hall A (1998) Rho GTPases and the actin cytoskeleton. Science 279: 509-514.
- 837 19. Martin TFJ (1998) Phosphoinositide lipids as signaling molecules: common themes for
838 signal transduction, cytoskeletal regulation, and membrane trafficking. Annual Review of
839 Cell and Developmental Biology 14: 231-264.
- 840 20. Gao Y, Dickerson JB, Guo F, Zheng J, Zheng Y (2004) Rational design and characterization
841 of a Rac GTPase-specific small molecule inhibitor. Proc Natl Acad Sci U S A 101: 7618-
842 7623.

- 843 21. Shutes A, Onesto C, Picard V, Leblond B, Schweighoffer F, et al. (2007) Specificity and
844 mechanism of action of EHT 1864, a novel small molecule inhibitor of Rac family small
845 GTPases. *J Biol Chem* 282: 35666-35678.
- 846 22. Nolen BJ, Tomasevic N, Russell A, Pierce DW, Jia Z, et al. (2009) Characterization of two
847 classes of small molecule inhibitors of Arp2/3 complex. *Nature* 460: 1031-1034.
- 848 23. Feig LA, Cooper GM (1988) Inhibition of NIH 3T3 cell proliferation by a mutant ras protein
849 with preferential affinity for GDP. *Mol Cell Biol* 8: 3235-3243.
- 850 24. Bourne HR, Sanders DA, McCormick F (1991) The GTPase superfamily: conserved
851 structure and molecular mechanism. *Nature* 349: 117-127.
- 852 25. Tolia KF, Hartwig JH, Ishihara H, Shibasaki Y, Cantley LC, et al. (2000) Type I alpha
853 phosphatidylinositol-4-phosphate 5-kinase mediates Rac-dependent actin assembly. *Curr*
854 *Biol* 10: 153-156.
- 855 26. Chao WT, Daquinag AC, Ashcroft F, Kunz J (2010) Type I PIPK-alpha regulates directed
856 cell migration by modulating Rac1 plasma membrane targeting and activation. *J Cell Biol*
857 190: 247-262.
- 858 27. Kolokoltsov AA, Fleming EH, Davey RA (2006) Venezuelan equine encephalitis virus entry
859 mechanism requires late endosome formation and resists cell membrane cholesterol
860 depletion. *Virology* 347: 333-342.
- 861 28. Radoshitzky SR, Warfield KL, Chi X, Dong L, Kota K, et al. (2011) Ebolavirus delta-peptide
862 immunoadhesins inhibit marburgvirus and ebolavirus cell entry. *J Virol* 85: 8502-8513.
- 863 29. Saeed MF, Kolokoltsov AA, Freiberg AN, Holbrook MR, Davey RA (2008)
864 Phosphoinositide-3 kinase-Akt pathway controls cellular entry of Ebola virus. *PLoS*
865 *Pathog* 4: e1000141.

- 866 30. Nanbo A, Imai M, Watanabe S, Noda T, Takahashi K, et al. (2010) Ebolavirus is internalized
867 into host cells via macropinocytosis in a viral glycoprotein-dependent manner. PLoS
868 Pathog 6: e1001121.
- 869 31. Pohjala L, Utt A, Varjak M, Lulla A, Merits A, et al. (2011) Inhibitors of alphavirus entry
870 and replication identified with a stable Chikungunya replicon cell line and virus-based
871 assays. PLoS One 6: e28923.
- 872 32. Karmysheva B, Mironova LL, Ovsianikova NV, Popova VD (1988) [Changes in cellular
873 microfilaments in viral infection]. Vopr Virusol 33: 711-717.
- 874 33. Paingankar MS, Arankalle VA (2014) Identification of chikungunya virus interacting
875 proteins in mammalian cells. J Biosci 39: 389-399.
- 876 34. Laakkonen P, Auvinen P, Kujala P, Kaariainen L (1998) Alphavirus replicase protein NSP1
877 induces filopodia and rearrangement of actin filaments. J Virol 72: 10265-10269.
- 878 35. Griffiths G, Fuller SD, Back R, Hollinshead M, Pfeiffer S, et al. (1989) The dynamic nature
879 of the Golgi complex. J Cell Biol 108: 277-297.
- 880 36. Radtke K, Dohner K, Sodeik B (2006) Viral interactions with the cytoskeleton: a hitchhiker's
881 guide to the cell. Cell Microbiol 8: 387-400.
- 882 37. Yamauchi Y, Helenius A (2013) Virus entry at a glance. J Cell Sci 126: 1289-1295.
- 883 38. Brandenburg B, Zhuang X (2007) Virus trafficking - learning from single-virus tracking. Nat
884 Rev Microbiol 5: 197-208.
- 885 39. Taylor MP, Koyuncu OO, Enquist LW (2011) Subversion of the actin cytoskeleton during
886 viral infection. Nat Rev Microbiol 9: 427-439.
- 887 40. Sanchez EG, Quintas A, Perez-Nunez D, Nogal M, Barroso S, et al. (2012) African swine
888 fever virus uses macropinocytosis to enter host cells. PLoS Pathog 8: e1002754.

- 889 41. Mercer J, Helenius A (2008) Vaccinia virus uses macropinocytosis and apoptotic mimicry to
890 enter host cells. *Science* 320: 531-535.
- 891 42. Amstutz B, Gastaldelli M, Kalin S, Imelli N, Boucke K, et al. (2008) Subversion of CtBP1-
892 controlled macropinocytosis by human adenovirus serotype 3. *EMBO J* 27: 956-969.
- 893 43. Wang JL, Zhang JL, Chen W, Xu XF, Gao N, et al. (2010) Roles of small GTPase Rac1 in
894 the regulation of actin cytoskeleton during dengue virus infection. *PLoS Negl Trop Dis* 4.
- 895 44. Schelhaas M, Shah B, Holzer M, Blattmann P, Kuhling L, et al. (2012) Entry of human
896 papillomavirus type 16 by actin-dependent, clathrin- and lipid raft-independent
897 endocytosis. *PLoS Pathog* 8: e1002657.
- 898 45. Bustelo XR, Ojeda V, Barreira M, Sauzeau V, Castro-Castro A (2012) Rac-ing to the plasma
899 membrane: the long and complex work commute of Rac1 during cell signaling. *Small*
900 *GTPases* 3: 60-66.
- 901 46. Innocenti M, Gerboth S, Rottner K, Lai FP, Hertzog M, et al. (2005) Abi1 regulates the
902 activity of N-WASP and WAVE in distinct actin-based processes. *Nat Cell Biol* 7: 969-
903 976.
- 904 47. Anitei M, Hoflack B (2012) Bridging membrane and cytoskeleton dynamics in the secretory
905 and endocytic pathways. *Nat Cell Biol* 14: 11-19.
- 906 48. Wang B, Wylie FG, Teasdale RD, Stow JL (2005) Polarized trafficking of E-cadherin is
907 regulated by Rac1 and Cdc42 in Madin-Darby canine kidney cells. *Am J Physiol Cell*
908 *Physiol* 288: C1411-1419.
- 909 49. Kraynov VS, Chamberlain C, Bokoch GM, Schwartz MA, Slabaugh S, et al. (2000)
910 Localized Rac activation dynamics visualized in living cells. *Science* 290: 333-337.

- 911 50. Fucini RV, Chen JL, Sharma C, Kessels MM, Stamnes M (2002) Golgi vesicle proteins are
912 linked to the assembly of an actin complex defined by mAbp1. *Mol Biol Cell* 13: 621-
913 631.
- 914 51. Anitei M, Stange C, Parshina I, Baust T, Schenck A, et al. (2010) Protein complexes
915 containing CYFIP/Sra/PIR121 coordinate Arf1 and Rac1 signalling during clathrin-AP-1-
916 coated carrier biogenesis at the TGN. *Nat Cell Biol* 12: 330-340.
- 917 52. Puertollano R, van der Wel NN, Greene LE, Eisenberg E, Peters PJ, et al. (2003)
918 Morphology and dynamics of clathrin/GGA1-coated carriers budding from the trans-
919 Golgi network. *Mol Biol Cell* 14: 1545-1557.
- 920 53. Wacker I, Kaether C, Kromer A, Migala A, Almers W, et al. (1997) Microtubule-dependent
921 transport of secretory vesicles visualized in real time with a GFP-tagged secretory
922 protein. *J Cell Sci* 110 (Pt 13): 1453-1463.
- 923 54. Diefenbach RJ, Miranda-Saksena M, Douglas MW, Cunningham AL (2008) Transport and
924 egress of herpes simplex virus in neurons. *Rev Med Virol* 18: 35-51.
- 925 55. Chambers R, Takimoto T (2010) Trafficking of Sendai virus nucleocapsids is mediated by
926 intracellular vesicles. *PLoS One* 5: e10994.
- 927 56. Collier KE, Heaton NS, Berger KL, Cooper JD, Saunders JL, et al. (2012) Molecular
928 determinants and dynamics of hepatitis C virus secretion. *PLoS Pathog* 8: e1002466.
- 929 57. Gaudin R, de Alencar BC, Jouve M, Berre S, Le Boudier E, et al. (2012) Critical role for the
930 kinesin KIF3A in the HIV life cycle in primary human macrophages. *J Cell Biol* 199:
931 467-479.

58. van Zeijl MJ, Matlin KS (1990) Microtubule perturbation inhibits intracellular transport of an apical membrane glycoprotein in a substrate-dependent manner in polarized Madin-Darby canine kidney epithelial cells. *Cell Regul* 1: 921-936.
59. Toomre D, Keller P, White J, Olivo JC, Simons K (1999) Dual-color visualization of trans-Golgi network to plasma membrane traffic along microtubules in living cells. *J Cell Sci* 112 (Pt 1): 21-33.
60. Jose J, Snyder JE, Kuhn RJ (2009) A structural and functional perspective of alphavirus replication and assembly. *Future Microbiol* 4: 837-856.
61. Battles JK, Dalrymple JM (1988) Genetic variation among geographic isolates of Rift Valley fever virus. *Am J Trop Med Hyg* 39: 617-631.
62. Mudhasani R, Tran JP, Retterer C, Radoshitzky SR, Kota KP, et al. (2013) IFITM-2 and IFITM-3 but not IFITM-1 restrict Rift Valley fever virus. *J Virol* 87: 8451-8464.
63. Radoshitzky SR, Abraham J, Spiropoulou CF, Kuhn JH, Nguyen D, et al. (2007) Transferrin receptor 1 is a cellular receptor for New World haemorrhagic fever arenaviruses. *Nature* 446: 92-96.
64. Schneider CA, Rasband WS, Eliceiri KW (2012) NIH Image to ImageJ: 25 years of image analysis. *Nat Methods* 9: 671-675.
65. Radoshitzky SR, Dong L, Chi X, Clester JC, Retterer C, et al. (2010) Infectious Lassa virus, but not filoviruses, is restricted by BST-2/tetherin. *J Virol* 84: 10569-10580.

Supporting Information

S1 Table. Summary of the primary siRNA screen.

The primary screen was performed using a pool of four siRNA duplexes per gene from a Dharmacon Membrane Trafficking library. The measured effects of each annotated siRNA pool on VEEV infection rate and cell number is normalized to that observed with control siRNA.

S2 Table. Summary of the follow-up siRNA screen.

For the deconvolution screen, the four individual duplexes siRNAs from each siRNA pool were used. The measured effects of each annotated siRNA duplex on VEEV infection rate and cell number is normalized to that observed with control siRNA.

S1 Fig. siRNA screen identifies host regulators of alphavirus infection.

(A) High-content quantitative image-based analysis was used to measure relative infection rates (normalized to control siRNA-treated cells) of CHIKV in HeLa cells pretreated with the indicated siRNAs. Cells were infected for 24 h (CHIKV, MOI=5), fixed and stained with antibodies against E2. (B) HeLa cells were pretreated with the indicated siRNAs and infected for 20 h with VEEV (MOI=0.5) or for 24 h with CHIKV (MOI=5). Cells were fixed, stained, and analyzed as in (A). Protein levels of N-WASP and actin (loading control) following siRNA treatment were determined by immunoblotting. Values represent the mean \pm SD, n = 3.

S2 Fig. Rac1, Arp3, and formation of a Rac1:PIP5K1- α complex are important for alphavirus infection.

(A) Primary human astrocytes were treated with increasing concentrations of CK548 and subsequently infected with EEEV or WEEV (MOI=0.005). Cells were fixed in formalin 19 h after infection, stained with virus-specific antibodies and analyzed using an Opera confocal

imager. Results are normalized to DMSO-treated samples. **(B)** HeLa cells were treated with CK548 or EHT1864 and subsequently infected with CHIKV or SINV (MOI=5). Cells were fixed 20 h (SINV) or 48 h (CHIKV) later and analyzed as in **(A)**. **(C)** Representative confocal images of **(Fig 2F)**. VEEV E2 glycoprotein staining is shown in green and nucleus/cytoplasm staining is shown in red. **(D)** Flp-In T-REx 293 cells pre-induced to express chloramphenicol acetyltransferase (CAT), wild-type Rac1, or variants thereof were infected with VEEV (MOI=0.1). After 18 h, virus titer in the supernatants was determined by plaque assay. **, $p < 0.01$, Student's t test (between samples and CAT). **(E)** Representative confocal images of **(Fig 2H)**. Coloring as in **(C)**. **(F)** Confocal images of Flp-In T-REx 293 cells that were induced as in **(D)**, inoculated with WEEV (MOI=0.005), fixed 18 h later, and stained with virus-specific antibodies (green) and nuclear stain (blue). **(G, H)** High-content quantitative image-based analysis of CHIKV infection rates in Flp-In T-REx 293 cells pre-induced as in **(D)**. Cells were fixed 24 h after virus inoculation and stained with virus-specific antibodies. **(I)** Representative confocal images of **(G, H)**. CHIKV E2 glycoprotein staining is shown in green and nucleus/cytoplasm staining is shown in red. All values represent the mean \pm SD, $n = 3$.

Fig S3. Rac1 and Arp3 act at a late stage of alphavirus infection.

(A) Time course of VEEV TC-83 (MOI=10) infection in HeLa cells. Media containing extracellular virus were harvested at the indicated time points for qRT-PCR analysis of virion copy number (left panel), and cells were fixed, stained with VEEV E2-specific antibody and analyzed with an Opera confocal reader by high-content quantitative image-based analysis (right panel). **(B)** High-content quantitative image-based analysis of relative VEEV TC-83 infection rates (normalized to DMSO-treated samples) in time-of-addition experiments. VEEV-infected

1000 HeLa cells (MOI=1) were treated with increasing concentrations of the Rac1 inhibitor EHT1864,
1001 or the Arp3 inhibitor CK548 at the indicated time points prior to (-1 h) or after (+1–7 h) virus
1002 addition. Cells were fixed 12 h after addition of virus and stained with virus-specific antibodies.
1003 Values represent the mean \pm SD, n = 3. (C) Plaque assays were used to measure VEEV titer in
1004 supernatants of HeLa cells pretreated with the indicated concentrations of the inhibitors. Cells
1005 were treated with inhibitors 5 h after inoculation with VEEV (MOI=0.5), and virus-containing
1006 media was harvested for analysis 17 h later. Values represent the mean \pm SD, n = 3. **, $p < 0.01$,
1007 Student's *t* test (between samples and DMSO). (D) BHK-CHIKV-NCT cells expressing a
1008 CHIKV replicon with a *Renilla* luciferase reporter were treated with increasing concentrations of
1009 EHT1864, CK548, or T705 (a nucleotide prodrug, positive control). After 48 h, *Renilla*
1010 luciferase (Rluc) activity was determined from the lysates.

1011

1012 **S4 Fig. Actin polymerization plays a role at a late stage of alphavirus infection.**

1013 (A) HeLa cells or primary human astrocytes were infected with VEEV (MOI=0.5) or VEEV TC-
1014 83 (MOI=0.005) for 3 h (HeLa) or 5 h (astrocytes) and then treated with increasing
1015 concentrations of nocodazole. After 6 h (astrocytes) or 17 h (HeLa), virus titer in the
1016 supernatants was determined by plaque assay. Values represent the mean \pm SD, n = 3. (B)
1017 Representative confocal images of (Fig 4C). VEEV E2 staining is shown in green, nucleus
1018 staining is shown in blue, and tubulin staining is shown in red (top panel: magnification: 10x;
1019 bottom panel: magnification: 40x). (C). Representative confocal images of (Fig 4C). VEEV E2
1020 staining is shown in green, nucleus staining is shown in blue, and actin staining is shown in red
1021 (top panel: magnification: 10x; bottom panel: magnification: 40x). (D) BHK-CHIKV-NCT cells
1022 expressing a CHIKV replicon with a *Renilla* luciferase reporter were treated with increasing

concentrations of the indicated inhibitors. After 48 h, *Renilla* luciferase (Rluc) activity was determined from the lysates.

S5 Fig. Alphavirus infection causes actin rearrangements into actin foci that co-localize with Rac1, PIP5K1- α , and E2.

(A) HeLa cells were inoculated with WEEV (MOI=2), EEEV (MOI=1), or SINV (MOI=5), fixed 24 h later, and stained with virus-specific antibodies and fluorescent phalloidin. High-content quantitative image-based analysis was used to measure virus infection rates (left panel) as well as number of actin foci per cell (right panel). ***, $p < 0.0001$, Student's t test (between samples and mock). (B) HeLa cells were transfected with an expression plasmids encoding VEEV nsP1-FLAG. Cells were fixed 24 h later and stained with antibodies against FLAG (green), and fluorescent phalloidin (red). Confocal images of single Z sections are shown as well as a Z stack image (merged Z sections) of actin staining. Representative actin filopodia are indicated by asterisks. (C-D) Basal-to-apical confocal section series of VEEV-infected HeLa cells (MOI=5). Co-localization of HA-tagged PIP5K1- α (C) or Rac1 (D) (blue), actin (red), and VEEV E2 (green), at different z sections is shown, as well as single channel intensities measured along lines crossing different actin clusters. Insets: zoom on actin filaments indicated by white arrows. Nuclei are indicated by asterisks. VEEV was added to (C) HeLa cells that were reverse-transfected with a plasmid encoding HA-tagged PIP5K1- α or (D) tetracycline-induced T-Rex HeLa cells that expressed Rac1 fused to eGFP. Cells were fixed 20 h later, permeabilized, and stained with VEEV E2-specific antibody, phalloidin, and an antibody against HA (C).

S6 Fig. Alphavirus E2 co-localizes with actin but not with tubulin.

(A) Representative images of VEEV-infected HeLa cells from Fig. 6A in confocal and STED microscopy modes. E2 glycoprotein is shown in green and actin in red. (B) Co-localization of tubulin (blue), actin (red), and E2 (green) in a VEEV-infected cell at different z sections from base (Section 7) to apex (section 25). HeLa cells were infected with VEEV (MOI=5) for 20 h and stained with antibodies against E2, tubulin, and fluorescent phalloidin. Pixel intensities of tubulin (red) and E2 (green) staining are shown (bottom graphs). (C) Representative images of VEEV-infected HeLa cells (as in B) stained with E2-specific antibodies (green), phalloidin (red) and CellMask (grey in merge). Analysis of cell borders based on CellMask staining was performed within the Columbus programming environment.

S7 Fig. Rac1 and Arp3 inhibitors block E2 transport to cell surface.

(A) High-content quantitative image-based analysis was used to measure the TGN46-to-plasma membrane E2 staining intensity ratio in VEEV-infected astrocytes. *, $p < 0.05$, **, $p < 0.001$, Student's t test (between samples and DMSO). (B) Representative confocal images of HeLa cells treated with DMSO, EHT1864 or CK548 at the indicated concentrations and subsequently infected with VEEV (MOI=0.5). Cells were fixed and stained with VEEV E2 (green) and GGA3 (red)-specific antibodies and counterstained with Hoechst 3342 (blue) 20 h after infection (magnification: 40x). Representative cells showing co-localization of E2 and GGA3 are indicated with white arrows. (C) Geometrical mean fluorescent intensity of cell-surface CD44 staining in HeLa cells treated with EHT1864, CK548, cytochalasin D, latrunculin A, or nocodazole as measured by flow cytometry. HeLa cells were treated with increasing concentrations of the inhibitors or DMSO (control). Six h later cells were dissociated and stained against CD44 and with a 7-AAD viability dye.

1069

1070 **S8 Fig. Localization of actin foci, Rac1, and PIP5K1- α relative to TGN46.**

1071 VEEV (MOI=5) was added to (A) HeLa cells, or (B) HeLa cells that were reverse-transfected
1072 with a plasmid encoding HA-tagged PIP5K1- α or (C) tetracycline-induced T-Rex HeLa cells that
1073 express Rac1 fused to eGFP. Cells were fixed 20 h later, permeabilized, and stained with VEEV
1074 E2- and TGN46-specific antibodies, as well as with phalloidin (A), and an antibody against HA
1075 (B). Co-localization of actin (A), PIP5K1- α (B) or Rac1 (C), with TGN46 (white), and VEEV E2
1076 (green), at a single z section.